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Abstract
The self-controlled case series (SCCS) method is commonly used to investigate associations 
between vaccine exposures and adverse events (side effects). It is an alternative to cohort 
and case control study designs. It requires information only on cases, individuals who have 
experienced the adverse event at least once, and automatically controls all fixed confounders 
that could modify the true association between exposure and adverse event. However, time- 
varying confounders (age, season) are not automatically controlled.
The SCCS method has parametric and semi-parametric versions in terms of controlling the 
age effect. The parametric method uses piecewise constant functions with a priori chosen age 
groups and the semi-parametric method leaves the age effect unspecified. Mis-specification 
of age groups in the parametric version may lead to biased estimates of the exposure effect, 
and the semi-parametric approach runs into computational problems when the sample size is 
moderately large. Moreover, both versions of SCCS represent the time-varying exposures using 
step functions with pre-determined cut-points. A less prescriptive approach may be beneficial 
when the shape of the relative risk function associated with exposure is not known a priori, 
especially when exposure effects can be long-lasting.
This thesis focuses on extending the SCCS method to avoid the aforementioned limitations 
by modelling the age and exposure effects using flexible smooth functions. Specifically, we 
used penalised regression splines based on cubic M-splines, which are piecewise polynomials of 
degree 3. We developed three new extensions: a method that represents only the age effect 
with splines, a method that uses splines to model only the exposure effect and a non-parametric 
SCCS method that represents both effects by splines. Simulation studies showed that these new 
methods outperformed the parametric and semi-parametric methods. The new methods are 
illustrated using large data sets.
Review of SCCS vaccine studies and directions on how to use the method are also given.
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Chapter 1
Introduction
Although vaccines or other drugs are tested extensively for relatively common adverse 
events (side effects) in clinical trials before they are licensed for use, not enough people 
are usually included in such trials to detect adverse reactions that occur only rarely. 
That is, the randomised double-blind controlled clinical trials used to assess the efficacy 
of vaccines and drugs before they are licensed are usually insufficiently powered, or too 
brief, to assess rare but serious side effects or modest increases in the risk of common 
disease outcomes that have a major population impact in absolute terms (Grosso et al., 
2011). Therefore vaccines and drugs used by the wider population need to be constantly 
investigated for safety.
In addition to assessing the risk of rare events, post-licensure studies also enable 
the evaluation of safety within groups such as the elderly, those with chronic medical 
conditions, and pregnant women, who might be deliberately excluded from vaccine or 
other drug trials. In the context of vaccine safety, by providing accumulating evidence, 
they can help to maintain the public confidence needed to keep vaccination uptake high 
enough to prevent disease outbreaks.
1
C h a p t e r  1. In t r o d u c t io n 2
Cohort and case-control study designs are commonly used methods to investigate 
the safety of drugs already on the market. The cohort method compares the risk of 
a potential adverse effect (outcome event) between individuals who are exposed to the 
drug of interest and those who are unexposed. This method, although effective, may 
have a potential problem of confounding variables (Farrington et al., 1996), because the 
exposed group and unexposed group of individuals could have different characteristics 
(socio-economic status, underlying health status, gender etc). Confounding variables are 
variables that are related to both exposure to the drug of interest and the outcome event. 
These variables, which might be difficult to measure and control, can alter the apparent 
relationship between the exposure and an outcome event.
The case-control method compares individuals who experienced the outcome event 
(cases) with individuals who did not experience the event (controls). Controls are usually 
chosen to be matched to cases on variables like gender, age etc. Case-control studies 
are less costly and faster to implement than cohort studies. However, as with cohort 
studies, they suffer from the problem of potential confounding variables that might bias 
the estimates, and may be associated with difficulties in selecting appropriate controls.
Alternative methods to cohort and case-control methods are study designs that use 
information only on individuals who have experienced the outcome event at least once 
(cases). These methods are attractive for three reasons listed in Farrington (2004). First, 
they can usually be implemented using data extracted from readily available databases 
such as hospital admission data or other case reporting mechanisms. Second, they can 
produce results quickly, for example, in response to public concerns or media attention 
about vaccine or other drug safety. Third, they are usually cheaper to carry out than 
methods requiring explicit denominators or separate controls.
C h a p t e r  1. In t r o d u c t io n 3
One of these methods is the self-controlled case series (SCCS) method, or case se­
ries method in short, that often combines the power and simplicity of the cohort design 
and the economy of the case-control method, while eliminating confounding by all time 
independent variables (variables that do not change their value with time) (Farrington, 
1995; Farrington and Whitaker, 2006). It was originally developed, by Farrington (1995), 
specifically for use in vaccine safety studies, but has since been applied in non-vaccine 
pharmacoepidemiology and in other areas of epidemiology (Whitaker et al., 2006; Welde­
selassie et al., 2011; Grosso et al., 2011).
In the SCCS method, a post-vaccination or duration of drug use risk period (exposure 
period) is defined a priori, and other times within the period during which each individ­
ual is observed (the observation period) constitute the control periods. Then the SCCS 
method compares the rate of incidence of an event in an exposure period with the rate of 
incidence in the control periods, when an individual is not exposed. The comparison is 
within individuals. The incidence rate in the control period is the baseline incidence rate; 
this is not estimated in the SCCS method. The estimated measure of the relationship be­
tween exposure and outcome event is a relative incidence. Because the comparison is made 
within an individual’s observation period, the method is self-matched; hence, all measured 
and unmeasured age-independent confounding variables, such as socio-economic status, 
birth weight, location, severity of underlying disease, gender, etc., which act multiplica- 
tively on the baseline incidence rate, are automatically controlled. However, time-varying 
confounders such as age and season are not automatically controlled for, but as with 
cohort methods they can be allowed for explicitly in the model (Farrington, 2004).
Careful control of age effects is particularly important in the study of paediatric vac­
cines and neurological events, such as febrile convulsions. The incidence of such events is
C h a p t e r  1. In t r o d u c t io n 4
highly age-dependent in the first two years of life, which is precisely the age at which many 
routine vaccinations take place. Partly for this reason, potential associations between vac­
cination and neurological events have been studied intensively over several decades. These 
studies have used a broad range of methods, including SCCS (Farrington et a l , 1995; Bar- 
low et a l , 2001; Huang et a l , 2010; Miller et al, 1981). Similarly the effect of exposure, 
the main focus of interest, should be modelled appropriately and carefully.
In its original form, the case series model took the multiplicative effect of age on the 
baseline incidence rate into account by dividing age into selected groups, with the age effect 
being represented by a piecewise constant step function. That is, the age effect is taken to 
be constant over the chosen age groups. We refer to this as the parametric version of the 
case series method. Its limitation is that it can be sensitive to mis-specification of the a 
priori selected age groups, which may lead to biased estimates of the association between 
exposure and outcome event. Another version of the SCCS method, in terms of modelling 
the age effect, is the semi-parametric SCCS (Farrington and Whitaker, 2006). In this 
method, the function that represents the age effect is not specified a priori, hence avoiding 
the limitation of the standard (parametric) SCCS method. However, as the number of 
cases in the study increases, the number of parameters to be estimated increases, which 
leads to computational problems (Farrington and Whitaker, 2006). In both the parametric 
and the semi-parametric versions of the SCCS method, the effect of age is represented by 
a step function; in the parametric version these age groups are chosen a priori, whereas 
in the semi-parametric version they are determined by the data.
The effect of exposure, in both versions, is modelled as a step function based on groups 
chosen a priori. Similar to the age effect, the use of step functions to model the exposure 
effect might have limitations: a poor choice of cut-points may be associated with cut-point
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bias and misclassification (Altman, 1991; Greenland, 1995b).
In this thesis, to avoid these limitations, we replace the step functions in the parametric 
and semi-parametric SCCS methods by smooth functions that are based on M-splines. 
M-splines are piecewise polynomial functions connected at points known as knots and 
their linear combination is known as a spline function. The likelihood function of the 
SCCS method, which may be derived from a cohort method by conditioning on the total 
number of events experienced by each individual, contains an integral in its denominator. 
The use of M-splines to represent the age and exposure effects not only removes the 
limitations of step functions, but also avoids the numerical integration of the integral in 
the likelihood function, because the integral of an M-spline can be expressed in terms of 
another spline known as an I-spline. The other advantage of using M-splines is that they 
are positive functions and therefore can be used to approximate a non-negative function by 
constraining their coefficients to be non-negative. In SCCS, the functions that represent 
age and exposure effects should be non-negative functions as they are relative effects.
1.1 Aims and Objectives
The main objective of the thesis is to develop new extensions to the self-controlled 
case series method in order to circumvent the limitations associated with the use of step 
functions in the standard and semi-parametric versions of the method. But first, to set the 
scene, a review of how the SCCS method has been used in vaccine studies is undertaken, 
and clear directions on how it should be used are given. Therefore the aims and objectives 
are:
• to investigate the limitations of the standard and semi-parametric SCCS methods 
using a simulation study;
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• To review how the self-controlled case series method has been applied in vaccine 
studies, clarify misconceptions about the method and present some recommenda­
tions on how it should be used, with the emphasis on promoting good practice;
• to represent the age effect with smooth functions as a linear combination of M-spline 
functions while representing exposure effect by a step function;
• to model the exposure-related relative incidence function using a linear combination 
of M-splines and use a piecewise constant function for the age effect; and
• to represent both the age and exposure effects using linear combinations of M-splines 
at the same time.
1.2 Thesis Outline
The thesis begins with a description of the self-controlled case series method and a 
derivation of the likelihood functions of the standard and semi-parametric versions of the 
method in C hap ter 2. In addition, C hap ter 2 presents a simulation study conducted 
to investigate the limitations of the standard and semi-parametric SCCS methods.
C hap ter 3 presents a critical review of vaccine studies that made use of the SCCS 
method between 1995 and beginning of 2014. This review includes discussion on: how 
the studies described their data and accuracy of the data, how observation periods and 
risk periods were chosen, how potential confounders were handled, potential sources of 
biases, comparison of SCCS results with other statistical methods, some methodologi­
cal issues, power and sample size issues and how sensitivity analyses were done. Also, 
recommendations on how the SCCS method should be used and reported are given.
C hap ter 4 introduces some of the smooth functions which could be used in modelling
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age and exposure effects to avoid the limitations investigated in C h ap te r 2 . The func­
tions discussed in this chapter are polynomial functions, fractional polynomials, truncated 
power functions, B-splines, M-splines and I-splines.
C hapters 5, 6 and 7 describe the extensions made to the standard SCCS method 
by replacing the step functions which represent age and exposure effects by smooth func­
tions. In C hap ter 5 the standard SCCS method is extended by representing the age- 
related relative incidence function as a linear combination of cubic M-splines (piecewise 
cubic polynomial functions) and the cumulative age-specific relative incidence by a linear 
combination of I-splines. The use of polynomial and fractional polynomials in the context 
of the SCCS method are also described in this chapter. To use M-splines to represent a 
function, it is first necessary to determine the number and position of the knots used to 
make them. Smoothing splines are spline functions where the knots are placed at data 
points: so prior knots do not need to be selected. This however greatly increases the 
computational burden, because the number of parameters to be estimated is about equal 
to the number of observations. Instead we use penalised regression splines, for which the 
number of knots is less than the number of observations and the knots need to be deter­
mined a priori. Selecting too small a number of knots under-fits the function and too large 
a number of knots over-fits it. So we use a large number of knots and introduce a penalty 
term to the log-likelihood function to control the roughness of the function. C h ap te r 5 
presents the derivation of a penalised log-likelihood function for the spline-based SCCS 
method. An approximate cross validation method used to choose a smoothing parameter 
that controls the tradeoff between roughness and fit is also derived in this chapter. Fi­
nally, C hap ter 5 presents a simulation study conducted to evaluate the performance of 
the new method and its application to investigate a potential association between pedi­
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atric vaccines and febrile convulsion. In this chapter the exposure effect is represented by 
a step function.
Chapter 6 presents a different extension of the standard SCCS method that models 
the exposure-related relative incidence function as a linear combination of cubic M-splines 
while the age effect is represented by a step function. Similar to Chapter 5, a penalised 
log-likelihood function is used. A simulation study to investigate the performance of this 
method relative to the standard method, and applications to data on pediatric vaccines 
and febrile convulsions, and thiazolidinedione (a class of medicines used to treat type 2 
diabetes) use and fractures are also presented.
In Chapters 5 and 6 step functions are still used to model one of either the exposure or 
the age effect. In Chapter 7, the works of Chapters 5 and 6 are combined in developing 
a non-parametric SCCS method, where both age and exposure effects are approximated 
by linear combinations of cubic M-splines. In this chapter we define the first, second and 
third integrals of an I-spline based on the definition for the integral of an M-spline given 
by Ramsay (1988). We also define the integral for the product of two spline functions 
expressed as linear combinations of cubic M-splines. Chapter 7 also presents a simulation 
study that evaluates the performance of the non-parametric SCCS method.
Finally, conclusions and possible future research are presented in Chapter 8.
Chapter 2
The Self-Controlled Case Series 
M ethod
The self-controlled case series method, which uses only information from cases, that is, 
individuals with an adverse event, was developed specifically for use in vaccine safety stud­
ies, but has since been applied in non-vaccine pharmacoepidemiology and in other areas 
of epidemiology (Whitaker et al., 2006). It automatically controls all age-independent 
multiplicative confounders, while allowing for an age-dependent baseline incidence. The 
method has two versions based on the way it handles the effect of age-dependent con­
founding variables: (1) the standard method, which models the effect of age using a 
parametric step function and (2) the semi-parametric method: that controls for age non- 
parametrically. In this chapter we describe how the two versions of the method work and 
derive their likelihood functions. And limitations of the SCCS models, which led to the 
extensions developed in this thesis, are investigated using a simulation study.
In Section 2.1, how the SCCS method works is described, followed by the derivation 
of the likelihood function for the standard version of the method and a general likelihood
C h a p t e r  2. T h e  S e l f - C o n t r o l l e d  C a s e  S e r ie s  M e t h o d 10
function in Section 2.1.1. Section 2.2 deals with the semi-parametric version of the method 
and how to fit the model. Finally, the limitations of the standard and semi-parametric 
SCCS models are given in Section 2.3 followed by a discussion in Section 2.4.
2.1 The Standard Case Series M ethod
The self-controlled case series method, in its standard framework, was developed to 
estimate the relative incidence of an acute event in a pre-defined post-vaccination risk 
period (Farrington, 1995). The relative incidence is a ratio of the incidence rate in a 
predefined post-exposure risk period relative to other times (control periods) within a 
defined period during which individuals are observed (the observation period). It is a 
conditional, retrospective, risk-interval cohort method and is applied as follows.
An overall study time-window, usually defined by age and calendar time boundaries 
(and also, sometimes, in terms of vaccination date), is chosen, ideally such that the chance 
that individuals experience both risk and control periods is maximised. The observation 
period, in particular, must be defined so that, had an event occurred at any point within it, 
the case would have been ascertained. Then, all or a random sample of individuals with at 
least one event (independent recurrences are permitted) within this study time-window 
are identified: these are the cases. The study time-window also determines individual 
observation periods for each case, namely the time spent by each individual within the 
study time-window (the observation periods generally differ between individuals).
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Figure 2.1: Self-controlled case series setup; where ai and bi are ages at the start and end of 
observation period for individual i respectively
Next, the vaccination or exposure to other drugs histories of the cases are collected. As 
in other epidemiological designs, ascertainment of cases must be independent of vaccina­
tion or exposure histories, dependence of exposure history on case ascertainment may lead 
to biased relative incidence estimates. A clear description of how the data  were obtained 
is therefore im portant in order for the reader to be able to assess any possible dependence. 
The vaccination dates of each case are used to define one or more risk periods, during 
which individuals are hypothesized to be at increased (or reduced) risk of the event of 
interest after (or, for reasons to be discussed later, before) vaccination. Risk periods are 
defined in terms of time since vaccination (with, preferably, a stated convention to  de­
scribe the day of vaccination, for example day zero) or duration of exposure to drugs other 
than vaccines, which are not point exposures. A rigorous report of these choices provides 
confidence tha t care was taken in the analysis, and enables the reader, in theory at least, 
to reconstruct the study exactly. In the context of point exposures like vaccine, the choice 
of risk periods should be made a priori and its rationale explained. Typically, the choice 
will be motivated by reference to previous studies or hypotheses, by biologically plausible 
mechanisms or by expert opinion. All other time within an individual’s observation pe-
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riod, that does not fall within a risk period, is included in that individual’s control period, 
which forms the study baseline (see Figure 2.1). Figure 2.1 shows an observation period 
(a*, bi\ for individual i divided into control and exposure groups. Diagnosis is the age at 
which the event of interest occurs (it can be anywhere within the observation period and 
an individual can experience more than one event provided that they are independent) 
and di and bi are ages at the start and end of the observation period respectively.
Justification for using only cases stems from the analytical strategy, which conditions 
on the number of events each individual experiences within the observation period: this 
number is regarded as a fixed quantity. A consequence is that non-cases contribute no 
information, and therefore need not be sampled. Estimation of parameters in the SCCS 
method is achieved by fitting a conditional Poisson regression model (it is essential that 
it should be a conditional model, in order to justify sampling only cases). The parameter 
of interest is the relative incidence, that is, the incidence in a risk period relative to the 
control or baseline periods. A further consequence of the conditioning is that the analysis 
is within-individuals, and, as a result, in the SCCS method all fixed confounding factors, 
known and unknown, are controlled for implicitly. Temporal confounding factors, such 
as age can be accounted for by subdividing each individual’s observation period into age 
categories, which are modelled explicitly.
2.1.1 Derivation of SCCS Likelihood
In this section we derive the likelihood function used to estimate the parameter of 
interest (relative incidence) in the standard SCCS method, where the effect of age is 
taken into account by dividing the observation period into age groups. We also derive a 
general likelihood function for the SCCS model where the age effect can be represented
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by a variety of functions.
Standard SCCS Likelihood Function
The assumptions made in deriving the likelihood function are: Assumption (1) that 
individuals experience events in a non-homogenous Poisson process; Assumption (2) that 
age-dependent exposures experienced by individuals are exogenous, so exposures are in­
dependent of prior events, and Assumption (3) that censoring of individuals at the end 
of the observation period occurs completely at random, i.e the occurrence of the event of 
interest must not censor or affect the observation period Farrington (1995); Farrington 
and Whitaker (2006); Whitaker et al (2006); Weldeselassie et al (2011). Discussion about 
deviations from these assumptions is given in Chapter 3.
Let (a*, bj\ be the observation period for individual i = 1, 2 often determined by 
a combination of calendar time and age constraints. And let individual i be exposed at 
age Cj and the risk period be (c*, d j so that k  is an indicator of exposure, k = 1 in the risk 
period and k = 0 in the control periods as shown in Figure 2.2. More than one exposure 
periods are possible. In order to control for age, if for example the number of age groups 
is 2, the observation period in Figure 2.2 is further divided into two segments as j  =  1 
and j  = 0.
K=0 I K=1
a i ^ Cj
K=1 K=0
di bj
” j=1 --------
Figure 2.2: Self-controlled case series model with two age and two exposure groups
In Figure 2.2, for this particular individual i, the observation period is divided into 4 
intervals. Let the length of interval (z, j, k) be denoted by and the number of events
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experienced in the interval be denoted by nijk. The disease incidence rate Aijk is assumed 
to be constant within an interval. Denote the baseline incidence rate of individual i in the 
age group j  — 0 and exposure group k =  0 by ip exp (7;) and let exp (or) and exp(/A) denote 
relative incidences associated with age group j  = 1 and risk period k = 1 respectively, 
relative to age group j  = 0 and exposure group k = 0 (with a0 = f30 = 0) , where p 
and exp(7 )^ are age-independent fixed and random individual effects that may depend on 
covariates that do not vary over the period 6J.
In the SCCS method, exposure, age and other variables are assumed to have a multi­
plicative effect on the baseline rate of incidence. And since events are assumed to arise in 
a non-homogenous Poisson process, constant within an interval, the Poisson rate in the 
first interval within the observation period of individual z, shown in Figure 2.2, is:
e*ooAioo =  eioo^exp(7i)exp(a0)exp(/30)
=  eioo^exp(7i),
as ao = (3q = 0. Similarly the rates in the second, third and fourth intervals are respec­
tively
emKoi = eioi^exp(7i)exp(/3i),
e*i iA<n =  ein^exp(7i)exp(ai)exp(/?i), 
e<ioAiio =  eiio^exp(7i)exp(ai).
In a case series analysis an individual is included in a sample if at least one event 
occurred in his/her observation period. Hence we condition on the number of events an 
individual experienced, in deriving the likelihood contribution of the individual. This leads 
to a multinomial distribution. Then the likelihood contribution of individual i according
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to the multinomial distribution, 4-nomial in this example, is:
(2-1}
where y n .y ^  Viz and y^  are the numbers of events (the values of ) in the intervals
1,2,3 and 4 respectively of individual i within the observation period, n* =  =
Ylj nijk is the total number of events experienced by individual i. Pn,Pi2 ,Pi3 and 
pi4 are probabilities of an event to a occur in a corresponding interval. Since the events 
occur as a Poisson process and are independent, the probabilities can be found from 
the following property. If 1ft, Yi2, . . . ,  1ft are independent Poisson random variables with 
parameters //i, • • •, ps then
r 4/ i y V j|~ B i n o m ( y 'y « , = £ ^ V  (2.2)
1=1 \ i=l l*>i=i
Yif\rii ~  Binom  (n*, = 5^ — j . (2.3)
\  2-fi=i M  J
Therefore, the expression for the parameters (probabilities) in the multinomial likelihood 
function is P r1—. For example1^1=1 Vl
em<P exp(7i)
—      ---------------------------------------------------------------------------------------------------
(p exp(7i) +  em  exp(ft) +  ein exp(ar +  f t)  +  e^o exp(«i))
_  ^00________________
eioo +  em  exP(ft) +  eiii exp(ai T f t)  -f e^o exp(o:i)
and in general
=  eijk exp (aj) exp (ft)
^  J2rs &irk exp(o!r) exp(ft) *
The individual effect exp(7*) and the baseline incidence p  cancel out, which implies 
that the SCCS method implicitly controls for all measured and unmeasured fixed con­
founding variables. Therefore, the likelihood contribution of individual i ignoring the 
constant in the multinomial likelihood since it does not depend on the parameters of
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interest, is
Li(at,P) = J J
jk
eijk exp (a, +  pk) Tlijk
y~vrg &irs exp(ar -f- fts) _
As individuals are independent the likelihood for all individuals is
N
£(«, /?)= n n
i=1 jk
eijk exp(aJ- +  pk) 
.53rs 6Xp(Q!r -f- Ps) _
n i j k
and the log-likelihood function is
N
»(«./*) =  £ £  ^ ijk^9  
i=l jk
The General Likelihood Function
eijk exp{oLj +  Pk)
.J2rs eirsexp(ar -\- ps)
(2.4)
As in the piecewise constant case, the general likelihood function of a case series 
method may be derived from a cohort likelihood by conditioning on the number of events 
each individual experiences and on the exposure history over the time period an individual 
is observed. Suppose that individual i in a dataset is observed in a period (a*, 6<] where i = 
1 , . . . ,  N  and experiences events tn , t i 2 , . .  - ,  tini. Within this observation period individuals 
experience exposures from different risks which can change the probability to experience 
an event. Denote the number of events that an individual experiences in the interval 
(ia ^ t \ by Ni(t). As in Farrington and Whitaker (2006), let x ^ t )  represent the vector of 
exposures that individual i experiences at age t  within the observation period. If there 
is one exposure, letting P to denote the effect of exposure Xi(t)P or using a different 
parametrisation exp(xi(t)P) represents exposure related relative incidence function (see 
below in this section). Again let x\ be the exposure history of individual i up to age t, that 
is, the function x\ = {^(s) : s < t}. Let Xi=x\l be the exposure history of individual i up 
to the end of their observation period. Letting the intensity process (hazard function) by 
which events arise be denoted by A*( |^a;|), we have a probability density function given by
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Xi(t\xl)S(t\xl). Here S(t\x l)  is a survival function which can be obtained from the hazard 
function as S(t\x f) = exp f * .  X ^ u lx fjd u ^ .
Since events within the observation period of an individual are assumed to be inde­
pendent, the unconditional likelihood that individual i experiences n* events that arise 
with intensity process (t|rz;|) at times j  = 1, 2, ...,7^  is
L i =  f l  exP { -  [  K (t\x l)d tX  . (2.5)
j -1  1 J a i  )
Assumption (2) (in page 13) implies that the event rate at age t, given the exposure 
history to age t, is equal to the event rate at age t, given the exposure history over the 
entire observation period, i.e. Xi(t\xf) =  A*(t|a?*). Thus, conditioning on the total number
of events an individual i experiences in their observation period and on the exposure
history Xi does not affect Ai(t\xi). This is the key assumption of the SCCS method, 
departures from which are discussed in detail in Farrington et al (2009). Departures 
from assumption (3) are discussed in Farrington et al (2011).
Now to find the conditional likelihood that an individual i experiences the events tij, 
j  = 1, 2, conditional on the total number of events experienced by the end of the
observation period, we need to have the expression for the probability that the count of 
events is n*. In SCCS method events are assumed to occur in a non-homogeneous Poisson 
process with intensity Aj(t|x j ,  therefore the total count A^(^) is a Poisson random variable 
with mean Xi(t\xi)dt). This leads to the probability
{ f a *  Ai(t|xi)dt) * f  rbi
P(Ni(bi) = rii) = ---- -----— exp | -  J  Xi(t\xi)dt j  (2 .6)
Therefore, from Equations (2.5) and (2.6) the conditional likelihood contribution of
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individual i given n* events occurred at times Uj, j  = 1, 2,..., n* is obtained as
Aiij'ij |%i)
Li 5  £  Xi)dt
U j=l ^i(tij\Xi) p  7)
{la ' K(t\Xi)dt} '
From this case series likelihood it can be seen that if individual i has no events, n* =  0, 
then L? = 1, implying that only individuals with at least one event in their observation 
period contribute to the likelihood. Hence, the case series method needs information only
on cases.
The most convenient way of parameterizing the incidence Xi(t\xi) is according to the 
proportional incidence model
Xi(t\xi) = A0(t)exp{7i + Xi(t)Tp )
= (p j^{t) exp {7* +  Xi(t)T(3} , (2.8)
where X0(t) =  is the baseline incidence at age t (to be discussed next), 7* is as
defined above, and (3 is a vector of the log-relative incidences that measure the association 
between exposures and event of interest. Then, combining Equations (2.7) and (2.8), the 
conditional likelihood contribution of individual i is
'ip(tij)ex p {x i(tij)Tf3}^=n
j=l Sat W )  eXP { Xi W P }  dt
Since individuals are independent the conditional likelihood of all individuals is given as
i - T T T T  e x p (2 9 )
The terms tp and exp (7*) cancel out and hence all fixed covariates that act multiplicatively 
on the baseline incidence are automatically controlled for. This is because the total 
number of events experienced by individual i, is a sufficient statistic to estimate the
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individual effects, exp(7j), which leads to the removal of exp (7;) from the conditional 
likelihood.
In the standard SCCS method '</>(£), which is the age-specific relative incidence func­
tion, is represented using a step function, so replacing t) and the exposure effect in 2.9
by step functions yields the log-likelihood function 2.4. In the semi-parametric version 
of SCCS (Section 2.2) ip(t) is left unspecified: the cumulative baseline relative incidence 
function is a step function with steps at the distinct event times.
2.1.2 F itting the Standard M odel
The log-likelihood function of the standard self-controlled case series method can either 
be maximised directly or fitted using as an associated Poisson regression model with 
log link function. To fit the associated conditional Poisson model, the data should be 
formatted such that there is one line for each interval within the observation period (see 
Figure 2.2). The number of events in an interval is used as a response variable in 
the model and log of interval lengths are included as an offset. Factors for age group, 
exposure group and individual are also listed for each of the intervals. The model fitted 
is
'fl'ijk rKJ Poisson(Ayfce»jfc)
log(A ijk) =  <Pi + 0£j+Pk, (2.10)
where (pi is an individual effect included to guarantee that the fitted marginal totals equal 
the observed values. As the (fi are nuisance parameters, it is convenient to fit the model 
as a conditional fixed effects Poisson regression model.
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2.2 Semi-Parametric SCCS
In the standard self-controlled case series method, the age-specific relative incidence 
is defined to be a step function and fitted by a priori choosing age groups over which the 
incidence is believed to be roughly constant. An extension of the standard model is a semi- 
parametric model in which the age-specific relative incidence is left unspecified except that 
it is non-negative and bounded (Farrington and Whitaker, 2006). The cumulative age- 
specific relative incidence function $(t) = f* 'ip(s)ds is estimated non-parametrically from 
non-decreasing step functions. The likelihood function of the semi-parametric method can 
be derived in a similar way to the standard SCCS method. Let the set of distinct event 
ages tij of all cases be denoted by S. Assume that there are M  distinct event ages sorted 
in an increasing order si,...,sm- Let the step function that represents the cumulative 
age-specific relative incidence function be constant outside S  and have jumps of height 
A\k(t), for t e  S, where A\k(sr) — exp(ar), r = 1,..., M, and without loss of generality 
let or =  0. Define a weight for each individual i and each sr 6  S  as wir = /(ai,6z](sr), 
where I(ai,bi\ is an indicator which takes a value 1 if sr is within the observation period of 
individual i and 0 otherwise. The weights assigned ensure that only event days within the 
observation period of an individual contribute to his/her likelihood and that the jumps 
in the cumulative function are at the event ages. Let be the value of ar corresponding 
to (the j th event of individual i). The cumulative age-specific relative incidence curve 
of the semi-parametric model is presented in Figure 2.3.
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Figure 2.3: Representation of age effect in the semi-parametric self-controlled case series method
Figure 2.3 shows tha t the cumulative age-specific relative incidence is constant between 
two event ages and jumps at each of the event ages.
2.2.1 S em i-P aram etric  SCCS Likelihood
The likelihood function for the semi-parametric model can be derived in a similar 
way to the standard SCCS by conditioning on the to tal number of events an individual 
experiences in their observation period. It can also be derived from the general likelihood 
function of SCCS (2.9) by replacing the effect of exposure and the cumulative age-specific 
relative incidence ('F(t) =  J^'ip(s)ds) with step functions. That is, in the num erator we 
have tij) =  exp(o:^) and in the denominator if>{t) exp {x*(t)T/3} dt is replaced by 
E iH i wirexp(ar +  x t (sr)T/3), which leads to the likelihood contribution of individual i
=  t~t exp(al3 +  Xi(tij)T (3) 
j = 1 S r = i  wir exp(ar +  Xi(sr)Tf3) ’
where x fo i j ), as defined before, represents the exposures. Once again, the individual 
effects p  and exp(7 )^ cancel out and lead to autom atic control of age-independent con­
founding covariates. The independence of individuals gives the SCCS semi-parametric
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likelihood function (La) for all individuals
exp(aij +  x i(tij)T/3)
(2 .11)
The function A/(t) represents a relative effect, and so is not identifiable without some 
further constraint. In the semi-parametric SCCS method (Farrington and W hitaker, 
2006), the constraint 'F(a) =  1 is used, so th a t ip is the baseline incidence at a.
2.2.2 F ittin g  th e  S em i-P aram etric  M odel
Fitting the semi-parametric model is similar to fitting a standard model with unit 
age groups, where the unit is the smallest separation between successive event times, i.e 
m in {s r + 1 — sr , r = 1 , . . . ,  M  — 1}. To fit the model, the data need to be expanded such 
th a t each individual has a row of information for each of the distinct ages a t event in the 
data set th a t falls within their observation period. Information on the number of events 
experienced by individual i, n ir (which is 0 or 1 since each interval has length of only 
one time unit), exposure status, x*(ty), and weight, wir, at age sr are included. As an 
example, consider a study of 6 cases with five distinct event ages 20, 75, 143, 160 and 200 
(two cases experienced their events at the same age). Let individual 1 have an observation 
period (10, 180], exposure period (135, 150] and their event occurred at age 75.
10 135 150 180
Age
Figure 2.4: An individual with one exposure period, four of the event ages falling within the
observation period
One of the event ages, 200, is outside the observation period of individual 1, hence
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its weight is zero. Therefore, the expanded data for individual 1 will have four rows with 
non-zero weight as presented in Table 2.1.
Table 2.1: Reformatted data for one case, used to fit the semi-parametric model
Id Events(nir) Risk group(a^) Age group Weight(w^)
1 0  0 0 1
1 1 0 1 1
1 0 1 2 1
1 0  0 3 1
1 0 0 4 0
Once the data are reformatted the conditional Poisson model is fitted to estimate the 
parameters of interest. The model has weights i%., response variable nir with mean \ r 
and a log link function
log(Xir) = 7z +  otr +  Xi(sr)P
where 7* is an individual effect included to constrain the total number of events experi­
enced by each individual to their observed values.
2.3 Limitations of SCCS
This section explores the limitations of the standard and semi-parametric versions of 
the self-controlled case series method. In the standard SCCS method the age groups 
should be specified a priori as described in Section 2.1.1. We, therefore, investigate the 
sensitivity of the parameter estimates related to exposure, in the standard SCCS method, 
to mis-specification of age groups. In the semi-parametric method the number of parame­
ters that need to be estimated increases with the sample size because the fitting procedure 
using standard software requires the data to be expanded to size of order TV2, where N  
is the number of cases. The age effect is represented by a vector of parameters whose
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dimension is of order N. When N  is moderately large, this may lead to computational 
problems. There may also be a loss of efficiency in estimation. We investigate these using 
simulation studies.
2.3.1 Limitation of the Standard SCCS
A major limitation of the standard SCCS method is that estimates of the exposure 
effect may be biased if the a priori chosen age groups are misspecified (Farrington and 
Whitaker, 2006). To investigate this limitation we conducted a simulation study. In 
the simulation study we selected the beginning and end of the observation period for all 
individuals to be 0 and 730 days respectively. The ages at exposure, c* had an exponential 
distribution, and were generated from an exponential distribution with a rate of 0.01. We 
took the risk period to be 50 days post exposure. Three values of the true exposure-related 
relative incidence were investigated: 1, 2, and 5.
15 age groups were used in simulating the data, with cut points at every 50 days 
between 0 and 730 with the last age group having a length of 30 days and the true age- 
specific relative incidence values were 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 15, 16, 18, 19 and 
20. Three different scenarios of sample size (number of cases), 50, 100 and 200, were 
considered. For each scenario 10,000 data sets were generated, (for more on how data are 
generated in the SCCS method see Section 5.3 of Chapter 5).
The 10,000 simulated data sets were then analysed using the SCCS method without 
any age effect, the standard SCCS with misspecified age groups (two age groups sepa­
rated at age of 350 days) and the standard SCCS method with the 15 correctly specified 
age groups used in generating the data sets. Results of these analyses are presented in 
Table 2.2. We computed bias and standard error of the bias for each scenario. The biases
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were calculated as:
Bias =  median of the 10,000 estimated exposure-related log relative incidences
— the true log relative incidence. (2.12)
Table 2.2: Simulation study results of investigating the effect of age groups’ mis-specification in 
the standard SCCS method. Bias of the exposure-related log relative incidence and their standard 
errors (SE) are presented
Number of Cases No age effect included Misspecified Correctly specified
Bias(SE) Bias(SE) Bias(SE)
True Relative incidence =  1
50 0.516(0.020) 0.168(0.020) -0.024 (0.020)
100 0.657 (0.004) 0.201(0.004) -0.012 (0.004)
200 0.599 (0.003) 0.177 (0.002) -0.005 (0.003)
True Relative incidence =  2
50 0.527 (0.004) 0.196 (0.005) -0.008 (0.005)
100 0.589 (0.003) 0.178 (0.003) -0.004 (0.003)
200 0.590 (0.002) 0.183 (0.002) 0.002 (0.002)
True Relative incidence =  5
50 0.554 (0.003) 0.196 (0.003) 0.035 (0.004)
100 0.585(0.002) 0.176 (0.002) 0.022 (0.003)
200 0.593 (0.002) 0.189 (0.002) 0.007 (0.002)
We used the median in calculating the bias because it is possible for all event ages 
to occur in the risk period only, or in the control period only, resulting in an undefined 
expected value of the estimated relative incidence. The standard errors of the biases 
were also calculated by trimming the unbounded estimates. The standard errors were
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calculated as
s e = S D 0 - J )
V n *
where (3 is the estimated exposure-related log-relative incidence, [3 is the true log-relative 
incidence, N* is the number of data sets with bounded estimates and SD is standard 
deviation of biases of each estimate.
The results in Table 2.2 show that when age is misspecified or ignored from the stan­
dard SCCS analysis the estimated exposure-related relative incidence is biased. All the 
bias estimates obtained from the standard SCCS method without any age effect and the 
mis-specified SCCS method with 2 age groups are significantly different from zero. How­
ever, for the model with correctly specified age groups there is not enough evidence to 
reject the null hypothesis that there is no bias in estimating the exposure-related relative 
incidence value. Except when the true exposure-related relative incidence was 5 there 
was a borderline significant bias. For the correctly specified model, the absolute bias 
reduces with an increase in the number of cases used in the analysis and increases with 
an increase in the true relative incidence. The biases for the correctly specified SCCS 
are always smaller than the other two models. These results indicate that a new way of 
modelling the age effect that does not require age groups to be defined a priori is needed.
2.3.2 Semi-Parametric M odel w ith Large D ata Sets
Given that the parametric SCCS method can be sensitive to mis-specification of age 
groups, which may lead to biased estimates of the association between exposure and event 
outcome, the semi-parametric SCCS method, in which the age-specific relative incidence 
function is left unspecified, was proposed by Farrington and Whitaker (2006). However, 
the semi-parametric SCCS method faces computational problems with large data sets,
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at least when fitted using standard software for log-linear models. We carried out a 
simulation study to investigate the computational demand of the semi-parametric method 
as the number of cases (and hence the number of parameters) in the model increases. We 
generated data using the same scenarios as in the previous section and fitted the semi- 
parametric model to each of the generated data  sets. The number of cases simulated 
ranged from 10 to 478. Beyond this number of cases, the computer programs we used 
failed completely.
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Figure 2.5: Time elapsed to estimate parameters in the semi-parametric SCCS model against 
the sample size used.
Figure 2.5 shows th a t the time elapsed to estimate parameters using the semi-parametric 
SCCS model increases as the number of cases in a study increases. It could not produce 
param eter estimates for data  sets with greater than  478 cases. This is because for each in­
terval (a,i, bi], i = 1, 2 , . . . ,  N  and each distinct event time, an indicator variable is defined
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to record whether that time lies within the interval, so that the data set is expanded to 
0 ( N 2). This typically causes capacity problems when N  is above 478 or so. In addition, 
the number of age parameters to be estimated is of order N.
2.4 Discussion
The self-controlled case series method, developed to estimate the relative incidence of 
an acute event following exposure to vaccines, has been described in this chapter. The 
method uses information only from individuals with an adverse health event and implic­
itly controls all measured and unmeasured fixed confounding variables but time-varying 
covariates should be included in the model. The two versions of the method; the standard 
and the semi-parametric SCCS were introduced and their limitations investigated.
The simulation studies showed that the standard SCCS method may lead to biased 
exposure related relative incidence estimates and the semi-parametric method fails to fit 
for large data sets.
The SCCS method has witnessed considerable methodological development aimed at 
weakening the assumptions it requires. Thus, methods have been developed to han­
dle event-dependent exposures and deaths (Kuhnert et al., 2011), dependent recurrences 
(Farrington and Hocine, 2010), event dependent observation periods (Farrington et al, 
2011). The method has also been extended to the prospective monitoring of vaccine safety 
(Musonda et al, 2008b; Hocine et al, 2009). Escolano et al (2013) extended the SCCS 
method for analyzing spontaneous reports of adverse events after vaccination aiming at 
rapid evaluation of a risk. When the timing of exposure onset is not known precisely, Mo­
hammed et al (2012) proposed to extend the SCCS method to take measurement errors 
into account. For this method, measurement error corrected SCCS, Mohammed et al
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(2013) developed a method that determines power and sample size. Simpson et al (2013) 
extended the standard SCCS to include multiple time-varying confounding exposures 
(drugs) and their interactions, from a large-scale longitudinal observational database. 
Choice of optimal risk windows in SCCS vaccine safety studies has been proposed by Xu 
et al. (2013).
To address the limitation of the standard SCCS method the semi-parametric SCCS 
method was proposed. However no extension has been developed to avoid the limitation of 
the semi-parametric SCCS that it may suffer from computational problems as the number 
of cases in a study increases as shown in the simulation study. Moreover, the exposure 
effect in both the standard and the semi-parametric SCCS methods is represented by a 
step function. Step functions are known to provide a rather crude approximation of the 
true relationship. Therefore, the parametric way of modelling the exposure effect may 
be sensitive to mis-specification of exposure groups. Hence new ways of modelling age 
and exposure effects that are not sensitive to mis-specification and have no computational 
problems are required. In Chapter 4 we introduce smooth functions which are some of the 
possible ways of avoiding the limitations associated with the standard and semi-parametric 
SCCS methods.
Chapter 3
R eview  of SCCS Vaccine Studies
The SCCS method has been applied both in vaccine, non-vaccine pharmacoepidemiol­
ogy and other areas of epidemiological studies. In this chapter we review how the SCCS 
method has been used in vaccine studies since its publication in 1995 and highlight good 
practice. We attempt to give some clear direction on how the method should be used and 
reported. Some misconceptions about the method and how it relates to other case-only 
study designs are clarified and some guidelines on reporting SCCS studies are given. How­
ever, our aims fall short of developing fully-fledged guidelines on reporting SCCS studies, 
which require detailed consideration of other applications in pharmacoepidemiology. Nev­
ertheless, we hope that this review will contribute towards the eventual elaboration of such 
guidelines. This review has been published in Weldeselassie et al. (2011).
The chapter has three sections. In Section 3.1 our review criteria and methods are 
described. In Section 3.2 we present the results of our review, including specific discussion 
on: data description and accuracy, choice of observation and risk periods, potential biases, 
comparison of SCCS with other methods such as cohort and case-control, methodologi­
cal issues, sensitivity analyses, software and good practice. Where appropriate, we also
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include general comments about the method and make recommendations. Section 3.3 is 
a brief discussion of our findings and areas for further research on the SCCS method.
3.1 M ethods
We identified SCCS studies which included a vaccine as an exposure, first published 
(in print or electronically) between 1995, when the SCCS method was first introduced, 
and the beginning of 2014. We identified papers by searching for those citing references 
Farrington (2004); Farrington et al. (1996); Farrington (1995); Farrington and Whitaker 
(2006); Whitaker et al. (2006, 2009); Andrews (2002); Musonda et al (2006) in the fol­
lowing databases : Scopus, JSTOR, Science Direct, British Library and all those within 
the ISI Web of Knowledge.
Methodological papers were excluded, unless they included a specific application using 
SCCS not reported elsewhere, and sufficient detail of this application was provided.
Each paper was reviewed against a standard form which was piloted on 13 papers (see 
Appendix A). The form included details on: vaccines and adverse events studied, data 
collection and description, study population, sample size, observation period, age groups, 
the allowance for any other temporal confounders, risk periods and their rationale, sen­
sitivity analyses undertaken, statistical features, reporting of results, whether key SCCS 
assumptions were met, any good, bad or unusual practice, and comparison with other 
study methods used in addition to SCCS.
3.2 Results
We identified 84 studies which met our selection criteria, four of them (Ali et al, 
2005; Burwen et al, 2006; Farrington et al, 1995; Gold et al, 2010) were papers with a
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methodological flavour, aimed at validating a surveillance system, but including a specific 
SCCS application. There were three notable exclusions. The first planned to use the 
SCCS method to study a possible association between vaccination and acute cerebellar 
ataxia (van der Maas et al., 2009). However, th a t analysis was not undertaken owing to 
sparseness of the data, and for this reason was excluded. Two further papers (France et al. , 
2004; Klein et a l , 2010) were excluded because, while referencing the SCCS literature, it 
was not clear th a t they intended to use it, and instead used a before and after vaccination 
design. As it turns out, this is in fact a special case of the SCCS design; we shall return 
to this issue later in the chapter. The papers were excluded because the authors could 
not be expected to report the study as if it were a SCCS study.
Figure 3.1: Distribution of vaccine studies using self-controlled case-series by year of publication. 
Figure 3.1 presents the distribution by year of publication of these 84 studies (refer­
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ences Andrews et al. (2001) and Sardinas et al. (2001) appeared in 2002, even though 
the journals are dated 2001; reference Gwini et al. (2011) was published electronically in 
2010). Thirty-eight of the 84 papers appeared in 2000-2010 and 42 papers appeared in 
2011-2013; Figure 3.1 suggests a moderate increase over the period 2000-2010 and a big 
increase in the period 2011-2013. There were also two studies until February in 2014.
Vaccines and Adverse Events Studied
Table 3.1 presents the vaccines and the adverse events studied between 1995 and 
2010. For ease of presentation, adverse events have been grouped, as for example purpura 
(which includes idiopathic thrombocytopenic purpura (ITP), allergic purpura, and other 
purpura). Similarly, vaccine types (e.g. intranasal and parenteral influenza vaccines) 
have been listed under the same heading. Measles/mumps/rubella (MMR) and other 
measles-containing vaccines were the most frequently studied (17 studies), followed by 
influenza vaccines (13 studies) and vaccines containing pertussis antigens (eight studies). 
The sample sizes (cases or numbers of events) included in SCCS analyses ranged from the 
very small (only seven events in one analysis in Farrington et al. (1995)) to the very large 
(8,180 cases in Gwini et al. (2011), 22,400 in Smeeth et al. (2004)).
Typically, several vaccines and/or adverse events were studied at the same time. One 
study (Payne et al., 2007) investigated concurrency of vaccination (administration of at 
least two vaccines on the same or adjacent days) as a risk factor. When several vaccines 
potentially related to the same outcome are administered at similar ages, their effects 
should be studied within the same model, as was done in Andrews et al. (2007). This also 
applies to non-vaccine exposures, as with influenza vaccination and influenza-like illness 
in GuillainBarre’ syndrome (GBS) (Stowe et al, 2008).
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Table 3.1: Vaccines and adverse events studied
Vaccine Adverse effect Reference
Any concurrent Hospitalization Payne et al. (2007)
DT, Td Convulsion Andrews et al. (2007)
Myocardial infraction, stroke Smeeth et al. (2004)
DTP, DTaP Convulsion Andrews et al (2007); Gold et al. (2010); 
Farrington et al. (1995);
Huang et al. (2010)
Encephalitis Ward et al (2007)
Immune haemolytic anaemia Naleway et al (2009)
Wheeze onset Mullooly et al (2002)
DTP/Hib/IPV Apnoea, convulsion, crying, 
diarrhoea, feeding problem,fever
Andrews et al (2010)
HBV Demyelination onset Hocine et al (2007)
Immune haemolytic anaemia Naleway et al (2009)
Wheeze onset Mullooly et al (2002)
Hib Wheeze onset Mullooly et al (2002)
Influenza Asthma exacerbation Kramarz et al (2000, 2001); 
Tata et al (2003)
Bells palsy Mutsch et al (2004); Stowe et al. (2006);
Cellulitis or abscess, UTI Burwen et al (2006)
COPD exacerbation Tata et al (2003)
Gastritis /  duodenitis Hambidge et al (2006)
GuillainBarre’ syndrome Hughes et al (2006); Stowe et al (2008); 
Juurlink et al (2006);
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Table 3.1: Continued
Influenza Myasthenia gravis
Myocardial infraction, stroke
MCCV Convulsions, purpura 
Encephalitis
Nephritic syndrome relapse 
Measles Acute respiratory tract infection, 
arthropod-borne, viral fever, 
gastroenteritis, pneumonia, tonsillitis 
Autism 
MMR Aseptic meningitis
Autism
Bacterial or viral infection 
Convulsion
Encephalitis 
Gait disturbance 
Purpura (including ITP)
Wheeze onset
Zinman et al. (2009)
Gwini et al (2011);
Smeeth et al. (2004)
Andrews et al. (2007)
Ward et al. (2007)
Taylor et al. (2007)
Ali et al. (2005)
Farrington et al. (2001); Taylor et al. (1999); 
Dourado et al. (2000); Miller et al. (2007); 
Farrington et al. (1995);
Andrews et al. (2002); Taylor et al. (1999); 
Farrington et al. (2001);
Miller et al. (2003); Stowe et al. (2009); 
Andrews et al. (2007); Miller et al. (2007); 
Farrington et al. (1995); Gold et al. (2010); 
Ward et al. (2007)
Miller et al. (2005)
Andrews et al. (2007);
Farrington et al. (1995);
France et al. (2008); Gold et al. (2010); 
Miller et al. (2001); Stowe et al. (2001); 
Mullooly et al. (2002)
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Table 3.1: Continued
OPV Intussusception Andrews et al (2001); Cameron et al (2006);
Sardinas et al (2001)
Wheeze onset Mullooly et al (2002)
Pneumococcal Bells palsy Stowe et al (2006)
Cellulitis or abscess, UTI Burwen et al (2006)
GuillainBarre’ syndrome Stowe et al (2008)
Myocardial infarction, stroke Smeeth et al (2004)
Rotavirus Intussusception Murphy et al (2001)
COPD, Chronic obstructive pulmonary disease; DT, diphtheria/tetanus vaccine;
DTaP, diphtheria/tetanus/acellular pertussis vaccine; DTP, diphtheria/tetanus/ 
pertussis vaccine; HBV hepatitis B virus vaccine; Hib, Haemophilus influenzae type 
b vaccine; IPV, inactivated poliovirus vaccine; ITP, idiopathic thrombocytopenic 
purpura; MCCV, meningococcal group C conjugate vaccine; MMR, measles/mumps/ 
rubella vaccine; OPV, oral poliovirus vaccine; Td, tetanus/diphtheria booster vaccine;
UTI, urinary tract infection.
In 22 studies, vaccines were given in multiple doses; in 12 of these, dose-specific effects 
were investigated. The SCCS method can only cope with a single outcome variable at 
a time. The most frequently studied events were convulsion (including febrile convul­
sion and aseptic meningitis) and purpura (six studies each). There were four studies of 
intussusception, and three each of autism and GBS.
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D ata Description and D ata Accuracy
All the 84 studies were felt to provide sufficient detail of how the data were collected, 
so that it would be possible to see any dependence between ascertainment of cases and 
vaccination history. Out of the 40 studies in period 1995-2010, 16 obtained data on vac­
cinations and outcomes from a single database [of these, seven studies used the United 
Kingdom’s General Practice Research Database (GPRD) and six the United States’ Vac­
cine Safety Datalink], 14 linked two or more databases, and in 10 data were obtained from 
other sources.
Case-note reviews were undertaken in 18 studies, and in two of these the review was 
commendably reported as blinded to vaccine history. In one study (Andrews et a l , 2007), 
case notes were used to identify vaccinations. This may bias results towards a positive 
association, in as much as vaccinations prior to the event are more likely to be ascer­
tained by case-note review than vaccinations after the event. However, in this study the 
association was not significant, and so the ascertainment procedure in this instance leant 
further weight, to the conclusions reached. Most studies had full information on the day of 
vaccination and the day of event (studies Farrington et al (2001) and Taylor et al (1999) 
used month as the time unit for analysis, but with long risk periods). In Burwen et al
(2006) and Dourado et al (2000), dates of vaccination were imputed rather than observed
\
exactly. The sensitivity to imputation errors depends on the lengths of the risk periods 
used, and it would be advisable to study this by sensitivity analyses, although none were 
reported. In Andrews et al (2010), vaccination dates were known exactly, but the types 
of vaccines used at different times were derived indirectly.
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Observation Periods and Risk Periods
A well-conducted SCCS study requires great rigour in the definition of observation 
periods and risk periods for each case. In all 84 studies, observation periods were defined 
with sufficient detail to reconstruct the study. The idiosyncrasies of specific databases 
need to be allowed for appropriately in defining observation periods. Thus, some studies 
excluded day of vaccination (or allocated it a special parameter) owing to the fact that, in 
some information systems, past events are retrospectively recorded on day of vaccination; 
left uncorrected, this would induce spurious associations on the day of vaccination. This 
effect is illustrated graphically in marked fashion in Tata et al. (2003). In one study in 
the GPRD (Andrews et al., 2010), events on the day of vaccination were validated by 
case-note review.
The choice of risk periods should be made a priori and its rationale explained. The risk 
periods were explicitly defined in all 84 studies. Typically, the choice of the risk periods is 
based on reference to previous studies or hypotheses, as in France et al. (2008) for example; 
on biologically plausible mechanisms (Farrington et al, 1995); or by expert opinion (Miller 
et al., 2005). Different risk periods may sometimes reflect different scientific questions. For 
example, in Farrington et al. (1995), the 6- to 11-day risk period post-MMR was chosen 
to capture febrile convulsions associated with the measles component of the vaccine, while 
the 15- to 35-day risk period was chosen to capture convulsions associated with the mumps 
component. Inevitably, in some circumstances the risk period is not known, and so the 
choice is arbitrary; if so this should be stated (Farrington et al, 2001). Three studies: 
Farrington et al. (2001); Hocine et al. (2007); Kramarz et al. (2001) used indefinite post 
vaccination risk periods. In several studies (e.g. Juurlink et al. (2006)) a sensitivity
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analysis was undertaken by varying the risk period. A further approach is to use several 
adjacent risk periods in the same analysis. For example, to investigate seizures and 
acellular pertussis vaccines, study Huang et al (2010) used the risk periods 0 days (i.e. 
the day of vaccination) and 1-3 days after vaccination. When results are similar across 
risk periods, or when data are lacking, contiguous risk periods can be combined. When 
a relatively long risk period is used, it is advisable to undertake secondary analyses to 
identify clustering or otherwise of cases within that risk period. Examples include Miller 
et al. (2001), where a clustering of ITP cases was found 15-28 days post vaccination 
within the 42-day risk period studied, and Farrington et al (2001), where no clustering of 
autism cases was found in adjacent 2-year intervals within the unlimited post-MMR risk 
period studied.
Confounders
SCCS studies adjust automatically for time-invariant multiplicative confounders. How­
ever, effect modification by fixed covariates can be investigated through interactions with 
the vaccine effect : for example in Gwini et al (2011) such effects were investigated, for 
sex and age at start of observation. The SCCS method, in common with other epidemio­
logical methods, is prone to bias from uncontrolled age- or time-varying confounders. In 
vaccine studies, particularly those undertaken in children, age (or in some cases season, 
or both) is likely to be the major confounder, and should, as a rule, be adjusted for in the 
analysis, unless observation periods are extremely short. Seven studies from 1995-2010 
did not report using any kind of temporal adjustment; in four of these, the observation 
period was less than a year. Of the remaining 33 studies, 19 adjusted for age only, three 
for season only, one for calendar time only, six for age and season, one for age and calendar
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time, and two for age, season and calendar time (e.g. Huang et al (2010)).
Only one study (Hocine et al., 2007) used the semi-parametric model (Farrington 
and Whitaker, 2006), in which it is not necessary to specify age classes. If a standard 
method of age adjustment is used, it is good practice to check that the age model used is 
adequate, by varying the number of age classes used. Two studies reported such sensitivity 
analyses (Hocine et al., 2007; Smeeth et al., 2004). One study (Hughes et al., 2006) 
controlled the time-varying confounding variable age as a continuous covariate and one 
study Mullooly et al (2011) used linear and quadratic functions, although no details of 
how these were achieved were given; such a method of control is not straightforward owing 
to the conditioning (see Chapters 5 and 7 on how age can be controlled as a continuous 
variable). Carlin et al (2013), used fractional polynomials to control for age in addition 
to the standard method.
Control for age-varying or time-varying confounders other than age or season require 
the confounder to be measured over time. For example, in an analysis of influenza vac­
cine and GBS (Stowe et al, 2008), the authors controlled for the possible confounding 
effect of influenza-like illness. However, it is often impractical to measure time-varying 
confounders. For example, the healthy vaccine effect is a form of confounding by an un­
measured time-varying factor. This affects SCCS studies as well as other study designs. 
The potential impact of such bias therefore requires careful discussion.
Discussion of Potential Biases
The three key assumptions of the SCCS method listed in Section 2.1.1 of Chapter 2 
should be checked, as far as possible, and discussed. We consider these three assumptions 
in turn.
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Assumption (1) : that the events are either recurrent and independent within in­
dividuals, or non-recurrent and uncommon, is not usually problematic. For recurrent 
events, sensitivity to the independence assumption can readily be tested by restricting 
the analysis to first events, provided these are uncommon in the population considered; 
see Farrington and Whitaker (2006); Whitaker et al. (2006) for an example with MMR 
and ITP. More complex approaches to correcting for non-independence of recurrent events 
are discussed in Farrington and Hocine (2010). Simulation studies in Farrington et al 
(2011) show that the bias is negligible when the risk that an unvaccinated individual will 
experience an event over the observation period is under 10%. Most adverse events of 
interest in post-licensure studies are much less common than this.
Assumption (2) : that the event should not affect the subsequent probability of vac­
cination, is perhaps the most important for vaccine studies. This assumption fails if the 
event is a contra-indication for vaccination (as with intussusception and rotavirus vacci­
nation since the publication of Murphy et al (2001)), or if vaccination after the event is 
more or less likely (as with GBS and influenza vaccination). A third possibility is that 
vaccination is deferred after (or more rarely, precipitated by) an event, so that the impact 
of the event on vaccination is short-lived. Nevertheless, an important feature of such 
biases is that their direction is predictable: if the event reduces the probability of subse­
quent vaccination, then the relative incidence associated with vaccination will be biased 
upwards. This is because vaccinations are then less likely to arise after the event. There 
are three main ways of coping with such bias: including pre-vaccination risk periods 
to allow for short-term deferral of vaccination (or indeed to investigate the presence of 
longer term effects); exclusion of all pre-vaccination time (so that the observation period 
begins with vaccination), which works provided the vaccine can only be given at most
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once during the projected observation period; and the use of more complex analytic tech­
niques (Farrington et al., 2009). Of the studies reviewed, 16 used pre-vaccination risk 
periods (see, e.g. Andrews et al (2001) and Sardinas et al. (2001)), and three (Juurlink 
et a l , 2006; Smeeth et al, 2004; Zinman et al, 2009) started observation at vaccination for 
some analyses. An extended version of the SCCS method (Farrington et al, 2009), that 
allows censored, perturbed or curtailed post-event exposures was applied to investigate 
the association between Guillain Barre’ Syndrome and influenza vaccines by three studies 
Dodd et al (2013); Galeotti et al (2013) and Romio et al (2014). Traversa et al (2011) 
used the extended method to investigate if sudden unexpected deaths were associated to 
vaccinations during the first two years of life.
Assumption (3) : that the observation periods are not event-dependent, may be vio­
lated, for example, if events increase short-term mortality, or the event of interest is death. 
This was not an issue in any of the 84 studies reviewed. SCCS methods for dealing with 
such situations are discussed in Farrington et al (2011, 2009); Kuhnert et al (2011).
Comparisons W ith Other Statistical M ethods
In addition to implementing the SCCS method, more than 12 studies used or reported 
results obtained on the same data using other study designs. These included cohort, case- 
control, and ecological methods. The different methods should produce the same results, 
provided that all confounding has been controlled and that the assumptions required are 
met.
Using several methods of analysis is recommended, as it can reinforce conclusions 
or shed light on possible sources of bias, when these differ for different study designs. 
Table 3.2 presents the results obtained using SCCS and other methods, for a selection of
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analyses.
Table 3.2: Selected relative incidence (RI) estimates from self-controlled case series method 
and RI or odds ratio (OR) from other study designs applied to the same case data, and 95% 
confidence interval (Cl)
Vaccine (adverse effect) SCCS Other study
(reference) RI (95% Cl) type RI or OR (95% Cl)
MMR (aseptic meningitis) 30.4(11.5-80.8) Before/after 14.3(7.9-25.7
(Dourado et al., 2000) ecological analysis
MMR (ITP) 5.38(2.72-10.62) Cohort 3.94(2.01-7.69)
(France et al, 2008)
Influenza (gastritis/duodenitis) 4.54(1.90-10.86) Case crossover* 4.33(1.23-15.21)
(Hambidge et al, 2006)
HBV (first demyelination) 1.68(0.77-3.68) Case-control 1.8(0.7-4.6)
(Hocine et al, 2007)
DTaP (seizure) 0.91(0.75-1.10) Cohort 0.87(0.72-1.05)
(Huang et al, 2010)
Influenza (asthma exacerbation) 0.98(0.76-1.27) Cohort 1.39(1.08-1.77)
(Kramarz et al, 2000)
Influenza (asthma exacerbation) 0.65(0.52-0.80) Cohort 1.4(1.2-1.5)
(Kramarz et al, 2001)
HBV (wheezing onset) 0.41(0.24-0.70) Case-control 0.59(0.22-1.59)
(Mullooly et al, 2002)
Oral rotavirus (intussusception) 29.4(16.1-53.6) Case-control 21.7(9.6-48.9)
(Murphy et al, 2001)
Intranasal flu vaccine (Bells palsy) 35.6(14.1-89.8) Case-control 84.0(20.1-351.9)
(Mutsch et al, 2004)
Concurrent vaccines (hospitalization) Identical Cox regression 0.90(0.75-1.09)
(Payne et al, 2007)
MCCV (nephritic syndrome relapse) 0.95(0.61-1.47) Before/after 1.05(0.95-1.15)
(Taylor et al, 2007) ecological analysis
For abbreviations refer Table 3.1 note.
* This description is incorrect : it is actually another SCCS (see text).
The results obtained using SCCS were broadly similar to those obtained by other
C h a p t e r  3 . R e v ie w  o f  S C C S  V a c c in e  S t u d ie s 44
methods, with the exception of studies of influenza vaccine and asthma exacerbation 
(Kramarz et al., 2000, 2001) where the SCCS method found a protective or null effect, 
but a cohort analysis found a positive association. The most likely explanation for this 
discrepancy is residual indication bias in the cohort study, children with more severe 
asthma being more likely to receive influenza vaccine. In the cohort study, underlying 
asthma severity was quantified using available proxy variables; self-control in the SCCS 
study was arguably more effective in correcting for indication bias. More generally, the 
results of a SCCS study should be unaffected by unmeasured or incompletely controlled 
confounders, and in this sense ought to be more reliable, provided that the assumptions 
of the method are satisfied.
In a study of hepatitis B vaccine (HBV) and wheezing onset (Mullooly et a l , 2002), 
the point estimates from SCCS and a case-control study were of the same order, but 
the greater precision of the SCCS method in this case produced a statistically significant 
effect. The better precision of the SCCS method was also noted in another study of HBV 
(Hocine et al, 2007), where it was pointed out that some cases cannot be used in matched 
case-control studies owing to lack of matching controls ; the SCCS method does not suffer 
from this problem. In one study (Hambidge et al, 2006) the alternative method was 
incorrectly described as a case-crossover design, when in fact it was another SCCS with 
a before and after vaccination observation period. The distinction between SCCS and 
case-crossover methods (Delaney and Suissa, 2009) stems from the fact that, as described 
above, SCCS studies are based on cohort designs, whereas case-crossover studies are based 
on case-control designs. The use of case-crossover methods for vaccine safety studies is 
discussed briefly in Farrington (2004).
The SCCS method is never exactly as powerful (and therefore, does not yield as precise
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estimates) as a cohort study with the same cases, unless, as often occurs in practice, 
there is unexplained between individual variation in the cohort study which inflates the 
uncertainty. However, when risk periods are short relative to observation periods, the 
power of the SCCS method approaches that of a cohort study. However, SCCS studies 
with long or indefinite risk periods (Farrington et al., 2001) may have substantially lower 
power than a cohort study with the same cases (see the discussion of Farrington and 
Whitaker (2006)). A SCCS study is usually more powerful than a case-control study 
with the same cases and with a single control per case (Farrington et al., 1996). (As the 
number of controls increases, the power of the case-control study increases.)
M ethodological Issues
An unusual feature of the SCCS method is that post-event time is included in the 
analysis. This is a consequence of the fact that the method works by conditioning, for each 
individual, on that person’s vaccination history over the entire observation period, and on 
the number of events arising within that period. It follows that observation time should 
not be censored at the event. One study (Hughes et al., 2006) did censor observation 
at the event, in this instance GBS, ostensibly because patients who have had GBS may 
be advised not to have further immunizations. If GBS patients are less likely to receive 
immunizations after experiencing the adverse event then, as noted above, a standard SCCS 
analysis would have resulted in an overestimate of the relative incidence. Censoring at 
event, however, produces bias of unpredictable direction, and is not recommended.
Several studies of potentially recurrent events, such as convulsions (Huang et al., 2010), 
ITP (Miller et al., 2001) or GBS (Stowe et al., 2008), considered repeat events to be part 
of the same episode if separated by less than some minimum time period r. This presents
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the methodological problem that, after an event, no other event can then occur for a time 
interval r: an instance of immortal time, which, if included in the analysis, may result 
in bias (Suissa, 2007). Generally r  is short and repeat events are relatively uncommon, 
so any such bias is likely to be small. A simple approach is to perform a sensitivity 
analysis restricted to first events, which also sidesteps the requirement for repeat episodes 
to be independent. One interesting study (France et al., 2008) excluded person-time for a 
period r  after each episode; however, the performance of such a strategy requires further 
investigation.
Several SCCS studies defined observation periods relative to the day of vaccination, 
either starting with vaccination and ending a fixed number of days after vaccination 
(Juurlink et a l , 2006; Zinman et a l , 2009), or starting and ending some fixed number 
of days before and after vaccination (Ali et al., 2005; Burwen et al, 2006); we refer to 
such studies as before and after designs. For some studies this was done for convenience 
of data collection. While not invalid, this approach results in short observation periods, 
which is not optimal, as information from events occurring at other times is not used. In 
addition, the short control periods may only include time when the risk of temporal bias 
is high. For example, bias from delayed vaccination following an event may artificially 
depress the incidence in the period immediately preceding vaccination. This effect is very 
apparent on the plots of intervals between vaccination and events in Burwen et al (2006), 
which shows a marked trough of hospitalizations in the week preceding vaccination (this 
week was, rightly, excluded from the analysis).
As explained in Section 2.1.1 of Chapter 2, the SCCS method is derived from a cohort 
model by conditioning on the number of events observed, as well as on vaccination history. 
Thus, a conditional (Poisson) model is used to estimate the parameters. Fewer than half
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of the 40 studies in 1995-2010 indicated that a conditional Poisson regression model was 
used, either explicitly (e.g. (France et al, 2008; Gwini et al, 2011; Hambidge et al, 
2006)) or with words to that effect (as in Gold et al (2010); Zinman et al (2009)). In a 
few studies it was unclear whether a conditional or unconditional model was fitted (e.g. 
(Payne et al, 2007)). The only circumstance in which an unconditional Poisson model 
(i.e. one in which the number of events per individual is not regarded as fixed) may be 
used in a SCCS analysis is when all individuals have identical observation periods and 
vaccination histories. In this special case, the conditional and unconditional methods give 
the same results. In two further instances, the method of analysis appeared somewhat 
idiosyncratic (Burwen et al, 2006; Hughes et al, 2006).
Useful P lots
Several studies (e.g. Dourado et al (2000); Stowe et al (2009); Tata et al (2003)) 
included plots showing the intervals between events and vaccination; these are useful for 
visualizing the association between exposure and event (although they are also prone to 
censoring effects), and for identifying pre-vaccination troughs. Such plots are trickier 
to draw for multi-dose vaccines, but are useful nonetheless (Murphy et al, 2001). Other 
studies (e.g. France et al (2008); Naleway et al (2009)) illustrated the case ascertainment 
procedure using a flow diagram, which presents clearly the inclusions and exclusions 
applied to assemble the cases, and hence can help the reader assess any biases that may 
have arisen in the process. Further useful plots include those illustrating the risk periods 
used (Gwini et al, 2011; Smeeth et al, 2004), those showing estimated age or season 
effects (Hocine et al, 2007) and, for complex analyses with many endpoints, graphical 
representation of the relative incidences (Andrews et al, 2010).
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Power and Sample Size Issues
In studies involving very uncommon events, power and sample size considerations are 
particularly important (Musonda et al, 2006). One study (Gwini et al., 2011) reported 
checking the sample size required to achieve 90% power to detect at least a doubling of 
risk. The relevant sample size is the number of events, and if this is too small the estimates 
and confidence intervals may not be accurate. To aid interpretation, it is important to 
report the numbers of events in risk and control periods. The larger the imbalance in the 
expected numbers of events in the risk and control periods, the worse the small sample 
bias. This is most likely to affect studies with very short risk periods. Simulation studies 
reported in Musonda et al. (2008a) suggest that the small sample bias is likely to be small 
provided at least 2.5 events are expected in the risk period. Note also that a small sample 
size may adversely affect the ability to control effectively for the effect of age and other 
time-varying confounders.
Sensitivity Analyses
Sensitivity analyses have been mentioned throughout this chapter. They provide a 
simple way of evaluating the robustness of the results; we focus here on where they may 
be used (other useful sensitivity analyses than those described here can doubtless be 
performed).
When the SCCS model is used with parametric adjustment for age we recommend 
checking the sensitivity of exposure risk estimates to choice of age group, by increasing 
the number of age groups (Hocine et al, 2007; Smeeth et al, 2004).
Sensitivity analyses of risk periods should be motivated explicitly (as in Juurlink et al. 
(2006)). Researchers may also wish to consider whether it would be sensible to explore
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sensitivity of results by adding washout periods to the chosen risk period, removing the 
day of vaccination or including pre-vaccination risk periods.
If recurrent adverse events occur in episodes, and there is a lack of clarity over whether 
repeat events are part of the same episode, sensitivity to the choice of definition of episodes 
can be checked. Note that analyses of first events only can be carried out to avoid any 
issue of lack of independence between adverse events.
If exact dates or timings of exposures or events are unknown and have to be imputed, 
sensitivity to how these timings are imputed should be explored.
When sensitivity analyses are performed, they should be reported, with full details 
when they relate to risk periods, washout periods and pre-vaccination periods. It is im­
portant to distinguish between them and the pre-planned primary analyses. If sensitivity 
analyses suggest possible departures from the assumptions of the method, this should be 
stated explicitly. If it is thought that departure from assumptions might affect the results, 
then, where possible, alternative methods of analysis should be used in conjunction with 
SCCS.
Software for SCCS Analyses
Twelve of the studies that appeared in 1995-2010 reported which statistical package 
was used to undertake the SCCS analysis. Six used Stata (StataCorp, USA), five used 
SAS (SAS Institute Inc.,US A) and one used GLIM (NAG, UK). Further information about 
fitting SCCS models using these packages and other standard softwares may be found in 
Whitaker et al (2006) and on the associated website (http://statistics.open.ac.uk/sccs).
The SCCS model is most conveniently fitted using software designed for Poisson re­
gression models with fixed effects (in this case, the levels of the fixed effects represent
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distinct individuals). This method of fitting the models exploits a convenient technical 
fact known as the ’Poisson trick’, whereby a multinomial likelihood (which applies for the 
SCCS method, see Farrington (1995); Farrington and Whitaker (2006)) can be maximised 
using a Poisson model. However, this trick has its limits : for example, fitting age as a 
continuous variable cannot be done in this way, because it does not allow for the fact that 
age varies within each risk or control interval, see Chapters 5 and 7 on how to control for 
age as a continuous variable.
3.3 Discussion
Review of vaccine studies that made use of the SCCS method from 1995 to the be­
ginning of 2014 was done in this chapter. The review was based on papers quoting key 
papers on the case-series method. We are aware of several independent reinventions of 
the SCCS method in different contexts : the bidirectional case-crossover method applied 
to fixed observation times (Navidi, 1998) and the time-stratified case-crossover approach 
(Lumley and Levy, 2000), developed for the analysis of environmental time-series data 
(see Vines and Farrington (2001); Whitaker et al. (2007), for a discussion of the connec­
tions with the SCCS method), and the method of Becker et al. (2004) applied to venous 
thromboembolism after long-haul flights. None of these versions of SCCS have so far 
been used in connection with vaccine safety. Thus, to the best of our knowledge, we have 
included all applications of SCCS methodology to vaccine studies that appeared by the 
beginning of 2014.
We identified and reviewed 84 papers which applied the SCCS method to vaccine stud­
ies. In general the method was applied appropriately. All 84 studies provided sufficient 
detail of how their data were collected, which enabled the reader to make sure that events
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are identified independently of vaccinations. Moreover, observation and risk periods were 
generally carefully specified. Most studies adjusted for age and/or season as appropriate.
The following key issues emerge when using the SCCS method. Ascertainment of cases 
and collection of data on exposure history should be independent, as bias may result if 
case ascertainment was influenced by knowledge of exposure status. The observation and 
risk periods should be clearly defined, and the choice of risk period should be justified. 
Where necessary, age and season effects should be allowed for, and when using the stan­
dard model, sensitivity to the choice of age and seasonal groups should be checked. Other 
relevant time-varying covariates (such as concurrent vaccinations and other exposures) 
which may be associated with both the exposure and outcome should be identified and, 
if possible, taken into account in the analysis. The validity of the assumptions required 
by the SCCS method should be carefully considered and appropriate supplementary sen­
sitivity analyses undertaken where these come into question.
A few papers suggest there remains a degree of confusion about what a SCCS study 
entails, in particular how it differs from a before and after vaccination analysis or from the 
case-crossover paradigm. This is wholly unsurprising, owing to the somewhat abstruse and 
technical, yet fundamental, distinction between conditional and unconditional analyses. 
In recent methodological paper Glanz et al. (2006) a before and after design is described, 
described as a risk interval method, which is in fact a special case of a SCCS design. 
The term case centred has also been used to describe such designs (Klein et al., 2010). 
We excluded two papers France et al. (2004); Klein et al (2010) with before and after 
analyses from our review because they did not describe the design as SCCS; several before 
and after analyses that did were included in the review. In fact, all these studies are 
special cases of the SCCS design. Nevertheless, the picture that emerges is dominated by
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the numerous impressive and often imaginative applications of the method.
This review has raised some further methodological issues worthy of further study. One 
such is how best to handle the immortal time after an event, during which recurrences are 
classified as part of the same episode, and whether ignoring this effect has any substantive 
bearing on the results. Another is to study and quantify the bias that results from 
censoring observation periods at events. Sensitivity analyses may be indicated in both 
circumstances. Further, while the SCCS method is only applicable with a single outcome 
variable at a time, it may be desirable to study several outcomes jointly. A bivariate SCCS 
method has been suggested for the analysis of antibiotic resistance (Hocine et al, 2009); 
perhaps similar ideas can be used for a multivariate SCCS applied to vaccine safety, in 
which several possibly dependent outcomes could be studied at the same time.
SCCS is a relatively new statistical methodology, and the issues that require partic­
ular emphasis and care in reporting have, therefore, only become apparent over time. 
The development of suitable guidelines for reporting such studies, in vaccine safety and 
pharmacoepidemiology more widely, may perhaps now be indicated.
All but two studies applied the standard SCCS method where the age and exposure 
effects are represented by piecewise constant step functions. However, the standard SCCS 
method has a limitation that misspecification of age groups might result biased estimates 
as presented in section 2.3 of Chapter 2 and only few of the reviewed studies did sensitivity 
analysis. Therefore, it worth modelling the age and exposure related relative incidence 
functions by smooth functions that avoid the limitations of the standard SCCS methods. 
In the next chapter we present some of the possible smooth function which could be used 
in the SCCS context.
Chapter 4
Basic Concepts of Sm ooth Functions
The standard self-controlled case series method, as described in Chapter 2, uses step 
functions to model the effects of age and exposure. Alternative ways of modelling, that 
avoid the use of step functions in general and their limitations in the SCCS method in 
particular, are presented in this chapter. In Section 4.1 we introduce polynomial functions 
followed by fractional polynomials in Section 4.2. Then we describe spline functions based 
on truncated power functions, B-splines, M-splines and I-splines in Section 4.3 followed 
by a discussion in Section 4.4
4.1 Polynomial Functions
The simplest way of replacing a step function with a smooth function is to use a 
polynomial of degree higher than zero. Polynomial function f( t)  can be constructed 
as a linear combination of functions, f( t)  = ]T)aihi(t), where hi(t) are known as basis 
functions.
For example the basis functions of a straight line model, /(£), are h0{t) = 1 and 
hi(t) =  t, where t is the variable of interest. Then f( t)  is expressed as a weighted sum of
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the basis functions, i.e
= S  = Qo +  Qfi t.
1=0
For this linear function the design matrix is:
T  =
where ti, t2, . . . ,  tn are the observations on t and n is the number of observations. These 
basis functions are graphically shown on the top row in panel a of Figure 4.1. On the top 
panels of the figure, the basis functions are denoted by solid lines and the corresponding 
curves fitted using these basis functions are presented on the bottom panels as dashed 
lines. The 100 data points denoted by circles were simulated from a normal distribution 
with a mean of sin(t) +  2 and a standard deviation of 0.5 and the solid line in the bottom 
panel shows the true curve. The domain of t ranges from 0 to 8.
To increase the flexibility of a polynomial function, that is to achieve a more flexible 
approximation of f(t), we can increase the order of the polynomial function by adding 
more basis functions. For example, for a quadratic model, the basis functions are h0{t) = 
1, hi(t) — t, and h2(t) = t2 and in general for a degree p polynomial model the basis 
functions are
h0(t) = 1, hx{t) = t, h2(t) = t2, h3(t) = t 3, . . . ,  hp(t) = tp
with a design matrix of
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T
1 t t 2x bn  bn
Then
t l
where the coefficients a 0, « i, a 2 . . . ,  determine the shape of the function /(£).
(c) D eg ree  3 po ly n o m ia l(b) D eg ree  2 p o lynom ia l(a) D eg ree  1 po ly n o m ia l
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Figure 4.1: Basis functions and fitted regression curves to 100 data points simulated from a 
normal distribution with mean sin{t) +  2 and standard deviation 0.5. Panels (a) represent a 
degree 1 polynomial, panels (b) a quadratic and panels (c) a cubic polynomial. The top row 
shows basis functions and the bottom row shows the fitted and true polynomial functions. In all 
the panels, data points are represented by circles, the true function is denoted by a solid line, 
the dashed lines denote the fitted polynomial curves
Basis functions for quadratic and cubic regression curves are presented in Figure 4.1
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on the top row of panels b and c respectively and their corresponding fitted curves are 
shown on the bottom row.
According to Ramsay and Silverman (1997), a good basis function should be chosen 
such that estimation of the coefficients cq and computation of the basis functions is fast, 
they are flexible enough to exhibit the required curvature where needed and of course, 
nearly linear when appropriate. They should be differentiable as required i.e one or more 
of the derivatives of the approximation made based on the basis functions should behave 
reasonably. And the other property taken into consideration to make a choice among 
the basis functions is that they allow one to do constrained modelling when required, for 
example by satisfying monotonicity, positivity conditions etc.
4.2 Fractional Polynomials
Polynomial regression, although a popular technique, has limitations in the fact that 
individual observations can exert an influence in unexpected ways on remote parts of the 
curve (Green and Silverman, 1994). Low order models such as quadratics lack flexibility, 
and higher order fitted curves have a propensity to produce artefacts, such as waviness 
and end-effects (Royston and Altman, 1997).
To address these limitations a family of fractional polynomials was introduced by 
Royston and Altman (1994) as generalizations of the conventional polynomial class of 
functions by considering not only positive integer powers, but also negative and fractional 
powers. A fractional polynomial of degree m  is defined as
m
f(t) =
1=0
C h a p t e r  4 . B a sic  C o n c e p t s  o f  S m o o t h  F u n c t io n s 57
where m  is a positive integer, and Hi(t) is given by
I tpi, if Pi 7^  Pi-i
m  = \
[ Ht- i  (;t) x log(£), if pi =  pi-1 
with Pi <  P2 < • • • ^  Pm a sequence of powers and p0 = 0. H0 = 1, if pi = 0 then 
Hi(t) = tPl is taken, by definition, to be Hi(t) = logt. Allowing non integer powers in 
fractional polynomials increases their flexibility even in lower order models and they fit 
better at extreme values of the observed range of covariates unlike conventional polynomi­
als. Royston and Altman (1994) argued that, in practice, fractional polynomials of degree
higher than 2 are rarely needed and suggested choosing the values of powers from a set
of numbers between -2 and 3, i.e {—2, —1, —0.5,0,0.5,1,2,..., max(3, m)}. For fractional 
polynomial models with m > 1, e.g m = 2 if p2 = p\ the models do not degenerate to 
models with fewer powers (Royston and Altman, 1997). That is ao +  a\Hi(t) +  a2H2(t) 
are not of the same degree as ao +  OL\Hi(t) if p2 = p\. The model has three parameters 
(degree 2)
a 0 +  a i tpl +  a2tpi logt.
To choose the best powers p\ and p2, when m = 2, fractional polynomial models with 
each possible pair of p\ and p2 are fitted and deviance values are computed. A model that 
gives the smallest deviance is chosen as the best model.
The basis functions for a function, f ( t ), approximated by a fractional polynomial 
model with m = 2 are:
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h0(t) = 1, hi(t) = tpi,h2(t) = tP2 if 0 ^  pi < p2 ±  0
ho(t) — 1, hi(t) = tPl,h2(t) = tPl logt H 0 7Lp1 = p 2 ^ 0
h0(t) = 1, hi(t) = logt,h2(t) = tP2 i f Pl = 0
h0(t) = 1, hi (t) = tpi, h2(t) =  log t Hp2 = 0
h0(t) =  1, hi(t) = logt, h2(t) = (logt)2 i f P l = p 2 = Q 
Fractional polynomials provide a much wider range of shapes for curves than allowed
by standard polynomials, including curves with asymptotes. However, they are still global
functions.
4.3 Spline Functions
Among the limitations of polynomial functions and fractional polynomials is their 
global nature. Tweaking the coefficients to achieve a functional form in one region can 
cause the function to have a bad fit in remote regions (Hastie et al., 2001). These problems 
can be addressed by using non parametric smoothing methods. One alternative to avoid 
the limitations of polynomial functions is by using splines, that is representing the function 
as a combination of local polynomials. Splines are functions constructed by combining 
pieces of polynomials. In this section we describe a piecewise polynomial representation 
of a function using truncated power basis functions, B-splines and M-splines.
4.3.1 Truncated Power Basis
A piecewise polynomial function f (t)  can be constructed by dividing the domain of t, 
say [a, 6], into intervals and fitting separate polynomial curves in each interval. The points 
that divide the intervals are known as knots. The function f (t)  is obtained by imposing 
continuity and differentiability on the piecewise polynomials up to a certain order at the
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knots, where two adjacent segments join. For example, if the domain of t is divided by- 
two inner knots k\ and k2, and three linear functions are fitted representing f (t)  on the 
three different intervals, then the function f ( t)  is constructed based on six basis functions 
and hence six parameters, two for each degree 1 function. The basis functions are
h0(t) = I(t < &i).l, hi(t) = I(t < ki).t,
h2(t) =  I  (hi < t <  k2). 1, h3(t) = I(ki  < t < k2).t, •
h4(t) = I(k2 < t). 1, h5(t) = I(k2 < t).t
Therefore, f(t) = that s^5
Q!o +  t, i f t < k i
f (t) =  ^ a2 +  a3t , if k\ < t < k2
ot/± +  a5t, if k2 < t
Let us now consider the data simulated in Section 4.1 and estimate the true function, 
f ( t) = sin(t) +  2, using a piecewise linear function. Let the domain of t be divided into 
three intervals at knots k\ =  2 and k2 = 6. The fitted curve denoted by dashed lines is 
shown in Figure 4.2, the solid line represents the true curve. The fitted curve has three 
pieces of degree 1 polynomials. In the figure, it can be seen that the estimated function is 
discontinuous at the knots. However, since the true function is continuous throughout the 
domain we want the estimated function to be continuous as well. Therefore, a constraint 
is imposed on the parameters such that the function is continuous at the knots. Each 
of the fitted pieces of polynomials is constrained to be equal to a polynomial in the 
next interval at the knot which connects them. In the example, the constraint means 
f ( k i )  — f i ^ i )  and f ( k 2 ) =  f ( k 2 ). This implies that a0 +  a^ki = a 2 +  a 3ki and 
ol2 +  a3k2 = a?4 +  a3k2. These constraints reduce the number of parameters that define 
the piecewise linear function from 6 to 4 =  (3 intervals) x (2 parameters for each interval)
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- (2 knots) x (1 constraint per knot).
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Figure 4.2: Piecewise linear function fitted to a data simulated from a normal distribution with 
mean sin(t) + 2 and standard deviation 0.5. The fitted curve is discontinuous and is represented 
by the three dashed lines and the solid line is the true function. The data are divided into three 
intervals at knots 2 and 6
A piecewise polynomial function constrained to be continuous at the knots can be 
constructed by using truncated power functions as basis, which directly take the constraint 
into account. A truncated power function of degree p for a knot ki is defined as:
( t- fc i)+  =  ( t - U pW < )
The +  indicates the function takes a value 0 for t to the left of ki and (t —ki)p otherwise, 
th a t is
(t -  ki)p, if t  > ki
0, if t < k[
(t -  kt)p
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The truncated power functions are used together with polynomial basis functions to 
form a truncated power basis. For example to fit a piecewise linear model with two knots 
at ki and k2, the truncated power basis comprises h0(t) =  1, h\{t) =  t, the polynomial 
part, and truncated power functions of degree 1, h3(t) = (t — k i)+ and hA{t) = (t — k2)+. 
Then, the piecewise linear function is estimated as:
f ( t )  =  Oo +  Oi\ t +  a 2 (t — ki)+  +  Oi2,{t — k2)+.
This function, expressed as a linear combination of truncated power basis functions, is 
known as a spline function. From the basis functions it can be seen th a t if the param eters 
associated with the truncated power functions, a 2 and a 3, are both estim ated to be zero 
then the function f ( t )  reduces to a single polynomial function of degree one. Panel (a) 
of Figure 4.3 shows a piecewise linear function fitted to the simulated data  presented in 
Figure 4.2 and the corresponding truncated power basis functions are shown in panel (b).
(a) Piecewise linear function (b) Degree 1 truncated power basis
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Figure 4.3: Panel (a) piecewise linear spline function fitted to simulated data, Panel (b) Linear 
truncated power basis used to estimate the piecewise linear function
It can now clearly be seen from Figure 4.3 th a t the use of truncated power basis leads to
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a function which is continuous everywhere, linear everywhere except at the knots and has 
different slopes for each interval. The fitted linear spline curve in panel (a) of Figure 4.3 
denoted by the dashed lines has sharp corners at the knots. This shows th a t the function 
does not have a continuous first derivative at the knots. If a smoother function is required, 
higher order truncated power basis functions can be employed, which are straightforward 
to construct. For example, a piecewise cubic polynomial function (cubic spline) with two 
knots has a truncated power basis th a t includes the degree three polynomial basis and 
two degree three truncated power functions, namely
h0(t) = 1, hi(t) = t, h2(t) = t2, h3(t) = t3
and
K i t )  = ( t -  £ i)3+ , h5(t) =  (t -  k2) l
(a) Quadratic spline (b) Cubic spline
t t
Figure 4.4: Panel (a) piecewise quadratic spline function fitted to simulated data, Panel (b) 
cubic spline function. In both the panels the dashed lines represent fitted curves and the solid 
lines represent true curve used to simulate the data points denoted by circles
A cubic spline has continuous first and second derivatives at the knots. Quadratic and
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cubic splines fitted to the simulated data are shown on panels (a) and (b) of Figure 4.4 
respectively.
In general, piecewise polynomials of order q or degree p = q — 1 connected at knots 
ki ,k2,... ,ks have truncated power basis 1 , t ,  ..., tp, (t — ki)+, ..., (t — ks)^ _ and their linear 
combination gives a spline function which has continuous derivatives up to order q — 1 as 
follows:
s
f ( t ) =  Qfo +  ait +  ... +  QLptP +  'y  ^OLpi{t — kl) + .
1 = 1
This function has two parts, a global polynomial of degree p and truncated power 
functions of degree p related to the knots. The design matrix is
T  =
1 ti . . .  . . .  ( t ! - k s)p+
1 tn . . .  tp (tn - k . . .  (tn - k s)
4.3.2 B-splines
Truncated power basis functions have an advantage of simplicity to construct which 
makes them attractive for statistical work, they however have a rather serious disadvan­
tage of generating considerable rounding error (Ramsay, 1988). The numerical precision 
problem occurs because these functions have a rapid growth without bound as t increases, 
especially when the domain of t is wide. Moreover, as they are far from orthogonal they 
can suffer from numerical instability when there is a large number of knots (Ruppert 
et al, 2003). When computed at some value of t , many or even all of the truncated power 
basis functions can be non zero leading to a design matrix containing only a few zeros, 
which prevents the use of sparse matrix techniques to reduce computational time. These 
limitations of the truncated power basis functions can be avoided by using reasonably
C h a p t e r  4 . B a sic  C o n c e p t s  o f  S m o o t h  F u n c t io n s 64
well-conditioned and more stable equivalent basis functions known as B-splines.
B-splines are piecewise polynomial functions derived from truncated power functions 
and have more stable numerical properties. A B-spline of order q, q > 1, is a combi­
nation of polynomial functions of degree q — 1 connected at knots. They are defined as 
appropriately scaled divided differences of truncated power functions (de Boor, 1978).
Divided differences are mathematical tools having various applications in numerical 
analysis including polynomial interpolation and derivation of B-spline basis functions. 
Let t0, be distinct real numbers and let /(to), . . . ,  f ( t n) be the associated
function values. Then to find a polynomial function, p(x) =  a 0 +  <^ it H +  ocntn, that
interpolates the data, divided differences can be used. The nth order divided difference of 
a function /  is the leading coefficient of the polynomial function p(x) and is denoted by 
M i , . . . , tn]f- If is evaluated as:
fj. j. + i f    [^ lj 2^, • • • , tn]f [^ 0 5 ^lj • • • j tn—1 \ f[t0, &1, • • • , fnj/ — -----------------   7------------------
t'n CO
where
[tolf = f i t  o)
and so
H — Co
etc. Now, to derive B-spline basis functions using divided differences, let the truncated 
power function of order q centered at t be denoted by T^{k)
Tf{k) = ( t -  k )\~\
In the derivation of the B-splines, the truncated power function (t — k)q+ l of the two 
variables t and k is taken by fixing t and considering (t — k)q+ l as a function of k only 
(de Boor, 1978).
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Let the function to be approximated by a spline be defined in the interval [a, b] and 
ki =  k2 = • • • =  kq < kq+1 < • • • < kq+s < kq+s+i = kq+s+2 =  • • • =  k2q+s , be a non­
decreasing sequence of knots in [a, b], where kq — a and kq+s+1 = b. s is the number of 
interior knots, kq+1 < • • • < kq+s, which are within the domain [a, b] and to create the 
B-spline basis functions, the first and last q — 1 knots are arbitrarily added. Usually the 
extra knots at the beginning of the sequence are all taken to be equal to a and the ones 
at the end equal to b. But it is also possible to give them arbitrary values. Then, the 
Ith B-spline of order q at t for the given knot sequence denoted by Bi(t\q) is defined as 
an appropriately scaled qth order divided difference at ki, ^ +1, . . . ,  ki+q of the truncated 
power function T/(&) (de Boor, 1978), by the rule
B ^ q )  = (-1  Y(kl+q -  kt)[kh . . . ,  kl+q]T?{k)
for I = 1,2,..., m  and m = q + s is the number of B-spline basis functions, which is equal 
to the number of interior knots plus the order q. [ki, . . .  ,ki+q]T^(k) is the qth divided 
difference at &/,..., ki+q of Here ki+q > ki, if ki+q = ki then Bt(t\q) is defined to
be zero.
Each Bi(t\q) is positive over the interval ki < t  < ki+q and zero elsewhere, i.e it is non 
zero over q intervals in the domain of t, [a, b], and each interval has q positive B-splines.
The qth divided difference of the truncated power function, in the definition of B- 
splines, is multiplied by (ki+q — ki)(—l)q so that at a given value of t the sum of the q 
positive B-splines is equal to one, i.e X); Bi(t\q) = 1. Each Bi(t\q) consists of q polynomial 
pieces of degree q — 1 that are joined at q — 1 inner knots and whose derivatives up to 
order q — 2 are continuous at the joining points. The other property of B-splines is that 
the integral of each of Bi(t\q) between ki and ki+q is J^l+q Bi(t\q)dt = kl+<f~kl.
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As an example let us consider evaluating B-splines of order 2 (q = 2) for the data 
simulated in Section 4.1 where the values of t range from 0 to 8. Let the inner knots be 
2, 4 and 6, then the set of knots including the minimum and maximum values of t will 
be {0,2,4,6,8}. To create a B-spline we add an arbitrary extra q — 1 = 1 knots at the 
beginning and end of the set, which gives a total of 7 knots {0,0,2,4,6,8,8}. Then, for 
example, the 3rd B-spline B3(t\2) (I = 3) is
B3(t\2) = (—l)2(fc3+2 — k3)[k3, ki, k5]Tf(k) 
n. j„ A k4 ,h ]T ? (k ) -[h ,k4\T?(k)
= { h ~ h )  ( v ^ ) -----------
T?(h)  -  T f j h )  J f jk i )  -  Tt2(k3)
&5 — &4
(* -6 ) + - ( t - 4 ) + (t — 4)+ — (t — 2)+
6 - 4  4 - 2
For t < &3 =  2
B3m  =
For &;3 =  2 < £ < & 4  =  4
(0) -  (0) (0) -  (t -  2)Bs(t |2)
2 2 
t - 2
For £;4 =  4< £ < £ ;5  =  6
(0) -  (i -  4) (t _ 4 ) - ( t - 2 )
2
6 — f
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And for t > k5 = 6
f ls ( t |2) =  ( t - 6 ) - ( t - 4 ) _ ( * - 4 ) - ( « - 2 )
Since the number of inner knots is 3, and the order is 2 the total number of basis functions 
is 5 and the remaining B-spline functions, Bi(t\2), B 2(t\2), B 4( t |2), and B 4(t |2) can be 
obtained in a similar way.
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Figure 4.5: B-spline basis functions of order 2: Left panel one basis function which is a combi­
nation of two linear functions and the right panel all the five B-spline basis functions
Graphically, B 3{t12), is a triangular hat function with a value of zero outside the 
interval between 2 and 6 and is presented in the left panel of Figure 4.5. The right panel 
shows all the five basis functions, the vertical dotted lines are the values of t where the 
knots are located. The data used to plot these basis functions are those simulated in 
Section 4.1. The first and last basis functions are discontinuous at the minimum and 
maximum values of t because there are repeated knots at those locations. Order two
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spline function fitted from B-spline basis functions of order two is shown in Panel a of 
Figure 4.7.
B-spline basis functions of order 4 are known as cubic B-splines because they are 
linear combinations of degree 3 polynomials, and can be obtained as explained for order 
2 B-splines. Figure 4.6 shows cubic B-spline basis functions. The inner knots are at 2, 4, 
and 6 with minimum and maximum values of t at 0 and 8 respectively. The left panel of 
Figure 4.6 shows the fourth B-spline, it covers four intervals and each interval is a piece 
of a degree three polynomial. And the right panel shows all the seven basis functions. A 
spline function fitted from these basis functions is presented in panel b of Figure 4.7
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Figure 4.6: B-splines of order four: Left panel one basis function which is a combination of 
four cubic polynomial pieces and the right panel all the seven B-spline basis functions
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a. Order 2 spline function b. Cubic spline function
Figure 4.7: Spline functions fitted using B-spline basis functions. In panel a B-splines of order 
two are used and in panel b cubic B-splines
From the computational perspective B-splines can be obtained using recurrence re­
lations given by the Cox-de Boor algorithm (de Boor, 1978), instead of being obtained 
directly from the truncated power functions. They are computed from B-splines of lower 
order. It is simple to compute B-spline of any order since the B-spline of order one is 
constant between two knots. Computing B-splines from the truncated power functions 
directly may lead to the same problem as using a truncated power basis (de Boor, 1978). 
The recursion algorithm was developed on the basis of the Leibniz formula for the qth 
order divided difference of a product, which states that, if a function f { t)  = g{t)h{t) then
the qth order divided difference of f ( t )  a t ki+q is given by
l+q
{kh . . . , k i +q\ f  = r]g)([kr , . . . , k i +q]h)
r ~ l
The Leibniz formula is applied to the truncated power function T q(k) = (t — k)q+ l by first
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expressing it as a product two functions as
(t — k)q+ 1 =  (t — k)(t — k) +
which leads to the following expression for a B-spline of order q:
(kl+q-l-kl)-^1^ ^  kl+q-kl + lBl+l(t\Q 1)? kl < t < kl+qkl+q t
0, elsewhere,
with
Bt(t\ 1) =
1, ki < t  < kt+i
0, elsewhere.
Once the B-spline basis functions are computed, their linear combination gives the 
desired spline function. The design matrix, denoting Bi(t\q) as Bi(t) and m  representing 
the total number of B-spline basis functions (number of interior knots +  order of the 
spline), is:
■^i(^i) . . .  Bm(ti)
T  = : : : :
Bi(tn) B2(tn) . . .  Bm(tn)
Then the spline function is defined as
m
i=i
The design matrix from B-splines contains few non zero elements unlike the one obtained 
from the truncated power basis, because a given order q B-spline basis is non zero only 
in q intervals in the domain of t. This leads to efficient computation.
Figure 4.7 shows spline functions fitted, using B-spline basis functions of order two 
(Panel a) and order four (Panel b), to a data set of 100 data points simulated from a 
gaussian distribution with mean sin(t) +  2 and standard deviation of 0.5. The values of t
C h a p t e r  4 . B a sic  C o n c e p t s  o f  S m o o t h  F u n c t io n s 71
range from 0 to 8. The fitted curves are denoted by dashed lines, the solid lines represent 
the true curve and the circles represent the data points.
berg (1947). They use a different method of normalization from the B-splines discussed 
in the previous section. They are normalized such that J ^ M ^ q )  = 1. The M-splines, 
like B-splines, have the properties that:
1. Mt(t\q) = 0 outside h < t  < ki+q,
2. they are positive functions in the interval kt < t  < ki+q,
3. each M-spline of order q is a linear combination of q polynomial pieces of degree
cated power functions or using the recursion algorithm of de Boor (1978). Given a knot 
sequence kx =  k2 = • • • =  kq < kq+1 < • • • < kq+s < kq+s+1 = kq+s+2 =  • • • =  k2q+s, an 
M-spline of order q is defined as
4.3.3 M -splines
M-splines, which are variants of B-splines, were first introduced by Curry and Schoen-
q -  1
4. Mi(t\q) has q — 2 continuous derivatives at the knots,
5. M-splines are related to B-splines as, Mi(t\q) = ( ^ q^ )Bi(t\q).
Similar to B-splines, M-splines can be computed directly as a divided difference of trun-
g[(t-ki)Mi(t \g-l)+(ki+q- t )M i+ i(t \g-l)]  
(g-1 )(ki+q-ki) ki < t  < ki+q
0 elsewhere
V
with
elsewhere.
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The spline function can now be obtained as a linear combination of M-splines,
m
m  =  E
1=1
Since M-splines are positive functions, their linear combination, X X i can be
used to approximate a non-negative function by constraining their coefficients to be non­
negative, on > 0. Mi(t\q) is zero outside [ki, ki+q] and positive inside this interval, therefore 
any change in the coefficient oq has an effect only in the interval hence local sensitiv­
ity to coefficient changes. The integral of f{t) can be constrained to be equal to one, 
f a  aiMi(t\q) = 1, by setting the sum of the coefficients to be one, X X  i ai ~  1j since 
jki+q — i  jn addition, as only Mi and Mm are non zero at /(a ) and f(b) respec­
tively, f(a) = 0 or f(b) = 0 can be obtained by setting a i =  0 or am =  0 respectively 
(Ramsay, 1988). Since each Mi(t\q) is a piecewise polynomial, linearity, differentiability 
and integrability properties of polynomials carryover to the spline function.
Cubic M-splines of order four with three interior knots are shown in the left panel of 
Figure 4.8. The shape of the M-splines are similar to the B-splines in Figure 4.6 but are 
different in their values at a given t. For B-splines the maximum value is one because 
they are normalized such that the sum of all B-splines at a given value of t is one however, 
M-splines can have a value greater than one.
4.3.4 I-splines
Ramsay (1988) defined integrated splines (I-splines) to be used as basis functions in 
regression analysis when monotonicity is required. I-splines are piecewise polynomials 
of degree q obtained by integrating M-splines of degree q — 1 and are thus defined for 
kh < t <  kh+1 as Ii(t\q) = f* Mt{u\q)du.
Thus for the same sequence of interior knots used in M-splines, I-splines are defined
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as
h(% ) = ST^ h (b. _  jL ) Mm{t\q+1)A ^ m = l \ hjrn+<1+1 ^ r n )  q + l  ’
I > h
h — q + 1 < I < h 
I < h — q +  1.
One of the properties of M-splines is th a t J^ l+q M t(t\q) =  1, therefore, I-splines are mono­
tone splines constrained between 0 and 1. A linear combination of I-splines is a monotone 
spline function if the coefficients cp are constrained to be non-negative. I-splines of order 
five can be seen graphically in the right panel of Figure 4.8.
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Figure 4.8: Left panel: M-spline basis functions of order f .  Right panel: I-splines of order 5 
obtained from the M-splines in the left panel.
The maximum value of an I-spline Ii(t\q) is one when the value of t is greater or equal 
to ki+q.
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4.4 Discussion
In this chapter, we described methods of approximating a curve with smooth functions 
that could be employed to model age and exposure effects in the self-controlled case series 
method. The parametric models presented (polynomial and fractional polynomials) are 
flexible ways of modelling, however they fail to follow deviations from the overall trend 
of the data. If one chooses a parametric model that is not of appropriate form, at least 
approximately, then there is a danger of reaching incorrect conclusions (Wand and Jones, 
1995). The restrictive nature of polynomials can be avoided by using non-parametric 
smoothing methods.
Piecewise polynomial models or splines are one class of smoothing methods which can 
be used to allow the data to decide the shape of the estimated function. The spline func­
tion is estimated by imposing continuity and differentiability conditions up to a certain 
order at the knots, where the pieces of polynomials are joined. The choice of knots is 
crucial in using splines. We demonstrated, in the previous sections, the use of different 
type of splines based on a priori chosen fixed knots. These types of splines are known 
as regression splines. Too large a number of knots can over-fit the data resulting in a 
rough function and too low a number of knots leads to under-fitting. There are several 
ways of defining the number and location of knots. Methods to automatically choose 
knots have been proposed in the literature including Friedman (1991); Smith and Kohn 
(1996); Dimatteo et al (2001), however these automatic knot selection procedures are 
quite complicated and computationally intensive (Ruppert et al, 2003). So another ap­
proach is to choose a large number of knots and constrain their influence by introducing 
a penalty as proposed by O’Sullivan (1986). The penalty term proposed by O’Sullivan
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(1986) is based on the second derivative of the fitted spline function, A / { /  (£)}2- A is 
known as a smoothing parameter that controls the tradeoff between smoothness and fit. 
Following O’Sullivan (1986) different types of penalties have been proposed in the litera­
ture including Eilers and Marx (1996), who apply a difference penalty directly to adjacent 
coefficients, and Ruppert et al. (2003) who make use of a ridge penalty as in ridge regres­
sion. The locations of the knots are usually chosen to be equidistant or selected based 
on quantiles. Smoothing splines, which are different from regressions splines, avoid the 
problem of choosing knots by using all distinct data points as knots, and to prevent over 
fitting a penalty similar to O’Sullivan (1986) is used. The use of smoothing splines is 
computationally demanding because the number of parameters to be estimated is equal 
to about the number of distinct number of observations.
When using regression splines, in addition to the choice of knots, the choice of basis 
functions, the order of the basis functions, continuity constraints on the function to be 
estimated, the penalty method and the method of choosing the smoothing parameter are 
important. The most commonly used basis functions as described in this chapter are 
polynomials, truncated power basis functions, B-splines, M-splines. Other types of basis 
functions include radial basis functions, and the convex spline basis (C-splines).
An alternative to splines which can be used to model time-varying covariates in SCCS 
is kernel smoothing (Wand and Jones, 1995). One of the advantages of kernel smoothers as 
compared to splines is their simple theoretical analysis (Ruppert et al., 2003). Similar to 
splines, kernel smoothers are local, so are able to follow deviations from the overall trend 
in the data unlike polynomials. Splines and kernel smoothers are obtained by fitting 
local polynomials but the way they are estimated is different. The kernel smoothers 
are estimated by fitting local polynomials at each data point based on neighbouring
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data points having different weights. Closer values are given higher weights, therefore 
have higher influence on the local polynomial fit at a point. But spline functions are 
estimated by fitting pieces of polynomials in different intervals and constraining them to 
be continuous at the knots where the intervals are joined.
In this thesis we will use cubic M-splines and I-splines as basis functions in modelling 
age and exposure effects for the self-controlled case series models. As noted by Ramsay 
and Silverman (1997), we want the basis functions to allow constrained modelling, namely 
a positivity condition. In the self-controlled case series models the functions related to 
age-specific relative incidence and exposure relative incidence should be positive func­
tions. Therefore, using M-splines as a basis enables one to fit a non-negative function by 
constraining their coefficients to be non-negative, since M-splines are non-negative func­
tions. In addition, the use of M-splines avoids numerical integration of the denominator 
in the log-likelihood function of the SCCS method because integrals of M-splines can be 
expressed as other forms of basis functions known as I-splines.
Chapter 5
Sm ooth Age Effect
For a self-controlled case series analysis, time dependent variables (e.g age), unlike fixed 
covariates, are not automatically controlled for, and therefore need to be included in the 
model. Confounding by temporal factors is likely to occur when both the event incidence 
and the opportunity for exposure vary with age or season. Examples include adverse 
events and childhood vaccinations; seasonal exposures such as respiratory infections or 
influenza vaccination; and studies in elderly populations of age-related conditions. There­
fore a careful control of age is important.
As discussed in Section 2.3 of Chapter 2, the methods for handling an age effect in the 
standard and semi-parametric versions of SCCS method have limitations. The standard 
method can be sensitive to mis-specification of age groups which may lead to biased 
estimates of the association between exposure and event outcome. The semi-parametric 
method may run into computational problems when the number of cases is moderately 
large and there may also be a loss of efficiency in estimation. In this chapter, we propose 
the use of smooth functions to represent the age-specific relative incidence function to 
avoid these limitations. We consider polynomial, fractional polynomial functions and a
77
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linear combination of M-spline functions.
The use of M-spline functions, in addition to addressing the above mentioned limi­
tations of the standard and the semi-parametric SCCS methods, avoids the integral in 
the case series likelihood function by replacing it with I-splines, which are integrated M- 
splines. The age-specific cumulative relative incidence function is then approximated by a 
monotone spline function, a linear combination of I-splines (Ramsay, 1988). A penalised 
log-likelihood approach is used in estimating the parameters related to the spline function. 
The methodology developed here is inspired by Joly et al. (1998), which we adapted for 
use with the SCCS method. Our methods have been programmed in R (R Development 
Core Team, 2012).
The outline of this Chapter is as follows. Section 5.1 describes how to fit an SCCS 
model with the log of the age-specific relative incidence function represented by a poly­
nomial function and reviews a recent paper by Lee and Carlin (2014) that used fractional 
polynomials to estimate parameters in the standard SCCS method. This is followed by 
a description of an M and I-splines based SCCS model in Section 5.2. In Section 5.3, a 
simulation study that evaluates the performance of the spline-based SCCS and its com­
parison with the standard and semi-parametric versions of SCCS is presented. In Section 
5.4, we apply the new spline-based SCCS to a large data set on febrile convulsions and 
paediatric vaccines, and some final remarks are made in Section 5.5. The contribution of 
this chapter has been published in Ghebremichael-Weldeselassie et al (2014a).
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5.1 M odelling of Age Effect Using Parametric Func­
tions
In this section, we consider modelling of the age effect with smooth parametric func­
tions, specifically polynomial and fractional polynomial functions. We also discuss the 
limitations of using such functions.
5.1.1 Polynom ial Functions
As a first step, we replace the log of the age-specific relative incidence function, 'i/j(t), 
in the SCCS likelihood function (2.9) by a smooth polynomial function. That is, will 
be the exponential of a polynomial function, while the relative incidence associated with 
exposure, Xi(t), remains as a parametric step function. The SCCS log-likelihood function, 
when the log of the age-specific relative incidence is represented by a polynomial function 
of order 2, is derived as follows. Suppose each individual i has just one exposure period 
(c*, di] as shown in Figure 5.1
Uua2*Cauis
(2
biC| di riAge
Figure 5.1: Relative risk for individual i in different periods within the observation period when 
the log of age-specific relative incidence function is represented by a linear function
In Figure 5.1 c* and di represent the start and end of the exposure risk period for 
individual while and bi represent the beginning and end of the observation period. In
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the first interval, a* to q, and third interval, di to the relative incidence rate is simply 
exp(a0 + Oilt), which is related only to age because there is no effect of exposure in those 
periods. Whereas, the incidence rate in the exposure period q  to is exp(«o +  x 
exp(yd), where exp(/5) is the relative incidence associated with exposure and =
a0 +  ait. The likelihood function for individual i will then be
L = TTT7________________ exp(o0 + Oiitjj) exp {:qfa-)/3}________________
-1- -1. -L JL f C j  /  , j j .  i rd i____ /  _ , / \   /  n\ i± ii=i j=i f *  exp(o:o + ct\t)dt + exp(a0 + ait) exp((3)dt + exp(a0 + ait)dt
________________________ ( a i ) e xp (a i t i j ) e xp{x i ( t i j ) l3}
expfoiq) — exp(o:iad 4- ej-
3
N  nnn^  (a (ai j) -f xp(/3) (exp(aidi) — exp(aiq)) + exp(oi^) -  exp^idj)%—1 j — 1
where Xi(t) = 1 if individual i is exposed at t and 0 otherwise. Note that ce0 the intercept 
of the linear function that represents log of the age effect cancels out. The log-likelihood 
function is then
N r i i  N  rii
i =  a \ t j j + Xi(tij)p
i—1 i=1 i—1 j=1
N  7li ,
-  J^ X /lo g  ( — (exp(«iCi) -  exp{aiOi) -f exp(/?)(exp(o;idi) -  exp(o;iq))+
• 1 - 1  \ aii=i i=i
exp(aibi) -  exp(aidi))) (5.1)
The parameters of interest are obtained by maximising the log-likelihood function ( 5.1). 
The log-likelihood can be derived in the same way for polynomials of higher order. How­
ever the integrals in the denominator can not be integrated analytically and have to be 
integrated numerically which makes estimation computationally costly.
5.1.2 Fractional Polynomials
A family of fractional polynomials, as mentioned in Chapter 4, were introduced by 
Royston and Altman (1994) to circumvent the limitations of the conventional poly­
nomial functions. Fractional polynomials use integers and fractions as powers. Usu­
ally fractional polynomials of order less than or equal to two (three parameters) are
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sufficient, where their powers are chosen from a set of numbers between —2 and 3, 
{—2, —1, —0.5,0, 0.5,1, 2,..., max(3, m)}.
In the context of the self-controlled case series method, Lee and Carlin (2014) used 
fractional polynomials to estimate parameters related to the age effect in the standard 
SCCS method. To apply the method of Lee and Carlin (2014), the data still need to 
be expanded as for the parametric SCCS and the effect of age is estim ated by only two 
parameters related to fractional polynomials. Let the observation period of individual i 
be divided into six age groups as presented in Figure 5.2.
b,a ci ii Age
Figure 5.2: Age groups used in estimating the age-specific relative incidence function using 
fractional polynomials
h i, h2, h3, h4, h5 and h6 in Figure 5.2 show the age groups. Using the standard  SCCS 
method 5 parameters are needed to estimate the age-specific relative incidence function. 
The method of Lee and Carlin (2014) needs only one or two param eters of fractional 
polynomials to estimate the jumps of the step function in Figure 5.2, by first specifying 
the age groups. It is also possible to use each day within the observation period as an 
age group, hence expand the data to size N  x T  where T  is the number of days in an 
observation period. However, instead of expanding the data to use fractional polynomials,
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it is possible to use the same procedure as for a polynomial function. The log-likelihood 
function, with log of age-specific relative incidence represented by a fractional polynomial 
function, can then be derived in the same way as for a polynomial function presented in 
Section 3.1.X, uuu wm cnou icv^unc/ numerical integration.
Unlike the standard and semi-parametric SCCS models the use of polynomial or frac­
tional polynomials to represent the age effect does not require the data to be expanded. 
The size of the data is only of order N, where N  is the total number of cases and the 
number of parameters estimated is much lower than for the standard and semi-parametric 
SCCS methods. However, there is the integral involved in the denominator of the SCCS 
likelihood function which might make computation difficult when the polynomial is of 
high order. This might be simplified by choosing a polynomial or fractional polynomial 
that represents the age-specific relative incidence function, t ), directly and not the log 
of it. This is possible since the basis functions for the age variable, when using the poly­
nomials or fractional polynomials, are always positive. To make the linear combination of 
the basis functions, combined linearly to form the age-specific relative incidence function, 
positive, their coefficients can be constrained to be non-negative.
5.2 M odelling of the Age Effect Using M -spline Func­
tions
The parametric models described in the previous section, polynomial and fractional 
polynomial functions are flexible. However, they are a priori defined shapes through their 
specific analytical form (Hens et al., 2012). Moreover, if a function to be approximated 
is badly behaved anywhere in the interval of approximation, then the approximation is
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poor everywhere (de Boor, 1978). The use of piecewise polynomial functions (splines) 
offer flexibility without the same limitations.
One possibility is to use truncated power basis functions, discussed in Section 4.3.1, 
to approximate ^(t). A linear combination of these basis functions gives a spline function 
that represents the age effect in the SCCS method. The use of splines avoids predefining 
age groups and there are few computational problems involved in estimating the param­
eters of interest as 'ip(t) can be represented with few parameters. However, the use of 
truncated power functions as a basis has the disadvantage of numerical instability when 
the number of knots is large (Ruppert et al, 2003). M-splines, which are derived from 
truncated power basis functions are more stable numerically. Since each of Mi, where Mi 
is the Ith M-spline basis function, is zero outside an interval [kh kl+q], any bad approxima­
tion within the interval does not affect the other parts of the function to be approximated, 
unlike polynomial functions.
We use a linear combination of M-spline basis functions to approximate /ip(t) follow­
ing Joly et al. (1998), who used these functions to approximate the hazard function in 
arbitrarily censored and truncated data, with an application to the age-specific incidence 
of dementia. In the SCCS setting, if a* and are as defined in Chapter 2, the start 
and end of the observation period for each individual i respectively, the spline function is 
defined between a and b where a = minla*; i = 1 , . . . ,  N}  and b = max-f^; i = 1 , . . . ,  N}  
respectively. So the interval [a, b] spans all the observation periods. The interior knots 
selected to define the M-spline basis functions should therefore be between a and b. All 
the required knots will then be defined by repeating the values of a and b the order of the 
M-splines, q, times or adding equidistant q — 1 knots below a and above b in addition to 
the interior knots chosen. Since it is a relative hazard, the age-specific relative incidence
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function has to be a positive function. In this respect, M-splines are very useful as they 
are positive functions and to keep their linear combination non-negative, their coefficients 
are constrained to be non-negative. Therefore, our approximation of the age-specific rel­
ative incidence function is a linear combination of cubic M-splines, namely M-spline basis 
functions of order 4, and is given by:
m
= ^ 2 9 ( ai)Mi(t) (5-2)
i=i
where m  is the number of basis functions, the coefficients g(cti) are parameters estimated to 
determine the shape of the function. The non-negativity of the function 'ip(t) is achieved 
by constraining the coefficients to be non-negative. We use g{ct{) = af, hence = 
Y^ JiLi oijMi(t). g(ai) = exp(c^) can also be used but it may have a convergence problem 
when g(ai) should be zero. Combining (2.9) and (5.2) we obtain the log-likelihood function 
for the SCCS model as:
j _  y ^  y 2'  j /  (Ylb= i ■Mi (tjj)) exp {Xj (tjj) r /3} \  .
~ h h  \Ja;(zr=i“? m t ) )e x P{Xi( t m d t J '
A motivating reason for using M-splines to approximate the age-specific relative incidence 
function is that the log-likelihood function contains integrals. These can be replaced by 
other spline basis functions known as I-splines without the need for numerical integration 
since I-splines are integrals of M-splines. For example, suppose that there is only one 
exposure period (q, di] for each individual i. Thus, Xi(t) is 1 if t is in the interval (q, dj\ 
and 0 otherwise. This yields the log-likelihood
I _  y ^  y 2^ i ( _________________K S i  aiMi(tjj)) exp {xj(tjj)p}_________________ ^
/  j  /  j  ® I r a 9  *  *  / 1 w  i ,  . /  n \  r d i /v - v m  o. *  *■ /  . w  i .  . rbi
i=1 j=1 . /* (E £ i  <*?M,(t))dt + exp(/3) f£(Y7= i ofM,(t))dt + /*< (££ , ajM,(t))dt
_  y ' y '  j ( _________________(E £ i  exp {gjfa)/?}_________________
h h  V i j G Z i  ^ M t(t))dt -  / * ( o ? W ) ) *  + exp(/3) / * ( J X j  of
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N m
_  y ^  y~^  j [ __________\z^i=i | /g ^
VE£i«f/,,,;i^W * + (exp(/9)-l)(Efe1^ /^ M !Wrft);
then as ij(£) =  f* M\(u)du, replacing the integral of M-splines with I-splines provides the 
log-likelihood
j y ^  y ^  i  (  (E E i a i ^ i (Uj ) )  exP {zj(tj j)P} \  , .
U  £  g U «  -  I ( * i )  +  ( e x p t f )  -  1 ) ( W )  -  I { c i ) ) J  ’ K m )
where I{y) = E E i «21|(2/)
5.2.1 Penalised Log-likelihood
As described in Chapter 4, approximating functions with splines requires determining 
the number and position of knots in advance. We use a large number of knots that over-fit 
the function and use a penalty that controls the balance between data fit and roughness. 
Following O’Sullivan (1986), we use a penalty function that measures roughness as the in­
tegrated squared second derivative, (ip* (t))2 dt, and define our penalised log-likelihood 
as
f.b /  m  \  2
pl = l - X j  \ y2 g (a i )M i(u )J  du
with = £ E i g(ai)Mi(t) = g (a )M "(t ), where M"(t) = M ^ t ) , . . .  M? (t)]T
and g(a) = [ g ^ ) ,  g(a2) , . . .g(at)]. Therefore,
f b
pi =  l — X g(a.)TM t”(t ) M  (t)g(ot)dt
J a
pb
— 1 — ^ i .01) 7 /  M T” (t)M" (t)dtg(a)
J a
= I ~ X((g(a))TAg(a))  (5.6)
where A =  A IT" (t)Af" (t)dt is an m  x m  matrix with (h, I) element Ja& M'^(t)Mi (t)dt, 
I is the log-likelihood function given in Equation (5.5), and A > 0 is a smoothing param­
eter that controls the balance between smoothness of the age-specific relative incidence
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function and the fit to the data. The larger the value of A, the smoother the age effect.
As discussed in Section 2.2, the function 'ip(t) is not identifiable without some further 
constraint as it represents a relative effect. In the present setting, it is convenient to use 
the constraint = 1, so that (p in Equation (2.8) is the average baseline incidence
over the interval (a, b]. In Farrington and Whitaker (2006), the constraint ip(a) = 1 
was used, so that tp is the baseline incidence at a. Therefore, to obtain the parameter 
estimates, the penalised log-likelihood function (5.6) is maximised for fixed A under the 
constraint ip{t)dt =  1. The cumulative relative incidence is represented as the integral 
of a linear combination of cubic M-spline functions of the form f*(22ZLi g(ai)Mi(u))du. 
Since the integral of an M-spline is an I-spline, the cumulative incidence is represented 
by a linear combination of I-splines of the form Xw=i From the definition of
I-splines all the Ii s evaluated at t = b are equal to 1. Hence the required constraint can 
be achieved by constraining the sum of the coefficients of the linear combination of cubic 
M-spline functions to be 1. That is, X S i 9(ai) =  Y^iLi af = 1*
5.2.2 Sm oothing Parameter Selection
The smoothing parameter A can be provided by the user or selected using automatic 
methods. We use a cross-validation method as in Joly et al (1998), in which an ap­
proximate cross-validation score is maximised with /3 set to zero. Let a  be the vector of 
parameters cq. Denote the cross-validation score V(X),
N
V(X) = ' £ k ( & _ i) (5.7)
i
where =  &_j(A) is the maximum penalised log-likelihood estimator of a  (with (3 = 0) 
when individual i is removed, and is the log-likelihood contribution of individual i. 
Using a first order Taylor approximation around a ,  the penalised maximum likelihood
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estimate when all observations are included, we get:
N  N-tv  -tv /  O J  \
i=1 i=l  ^ '
Following O’Sullivan (1988a) d_* can approximated as: d_* « d — [H — 2AS]~1d_;, where 
H  =  gal1 t  (dt) is the log-likelihood part of the Hessian of the penalised log-likelihood
evaluated at d , d_f =  —df =  —( ^ ( d ) )  is a score vector when individual i is removed 
and 2AS is the penalised part of the Hessian, that is 2AS =  •
Therefore F(A) is approximated by V (A), where
> (A ) =  ^ ( / i( a ) - t - |^ ( a ) [ a - [ ^ - 2 A S ] - 1d_j - d ] )
i= 1 ' '
N
=  1(a) +  - Z l l *  ~  2AS]“1d_<]
i=1 
N
= ;(d) +  J ] d I j [H -2A S ]-ia_j
i=1 
N
=  l(a) +  ' £ t r ( d T_i ( H - 2 \ S } - 1d„i)
i=l
N
= l(a) +  J 2 t v ( ( H - 2 \ S ] - 1d . id T_i)
i=1
N
=  /(d) +  t r ( [^ -2 A S ]-1^ d _ id ! i)
-  '<“ )+*' (i"  -  “ s i " E  ( - £ < “))" ( - f s (4i
-  ([" -  2Asr ‘ £  ( £ ( &>)r (fs<4>))
Under regularity conditions E  =  - E  , hence
U(A) «  U(A) =  /(d) -  tr([tf -  2AS]-1ff). (5.8)
The matrix S depends on g(ai). If g{a{) =  ai then S =  A, where A is as defined in 
Section 5.2.1. But here we take g{ai) = of, therefore denoting point wise product of
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matrices by o
S =  4 (A o (a a T)) +  2(diag(Aa2)).
This can be shown as follows:
Let p{oc) = (g(cc))T Ag(oc) and 6 = g(oc). If g{a{) = af  then, since A is symmetric, 
we have
fdOT '„ 1 d2p(a) ( d 0 \  ( d 0 \  ,nT A d
“ 2 dotdaT ~  ( d a )  ( d a  J  +   ^ ^ d ^ vec doc j
= 4 (A o (aaT)) +  2(diag(Aa2)). (5.9)
The quantity tr([H — 2AS]-1^ )  can be interpreted as a model degrees of freedom. We 
checked the validity of the approximation in simulation studies (see Section 5.3). The 
penalised log-likelihood function (5.6) is maximised, with /3 =  0, for a grid of A values, 
and the value of A that maximises the approximate cross-validation score (5.8), is used in 
a final optimisation step with the full model to obtain the relative incidences related to 
exposure.
5.2.3 Fitting the Spline-Based SCCS M odel
The information needed to fit the spline-based SCCS model is the same as for the 
standard SCCS. Instead of selecting age groups, a suitable (large) number of knots is 
chosen. A large number of knots is chosen deliberately to over-fit, and we use a penalised 
log-likelihood to control the balance between the smoothness and roughness of the fitted 
curve. Usually between eight and 15 knots are sufficient (Rondeau and Gonzalez, 2005; 
Joly et al, 1998). The knots will include the values a and b, namely, the minimum age 
at the start of all observation periods and maximum age at the end of all observation 
periods. The number of knots will depend to some extent on the degree of age variation 
- the more variation, the more knots should be used. The knots can be equidistant or
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chosen based on quantiles of the event times. These choices usually have little impact on 
results.
In a first step, A is chosen using the approximate cross-validation method ignoring 
the exposure effect. Then, the parameters are estimated by maximising the penalised 
log-likelihood function (5.5) with the chosen value of A, and under the constraint that the 
coefficients of the age-specific relative incidence function sum to one. The inverse of the 
Hessian of the penalised log-likelihood is used as a variance estimator of the parameters 
(Rondeau and Gonzalez, 2005). These standard errors are Bayesian related standard 
errors proposed by O’Sullivan (1988a), considering the penalty term in the penalised 
log-likelihood function (5.6) as a prior. For more detail, see Section 6.1.1 of Chapter 6.
Multiple risk periods can readily be incorporated. In addition to incorporating an 
indicator for the new exposure status in the numerator of the log-likelihood function (5.5) 
we add (exp(p) — l)(X X i aUi{ei) ~~ E S i  afli(si)) i*1 its denominator, where exp(p) is 
the relative incidence of the new exposure and s* and e* are the ages at the start and end 
of the risk period associated with the new exposure for individual i , respectively. The 
log-likelihood function with two risk periods is given as
( ___________ ( S £ i  t fMiiUj))  exp exp f a f e M ___________ \
V W  -  7(«i) + (exp(/?) -  1 -  1(a)) + (exp(p) -  1 )(I(ei) -  I(si))J ’
(5.10)
where yfoij) is 1 if tij is within the risk period (s*, ej and 0 otherwise, /(e*) and I(si) are 
linear combinations of I-splines given by /(s^) =  Y^ JiLi af^i(si) and 7(e*) =  YmLi 
respectively. Further exposures can be added in the same way; some care is required in 
handling overlapping risk periods.
The new spline-based SCCS method has been implemented in R 2.15.1 R Develop­
ment Core Team (2012), and the optimisation of the constrained penalised log-likelihood
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maximisation is done using R function auglag from package alabama.
5.3 Simulation Study
We conducted a simulation study to investigate the performance of the new method 
and to compare it with the piecewise constant and semi-parametric versions of the SCCS 
method. We also made a comparison of the new method with SCCS with no age effect 
included in the model. The simulation study evaluated how well the new method estimates 
the age-specific relative incidence function and exposure-related relative incidence.
5.3.1 Design of the Simulation Study
The parameters which need to be specified in the simulation are: the observation 
period (age at start of observation and age at end of observation), the distribution of 
age at exposure, q, the length of the post exposure period, the exposure-related relative 
incidences, the age-specific relative incidence function, and sample size.
The observation periods for all cases were taken to be from age of 0 to 500 days, that 
is di = 0 and bi = 500 for all i. We assumed only one exposure period (q, d j of length 50 
days, so di = Ci +  50, where q  is age at first exposure of individual i.
The exposure variable Xi(t) takes the value 1 in (q, q  +  50] and 0 elsewhere. Three 
different scenarios for the distribution of ages at start of exposure (q) were considered: 
(a) exponentially decreasing (q sampled within [0,500] from an exponential density with 
rate 0.02), uniformly distributed (q sampled from U[0,500]) and exponentially increasing 
(500 — Ci sampled within [0,500] from an exponential density with rate 0.02).
The baseline incidence at age t was defined to be A0(£) oc 5 exp (St) +  2, and three 
scenarios were investigated: exponentially decreasing (with 8 =  —0.003), constant (8 = 0)
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and exponentially increasing (5 = 0.003). That is, at each day of age in (0,500] age-specific 
relative incidences were generated.
True exposure-related relative incidences of 1, 2, and 5 were investigated, with sample 
sizes 50, 100 and 200. In the simulations just one event was simulated per individual; 
this involved no loss of generality as multiple events within an individual are treated as 
independent in SCCS.
We then generated age at event for each individual conditional on the exposure status 
and number of events an individual experiences, one event per individual in this case, 
from multinomial distributions with daily categories. 10,000 samples were generated for 
all combinations of the scenarios.
The new spline-based, semi-parametric and standard SCCS methods were fitted to 
each of the generated samples. Nine age groups, with cut-points at 30, 92, 155, 218, 281, 
344, 407 and 470 days, were used to fit the piecewise constant SCCS model. We also 
fitted an SCCS without age effect to quantify the bias in the exposure effect when age is 
ignored. In fitting the spline-based SCCS we used M-splines of order 4 and the number 
of interior knots was chosen to be 10 hence the number of basis functions was m = 14. 
The values of a and b respectively are 0 and 500 days.
We evaluated the performance of the new method in terms of its fit to the true age- 
specific relative incidence function and in terms of reflecting the true exposure-related 
relative incidence. For each of the 10,000 samples the mean of the estimated integrated 
squared errors (MISE) and their standard deviations were calculated. The MISE val­
ues computed were for the cumulative age-specific relative incidence function to make it 
comparable with the estimates obtained from the semi-parametric SCCS method. The
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integrated squared errors (ISE) for each sample are defined as:
/*500
/ W *) -Jo
where \I>(t ) is true age-specific cumulative relative incidence and i){t) is estimated cu­
mulative relative incidence. After fitting the models for each sample we estimated the 
cumulative relative incidence at each day of age from 0 - 500 and approximated the ISE 
values as:
500
£ ( * ( * )  -  m f -
t=o
We then find the MISE values by taking the mean of the ISE values. To investigate the 
performance of the new method in estimating the exposure-related relative incidence we 
computed the mean, median and standard deviation of the 10,000 log relative incidence 
estimates (/3), the coverage probability of the 95% confidence intervals, empirical standard 
errors and average model-based standard errors of p. We use the median as well as 
the mean because there is a non zero probability that all events will occur in the risk 
period only or in the control period only, so that in finite samples the expectation of (3, 
and hence the bias =  expectation of (3 - true relative incidence (ft), is undefined. (All 
quantities involving expectations should therefore be regarded as having been trimmed, 
by removing samples resulting in unbounded estimates.)
5.3.2 Results
In this section, we present results of simulations conducted to evaluate and compare 
the performance of the spline-based SCCS in terms of estimating both the age-specific 
relative incidence function and the relative incidence related to exposure.
C h a p t e r  5. S m o o t h  A g e  E f f e c t 93
Performance in Estimating the Age Effect
Tables 5.1 and 5.2 show results from the simulation in evaluating the performance of 
the new method relative to the semi-parametric SCCS model in estimating the cumulative 
age-specific relative incidence function. MISE values and standard deviations of ISE values 
are presented.
Table 5.1: Mean integrated squared Error (MISE) and Standard Deviation (SD) for estimat­
ing the cumulative age-specific relative incidence using spline-based and semi-parametric SCCS: 
simulations based on different scenarios of age at exposure (AE), age-specific relative incidence 
(ASRI) and exposure relative incidence (RI).
#  of cases Spline-based Semi-parametric Spline-based Semi-parametric
MISE(SD) MISE(SD) MISE(SD) MISE(SD)
ASRI increasing & AE decreasing, RI=5 ASRI & AE decreasing, RI=2
50 2.004(2.084) 2.208(2.103) 1.911(2.010) 2.102(2.027)
100 0.977(1.012) 1.055(1.012) 0.950(0.962) 1.029(0.965)
200 0.513(0.531) 0.548(0.531) 0.468(0.491) 0.502(0.490)
ASRI increasing & AE increasing, RI=5 ASRI increasing & AE uniform, RI=1
50 1.771(2.161) 2.016(2.174) 1.288(1.322) 1.442(1.312)
100 0.910(1.052) 1.006(1.054) 0.656(0.679) 0.724(0.679)
200 0.444(0.538) 0.484(0.541) 0.326(0.344) 0.354(0.343)
We can see from Table 5.1 that the performance of the new method in approximating 
the true age-specific relative incidence is similar to though slightly better than the semi- 
parametric method as the MISE values are slightly lower for the new method. The 
reduction in the MISE is of the order of 7%, representing a slight gain in efficiency. 
The results presented in Table 5.1 show how the MISE values vary with a change in 
the number of cases for different scenarios of age at exposure, relative incidence and 
age-specific relative incidence function. The MISE values in Table 5.1 decrease with an
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increase in the number of cases used in the simulations.
Table 5.2: Mean integrated squared Error (MISE) and Standard Deviation (SD) for estimating 
age-specific relative incidence using spline-based and semi-parametric SCCS: simulations based 
on two scenarios of age at exposure (AE), age-specific relative incidence (ASRI) and exposure 
relative incidence (RI) for 50 and 100 cases.
50 cases 100 cases
True RI Spline-based semi-parametric Spline-based semi-parametric
MISE(SD) MISE(SD) MISE(SD) MISE(SD)
Constant ASRI and increasing AE
1 1.469(1.738) 1.615(1.744) 0.706(0.847) 0.771(0.849)
2 1.576(1.719) 1.736(1.728) 0.764(0.908) 0.835(0.908)
5 1.697(2.008) 1.896(2.003) 0.888(1.136) 0.974(1.137)
Increasing ASRI and Uniform AE
1 1.312(1.517) 1.458(1.514) 0.668(0.723) 0.736(0.723)
2 1.252(1.458) 1.408(1.456) 0.654(0.703) 0.722(0.699)
5 1.340(1.474) 1.507(1.486) 0.683(0.767) 0.755(0.768)
Decreasing ASRI and Increasing AE
1 1.465(1.663) 1.618(1.619) 0.744(0.847) 0.807(0.828)
2 1.575(1.845) 1.724(1.800) 0.759(0.795) 0.822(0.787)
5 1.589(1.826) 1.772(1.831) 0.846(1.017) 0.924(1.001)
Results for scenarios where the age-specific relative incidence function is constant, 
exponentially increasing and decreasing with uniformly distributed and exponentially in­
creasing age at exposure are presented in Table 5.2. Results relating to the comparison 
of spline-based and semi-parametric methods in this Table are similar to the ones pre­
sented in Table 5.1. In general, the Mean Integrated Squared Error increases with an 
increase in the true exposure-related relative incidence value. For both the spline-based 
and semi-parametric methods, the efficiency in estimating the age-specific relative inci­
dence function increases with an increase in sample size, because the MISE values decrease
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as the number of cases increase. The spline-based method has a slightly higher efficiency 
in estimating an exponentially increasing or decreasing age effect than  a constant function.
a. Spline-based SCCS b. Semi-param etric SCCS
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Figure 5.3: Estimated cumulative age-specific relative incidence curves of the first 1,000 sim­
ulated data sets, Panel a represent results from spline-based method and Panel b results from 
semi-parametric SCCS. In the top panels the true curve is exponentially increasing, in the middle 
panels a constant and in the bottom panels an exponentially decreasing function
Figure 5.3 shows estimated age-specific cumulative relative incidence curves from the
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spline-based and semi-parametric methods fitted to the first 1,000 simulated data sets. 
The white bold lines represent the true curves. The top panels show results when the true 
age-related relative incidence function is exponentially increasing, the middle panels when 
it is a constant function and the bottom panels are when the true curve is an exponentially 
decreasing. Results in panel a of Figure 5.3 are from the spline-based method and results 
in panel b are from the semi-parametric SCCS method.
From Figure 5.3 both the spline-based and semi-parametric SCCS methods seem to 
approximate the true age-specific relative incidence functions well. The variabilities in 
estimating the constant function seem to be more than the exponentially increasing and 
decreasing age-specific relative incidence functions.
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Figure 5.4: Cumulative age-specific relative incidence curves for a single simulated sample: 
True curve (bold line), a curve estimated using spline-based SCCS from a single simulated data 
set (dashed line) and the step function estimated using the semi-parametric model from the same 
single simulated data set.
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Figure 5.4 shows the cumulative age-specific relative incidence from the spline-based 
SCCS, the semi-parametric SCCS and the true cumulative incidence for a single sample 
of simulated data of 200 cases. From the plot it seems that the two estimation methods 
give similar results for this data set.
For this same sample of simulated data, we evaluated the approximate cross-validation 
score given in Equation (5.8) at a smoothing parameter (A) value of 100,000. We also 
calculated the exact cross-validation score by leaving out one case at a time and fitting 
the spline-based SCCS iteratively. The two values were close to each other, 1,182.798 and 
1,183.045 respectively.
Performance in Estimating the Exposure Effect
The mean and median of the log exposure-related relative incidence log(RI) — (3, 
empirical standard errors and average model-based standard errors of /3, for a scenario 
in which both the age-specific relative incidence function and age at exposure decrease 
exponentially, are shown in Table 5.3. The coverage probabilities of the 95% confidence 
intervals for are also presented. Table 5.3 shows that the bias in estimating the exposure- 
related relative incidence using the new method is small with these sample sizes. It is 
similar to or smaller than the bias for the semi-parametric method, and smaller than the 
bias of the parametric method. The empirical and average model-based standard errors for 
the spline method lie between those achieved by the parametric method (which are lower) 
and the semi-parametric method (higher). The spline-based confidence intervals tend to 
be slightly conservative, though not as badly so as those for the parametric method. As 
expected, the SCCS without age effect produces very biased results and has a generally 
poor performance, underlining the importance of age adjustment in SCCS models.
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Table 5.3: Simulation results from a scenario where age at exposure and age-specific relative 
incidence decrease exponentially. Mean, Median, Empirical standard errors (ESE), Average 
model based standard error (AMSE) and 95% coverage probability (P95) for the log relative 
incidence, log(RI) = (3, are presented.
Spline-based SCCS
log(RI) 50 cases 100 cases
Median Mean ESE AMSE P95 Median Mean ESE AMSE P95
1.609 1.657 1.690 0.486 0.429 94.107 1.624 1.637 0.287 0.269 94.614
0.693 0.697 0.707 0.394 0.371 94.482 0.697 0.701 0.274 0.262 95.358
0.000 -0.005 -0.009 0.442 0.408 94.343 -0.005 -0.004 0.448 0.412 94.098
semi-parametric SCCS
1.609 1.657 1.700 0.512 0.484 95.600 1.630 1.646 0.291 0.281 94.600
0.693 0.709 0.717 0.404 0.398 95.300 0.704 0.706 0.276 0.270 94.700
0.000 0.004 -0.005 0.453 0.440 95.080 -0.004 -0.004 0.460 0.447 95.410
Parametric SCCS
1.609 1.452 1.478 0.438 0.422 92.520 1.520 1.525 0.273 0.264 92.450
0.693 0.601 0.604 0.400 0.388 94.230 0.605 0.610 0.256 0.255 94.080
0.000 -0.132 -0.144 0.414 0.399 93.640 -0.105 -0.111 0.288 0.285 94.020
SCCS without age effect
1.609 2.140 2.165 0.305 0.309 56.020 2.125 2.121 0.217 0.215 33.540
0.693 1.181 1.185 0.288 0.288 59.480 1.122 1.124 0.202 0.203 42.970
0.000 0.539 0.534 0.320 0.314 56.280 0.539 0.545 0.314 0.313 54.930
Table 5.4 presents results for a scenario where ages at exposure are uniformly dis­
tributed and age-specific relative incidence function increases exponentially. In this sce­
nario there is less confounding effect of age on the exposure-related relative incidence as 
the chance to get exposed does not depend on age. As a consequence the SCCS method 
with age excluded in the model gave better results as compared to the previous scenario 
where age at exposure and age-specific relative incidence decrease exponentially. It has
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less bias and the coverage probability is closer to 95%. However ignoring age still has 
lower performance than the semi-parametric and spline-based SCCS methods. The spline 
method shows similar performance to the previous scenario, that is as good as or better 
than the semi-parametric and the standard methods.
Table 5.4: Simulation results from a scenario where age at exposure is uniformly distributed 
and age-specific relative incidence function increases with age exponentially. Mean, Median, 
Empirical standard errors (ESE), Average model based standard error (AMSE) and 95% coverage 
probability (P95) for the log relative incidence, log(RI) = (3, are presented.
Spline-based SCCS
log(RI) 50 cases 100 cases
Median Mean ESE AMSE P95 Median Mean ESE AMSE P95
1.609 1.626 1.611 0.336 0.325 94.660 1.625 1.622 0.235 0.231 94.852
0.693 0.664 0.648 0.423 0.402 95.300 0.689 0.674 0.282 0.281 96.400
0.000 -0.024 -0.087 0.528 0.515 96.690 -0.045 -0.078 0.376 0.365 96.400
semi-parametric SCCS
1.609 1.648 1.653 0.352 0.337 94.114 1.641 1.638 0.240 0.234 94.604
0.693 0.688 0.663 0.430 0.408 94.800 0.695 0.683 0.285 0.283 96.100
0.000 -0.019 -0.081 0.532 0.519 96.790 -0.042 -0.075 0.377 0.367 96.400
Parametric SCCS
1.609 1.597 1.589 0.340 0.326 94.600 1.598 1.595 0.235 0.232 95.021
0.693 0.659 0.638 0.419 0.403 96.100 0.667 0.659 0.283 0.282 96.200
0.000 -0.031 -0.087 0.536 0.517 96.891 -0.046 -0.077 0.375 0.365 96.300
SCCS without age effect
1.609 1.549 1.533 0.314 0.311 93.871 1.521 1.520 0.220 0.221 94.379
0.693 0.628 0.647 0.404 0.393 96.400 0.671 0.672 0.275 0.278 96.200
0.000 0.140 0.053 0.521 0.508 94.383 -0.046 -0.082 0.370 0.362 97.100
While the spline-based, the semi-parametric and the standard methods show similar 
performance, when the effect of age is kept constant and age at exposure increases expo­
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nentially, the SCCS without age effect performed well. And this is because keeping the 
age-specific relative incidence function to be a constant function means that the effect of 
age is cancelled out in the SCCS log-likelihood function. That is the true model is an 
SCCS model with no age effect. Results for this scenario are presented in Table 5.5.
Table 5.5: Simulation results from a scenario where age at exposure increases exponentially and 
age-specific relative incidence function is constant. Mean, Median, Empirical standard errors 
(ESE), Average model based standard error (AMSE) and P5% coverage probability (P95) for the 
log relative incidence, log(RI) — (3, are presented.
Spline-based SCCS
log(RI) 50 cases 100 cases
Median Mean ESE AMSE P95 Median Mean ESE AMSE P95
1.609 1.621 1.633 0.471 0.483 97.080 1.640 1.645 0.368 0.360 94.700
0.693 0.667 0.643 0.666 0.630 95.996 0.650 0.643 0.440 0.436 96.200
0.000 -0.047 -0.062 0.729 0.779 97.092 -0.004 -0.063 0.571 0.538 97.189
semi-parametric SCCS
1.609 1.635 1.653 0.482 0.492 96.982 1.646 1.653 0.372 0.363 93.894
0.693 0.687 0.659 0.677 0.639 95.796 0.646 0.655 0.444 0.439 95.800
0.000 -0.015 -0.041 0.743 0.787 97.508 0.005 -0.045 0.571 0.541 96.586
Parametric SCCS
1.609 1.563 1.575 0.476 0.477 96.797 1.562 1.574 0.361 0.354 94.700
0.693 0.640 0.618 0.654 0.624 96.697 0.617 0.617 0.440 0.429 96.300
0.000 0.016 -0.035 0.719 0.771 97.399 -0.001 -0.051 0.560 0.531 96.790
SCCS without age effect
1.609 1.596 1.549 0.350 0.353 95.000 1.557 1.564 0.253 0.249 95.700
0.693 0.556 0.563 0.531 0.498 96.296 0.629 0.611 0.356 0.349 96.100
0.000 -0.004 -0.099 0.599 0.657 96.982 0.051 -0.080 0.506 0.467 97.392
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5.4 Analysis of Febrile Convulsion Data
We apply the new spline-based SCCS method to data on febrile convulsions and pae­
diatric vaccines collected in England and Wales in the period of 1991-1994. SCCS with 
piecewise constant age-specific relative incidence function was also applied for comparison 
purposes.
The aim of the analysis is to investigate the association between febrile convulsions and 
diphtheria/tetanus/pertussis (DTP), Haemophilus influenza type B (Hib) and measles/ 
mumps/ rubella (MMR) vaccines. Febrile convulsions or seizures are a relatively common 
childhood condition, referring to a child having a seizure (fit) when they have a high 
temperature. It occurs when the electrical impulses, used to communicate brain cells 
(neurons), become disrupted. This can cause the brain and the body to behave abnormally 
(NHS, 2013).
DTP vaccine is given to prevent three diseases: diphtheria, tetanus, pertussis (whoop­
ing cough), and the Hib vaccine is a vaccine developed to prevent invasive disease caused 
by Haemophilus influenzae type b bacteria. The disease is a bacterial infection that can 
cause a number of serious illnesses such as pneumonia or meningitis, especially in young 
children (NHS, 2013). The Hib vaccination is offered to children at two, three and four 
months of age, which we denote here as Hibl Hib2 and Hib3 respectively. It is usually 
given along with DTP and polio vaccines. Another type of Hib vaccine is also given if 
the first three doses are missed, denoted here as Hibonly. MMR is a combined vaccine 
that protects against measles, mumps and rubella (German measles). Measles, mumps 
and rubella are very common, highly infectious conditions that can have serious, poten­
tially fatal, complications, including meningitis, swelling of the brain (encephalitis) and
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deafness (NHS, 2013). The first MMR vaccine is given usually within 12 to 13 months 
of age and a second dose of the vaccine is given between ages of three and five. Here we 
only study the effect of the first MMR dose in causing febrile convulsion.
The data  set includes 2,389 children aged 29-730 days in the period 1991 to 1994, who 
had 3,826 febrile convulsion events. Of the 2,389 cases, 2,021 cases had an MMR vaccine 
record. DTP vaccine was given in three doses, DTP1, DTP2 and DTP3. The number of 
cases vaccinated with DTP1, DTP2 and DTP3 were 1,624, 1,684 and 1,726 respectively. 
And the numbers of Hib vaccinated children were 1,706, 1,636, 1,552 and 880 for H ibl, 
Hib2, Hib3 and Hibonly respectively.
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Figure 5.5: The distribution of age at DTP and MMR Vaccines. DTP was taken in three doses
The average ages at which DTP1, DTP2, DTP3 and MMR vaccines were taken are
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74.3, 119.1, 167.7 and 437.0 days respectively. The mean of ages at H ibl, Hib2, Hib3 
and Hibonly are 136.1, 177.0, 221.9, and 520.9 days respectively. The distributions of 
ages at exposure to the DTP and MMR vaccines are presented in Figure 5.5. Figure 5.6 
presents the distributions of ages at Hib vaccines. The figures show th a t the chances of 
being exposed to the vaccines depend strongly on age hence age might have a confounding 
effect if it is related to the rate of baseline incidence too. Therefore appropriate modelling 
of age effect is desirable.
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Figure 5.6: The distribution of age at exposure to Hib vaccine. Hib was given in three doses 
and one dose Hibonly if the first three are missed
Febrile convulsions are relatively rare but potentially recurrent events, most cases 
experiencing a single convulsion over the two years. Furthermore, febrile convulsions are 
not contra-indications to vaccination, and carry a very low m ortality risk. Thus, there is
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no reason to doubt that conditions (1) to (3) of Section 2.1.1 in Chapter 2 are valid for 
these data.
The large number of cases precludes us from using the semi-parametric method because 
the method does not work for large number of cases as seen in the simulation study 
conducted in Section 2.3 of Chapter 2. We estimated relative incidences (RI) for febrile 
convulsion in risk periods following these vaccines compared to control periods, using both 
the spline-based and standard SCCS methods.
In a first analysis, we considered exposures to DTP and MMR vaccines. We estimated 
the relative incidences associated with exposure to the three doses of DTP (DTP1, DTP2, 
DTP3) using risk periods of 0-7 days for all the doses and MMR vaccine with a risk period 
of 6-11 days post vaccination. Exposure status was represented by four time-varying 
indicator variables, taking the value 1 in the relevant risk period and 0 in the control 
periods.
Overlapping risk periods were coded to the latest vaccine (Whitaker et al (2006)). For 
the standard method, age was divided into 23 equal intervals of 1 month, apart from the 
first age group which had 32 days and the last 40 days. The values of a and b respectively 
are the minimum age at start of observations (29 days) and maximum age at end of 
observation of the cases (730 days). In the spline-based SCCS analysis the age-specific 
relative incidence function was approximated by a linear combination of cubic M-splines 
with 14 knots (12 interior plus a and b). Therefore, the number of M-spline functions 
was m = 16. The internal knots were at roughly equal intervals. We maximised the 
penalised log-likelihood function (5.6), excluding the covariates that represent DTP and 
MMR vaccines, at different values of the smoothing parameter A. The value of A at which 
the approximated cross-validation score is maximum was found to be 1.07 x 109. We then
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maximised the penalised log-likelihood function (5.6), fixing A at 1.07 x 109 to obtain 
the relative incidences of febrile convulsion related to DTP1, DTP2, DTP3 and MMR 
vaccines. Results of these analysis are presented in Table 5.6
Table 5.6: Relative incidence (RI) and 95% Confidence intervals (Cl) for febrile convulsion due 
to exposure to three doses of DTP and MMR vaccines. Three parameter estimates for DTP and 
one for MMR for the risk period of 6 -11 days after vaccination ____________
Spline-based SCCS Standard SCCS
Vaccine Risk period RI 95% Cl RI 95% Cl
DTP1 0-7 1.068 [0.643 , 1.775] 1.26 [0.775 , 2.048]
DTP2 0-7 0.995 [0.584 , 1.696] 0.937 [0.542 , 1.619]
DTP3 0-7 1.413 [0.923 , 2.160] 1.293 [0.830 ,2.014 ]
MMR 6-11 3.214 [2.656 , 3.885] 3.386 [2.806 , 4.088]
Table 5.6 shows that results from both the spline-based and standard SCCS methods 
are similar. There was no significantly increased risk of febrile convulsion of the three 
doses of DTP whereas exposure to MMR vaccine had a significant effect with a relative 
incidence of 3.214[2.656 , 3.885] and 3.386[2.806 , 4.088] from spline-based and standard 
SCCS analysis respectively.
Table 5.7: Relative incidence (RI) and 95% Confidence intervals (Cl) for febrile convulsion due 
to exposure to DTP and MMR vaccines._____________________________________
Spline-based SCCS Parametric SCCS
Vaccine Risk period RI 95% Cl RI 95% Cl
DTP all doses 0-3 1.905 [1.349 , 2.668] 1.420 [0.963 , 2.092]
4-7 1.391 [0.933 , 2.075] 1.184 [0.774 , 1.812]
8-14 1.225 [0.899 , 1.670] 0.974 [0.693 , 1.366]
MMR 6-11 3.781 [3.120 , 4.492] 3.451 [2.854 , 4.175]
15-35 1.241 [1.050 , 1.453] 1.197 [1.013 , 1.414]
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The second analysis was performed by considering any DTP vaccine with three differ­
ent risk periods (0-3, 4-7 and 8-14 days after vaccination), and two risk periods after MMR 
vaccination (6-11 and 15-35 days). Results are presented in Table 5.7 and Figure 5.7.
The fitted age-specific relative incidence curves obtained from the standard and the 
spline-based SCCS are presented in the left panel of Figure 5.7. The right panel of 
Figure 5.7 shows the cumulative age-specific relative incidence curves, where the dashed 
line is from the spline-based SCCS and the solid line from the param etric SCCS. The model 
degrees of freedom obtained for the optimum smoothing param eter value was 7.962.
0 100 200 300 400 500 600 700
Age (Days)
~i----- 1----- 1----- 1----- 1----- 1----- r~
100 200 300 400 500 600 700
Age (Days)
Figure 5.7: Left: Age-specific relative incidence; step function estimated by parametric SCCS, 
smooth curve estimated by spline-based SCCS. Right: Cumulative age-specific relative incidence; 
dashed line estimated by parametric SCCS and solid line estimated by spline-based SCCS.
Table 5.7 presents exposure-related relative incidence estimates from both  methods.
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It shows that the two methods gave similar results for MMR with significant associations 
between febrile convulsion and MMR vaccines in both risk periods, in line with other 
analyses (Farrington et al., 1995). RI estimates for DTP vaccines in the risk periods 4-7 
and 8-14 days were not significantly different from 1 for the two methods. However, there 
was a difference for the 0-3 days risk period. The RI estimate using the spline-based 
method was significantly greater than 1 whereas with the standard method it was non­
significant. This is due to the very strong age effect in the first year of life, which is 
inadequately controlled using the standard model with age groups of length one month. 
Thus, the spline-based method suggests that there may be an association between DTP 
vaccination and convulsions within 3 days post-vaccination, which was not identified using 
the piecewise constant model.
The DTP and Hib vaccines are usually given at the same time. In the data set there 
were large numbers of cases vaccinated with the two vaccines at the same time. The 
number of cases who took DTP1 and Hibl, DTP2 and Hib2 and DTP3 and Hib3 were 
909, 875 and 838 respectively. Since overlapping risk periods were coded to the latest 
vaccine, we had two final analyses in the investigation of the association between the 
paediatric vaccines and febrile convulsion. We first assumed that DTP was given before 
Hib so that the risk period following DTP will be coded by the risk period of Hib if they 
were both given at the same time. And the second analysis was performed assuming that, 
for individuals vaccinated with DTP and Hib at the same time, Hib was taken before 
DTP. In these analyses we used one risk period of 0-3 days post DTP vaccination, one 
risk period of 0-7 days post Hib, one risk period of 0-7 days post Hibonly vaccine and 
two risk periods after exposure to MMR vaccine (6-11 and 15-35 days). Results of the 
analyses are shown in Table 5.8.
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Table 5.8: Relative incidence (RI) and P5% Confidence intervals (Cl) for febrile convulsion due 
to exposure to DTP Hib, Hibonly and MMR vaccines._________________________
Spline-based SCCS Parametric SCCS
Vaccine Risk period RI 95% Cl RI 95% Cl
Assuming DTP was taken before Hib
DTP any dose 0-3 1.551 [0.923,2.608] 1.154 [0.633 , 2.106]
Hib any dose 0-7 1.352 [1.026 , 1.783] 1,296 [0.926 , 1.815]
Hibonly 0-7 1.019 [0.549 , 1.893] 1.016 [0.544 1.896]
MMR 6-11 3.794 [3.151 4.537] 3.464 [2.864 , 4.189]
15-35 1.248 [1.061 1.469] 1.203 [1.018 , 1.420]
Assuming Hib was taken before DTP
DTP any dose 0-3 1.831 [1.297 , 2.586] 1.431 [0.974 , 2.103]
Hib any dose 0-7 1.131 [0.715 , 1.789] 0.984 [0.555 , 1.745]
Hibonly 0-7 1.045 [0.560 , 1.949] 1.050 [0.563 , 1.960]
MMR 6-11 3.789 [3.157 , 4.546] 3.462 [2.863 , 4.186]
15-35 1.246 [1.057 , 1.469] 1.202 [1.018 , 1.420]
The relative incidence of exposure to Hibonly vaccine was found to be non-significant 
in both analyses using both methods (Table 5.8). When DTP was assumed to be given 
before the Hib vaccine the RI estimate associated with exposure to DTP was found to be 
non significant whereas exposure to Hib vaccine has an increased risk of febrile convulsion 
for the spline-based SCCS analysis but not for the standard method. The result was 
reversed when we assumed Hib vaccine to be given before DTP. Relative incidence of 
febrile convulsion in the period 0-3 days post DTP vaccine was significantly different 
from 1 in the spline-based analysis.
To investigate the sensitivity of exposure-related relative incidence estimates with a 
change in the value of a smoothing parameter, we fitted the spline-based SCCS to the data 
with different values of the smoothing parameter. We considered any DTP dose vaccine
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with three risk periods and MMR vaccines with two risk periods. The relative incidence 
estimates of exposure to DTP and MMR vaccines with varying smoothing parameter are 
presented in Figure 5.8.
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Figure 5.8: Estimated relative incidence after exposure to MMR and DTP vaccines for specified 
risk periods (in days: see legend) for different values of the smoothing parameter A.
The relative incidence estimates were found to be insensitive to the choice of smoothing 
parameter. From Figure 5.8, it can be seen that the exposure to vaccine related relative 
incidence estimates remain similar for varying smoothing parameter values within this 
range.
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5.5 Discussion
Modelling of the age effect in the SCCS model with smooth functions was presented 
in this Chapter. Using a polynomial function to model the log of the baseline incidence is 
one way of avoiding the limitations associated with the standard SCCS method. However 
the use of polynomial functions to represent the log of the age-specific relative incidence 
function has two limitations: (1) bad fit in one part of a function affects the whole 
function and (2) for higher order polynomial functions the integral in the denominator 
of the SCCS log-likelihood function has to be integrated numerically, hence adding to 
the computational complexity. We suggest to solve problem (2) by directly modelling 
the age-specific relative incidence function by a polynomial function and constrain the 
coefficients of the polynomial to be non-negative. This can help to analytically integrate 
the denominator of the SCCS log-likelihood function.
Lee and Carlin (2014) proposed the use of fractional polynomials to estimate the pa­
rameters in the piecewise constant function representing the age effect in the standard 
SCCS method. However, although the proposed method reduces the number of parame­
ters that need to be estimated compared to the standard and semi-parametric methods, 
there is a need to pre-define age groups. Moreover, if each day within an observation 
period is used as an age group it may face the same computational problem as for the 
semi-parametric method since the data will have to be expanded. However, fractional 
polynomials can be used to estimate a smooth age effect. We suggest to represent the 
age-specific relative incidence with fractional polynomials by constraining their coeffi­
cients to be non-negative to analytically integrate the denominator of the log-likelihood 
function. Using this approach the data are not required to be expanded.
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Modelling the age effect using a linear combination of cubic M-splines avoids the 
problem of sensitivity to mis-specification of age groups in the standard (piecewise con­
stant) version of the SCCS method and the computational problem of the semi-parametric 
SCCS method. The performance of the new method is as good as or better than the semi- 
parametric and the standard versions of the SCCS method for small and moderate sample 
sizes. For large samples the semi-parametric SCCS is computationally demanding but the 
new method works well. For example, for our convulsions data with 3,826 events and 5 
risk periods, the spline model took less than two minutes to fit on a standard desktop 
computer. Part of the problem with fitting the semi-parametric model relates to the use 
of standard software for fitting Poisson models and maximising conditional likelihoods, 
which require the data to be expanded. There may be others ways of proceeding that 
avoid this step. However, when there are N  cases, O(N) parameters must be estimated, 
which is likely to be problematic for large data sets. The spline-based model provides a 
more economical representation of the age effect in such settings.
Like the standard SCCS methods, the spline-based method requires the three assump­
tions which were set out in Section 2.1.1 of Chapter 2. As described in Section 5.4, these 
conditions are likely to be met in our application to febrile convulsions. More generally, 
if the event of interest is not recurrent, or if recurrences are not independent, then the 
SCCS model can validly be applied to the first event provided the risk of a first event is 
low (say less than 10% during a typical observation period (Farrington et al., 2011)). If 
exposures are not exogenous, then a modified SCCS method can be applied (Farrington 
et al, 2009). A further version of the method can be used if observation periods are 
not event-independent (Farrington et al., 2011). On the other hand, experience with the 
method suggests that results are typically robust to mild departures from the hypothe­
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ses. More work is required, however, to characterise the circumstances in which such 
robustness cannot be taken for granted.
Our aim in the present chapter was to model the age effect non-parametrically, this 
effect seldom being of primary interest. The exposure effect, on the other hand, is modelled 
parametrically using step functions, selected on the basis of prior knowledge or hypotheses. 
In some applications, however, it might be important to estimate the exposure effect more 
flexibly, notably in exploratory analyses. To this end, we extend the spline-based model 
to allow flexible modelling of the exposure effect in Chapter 6.
Chapter 6
Flexible M odelling of Vaccine Effect
The effect of the time-varying confounding variable age, in the SSCS method, has been 
modelled in three different ways as discussed in Chapter 2 and Chapter 5: (1) para­
metric SCCS where the age effect is included in the model as a step function, (2) semi- 
parametric SCCS where the age effect is left unspecified and (3) spline-based SCCS where 
the age-specific relative incidence is represented by a linear combination of cubic M-splines, 
whereas the effect of exposure to vaccines and other drugs is always represented by piece- 
wise constant functions. The focus of this present chapter, therefore, is the representation 
of the relative incidence function associated with exposure within SCCS vaccine studies 
using flexible functions. This work is an extension to the standard SCCS method, re­
cently proposed by Ghebremichael-Weldeselassie et al (2014b). There has been much 
work on flexible ways of modelling the exposure effect for standard study designs (case 
control and cohort study designs). These involve representing the exposure history as a 
convolution of past exposures that combines information about duration, intensity and 
timing of exposure in one summary measure, as proposed by Breslow et al. (1983) and 
Thomas (1988). Letting z(u) to be dose or intensity of exposure at time u and w(u,t)
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a function that assigns weights to past exposures, the weighted cumulative exposure at 
time t is defined as
W CE(t) = f  z(u)w{u,t)du.
J o
Within this context, interest has focused on modelling the weight function w(u,t), 
whether by a priori chosen parametric models (Vacek, 1997; Langholz et al, 1999; Abra- 
hamowicz et al, 2006) or spline models of varying complexity (Hauptmann et al, 2000, 
2001; Berhane et al, 2008; Sylvestre and Abrahamowicz, 2009), with applications to en­
vironmental and drug exposures.
Four alternative parametric forms of the weight function were selected a priori by 
Vacek (1997) in a case control study design and the fits of the resulting models were 
compared to select the best fit to the data. Langholz et al (1999), in the same study 
design, proposed to fit the weight function as parametric bilinear and exponential decay 
functions of time since exposure and applied it to a data on Colorado Plateau uranium 
miners to analyze latency effects of exposure to radon on lung cancer. Abrahamowicz 
et al (2006) on the other hand proposed to use a priori selected parametric forms of the 
weight function or latency function to study the risk of fall related injuries among elderly 
new users of three benzodiazepines (nitrazepam, temazepam, and flurazepam) in a cohort 
study design using the Cox proportional hazards model.
In the case of vaccines, a point exposure occurs at the age of vaccination c, so z(u) is 
a Dirac delta function. Setting w(u, t) = w(t — u) we obtain the WCE function
W CE(t) = w(t — c) for t > c, 0 otherwise.
While our focus is on vaccines, the approach developed here has broader applica­
bility, as will be shown in one of our examples in Section 6.3. In the standard SCCS
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methodology, WCE{t) (exposure-related relative incidence function) is represented by a 
step function, with pre-determined cut-points. This may not be biologically plausible 
and may incur losses in efficiency (Greenland, 1995a; Weinberg, 1995; Zhao and Kolonel, 
1992). Furthermore, a poor choice of cut-points may be associated with cut-point bias and 
misclassification (Altman, 1991; Greenland, 1995b). We therefore propose a more flexible 
way of modelling the exposure effect in SCCS studies. We represent the exposure-related 
relative incidence function (which is a function of time since exposure or time since start 
of exposure in the context of drugs other than vaccines) as a linear combination of cubic 
M-spline basis functions described in Chapter 4.
The chapter is organized in four sections. In Section 6.1 we discuss representation of 
the exposure-related relative incidence function (w(t — c)) as a linear combination of cubic 
M-splines. Section 6.2 presents a simulation study conducted to evaluate the performance 
of the new method and compare it with the existing step function approach followed by 
application of the new approach, to febrile convulsions and MMR vaccine, and to fractures 
and thiazolidinedione use in Section 6.3. And finally in Section 6.4 we make some final 
remarks.
6.1 Spline-Based Exposure Risk Function
Regression splines provide smooth estimates with continuous first two derivatives and 
are flexible enough to represent a variety of clinically plausible shapes (Smith, 1979). 
Hauptmann et al (2000) used constrained regression splines to represent the weight func­
tion in assessing the impact of exposure to smoking on lung cancer in a case control study. 
The weight function was represented as a linear combination of B-splines and the coeffi­
cients of the B-spline basis functions were constrained to be positive in order to obtain
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non-negative weight function. Similarly Sylvestre and Abrahamowicz (2009) proposed the 
use of regression splines based on B-splines to model the weight function in cohort studies. 
The authors parameterized their model such that there will be no need for constrained 
optimisation. In Sylvestre and Abrahamowicz (2009) the weighted cumulative exposure 
is calculated at each time during follow up whereas in Hauptmann et al (2000) it is eval­
uated only once at the end of follow up. Such extensions to model exposure effects were 
not introduced in the self-controlled case series method.
In the SCCS method we propose to approximate the exposure-related relative incidence 
function (the weight function) using regression splines based on M-splines. To begin 
with, we specify a nominal maximum risk period over which the exposure-related relative 
incidence function can be different from 1; outside this interval (which may be unbounded 
to the right), the function will take the value one. The argument of this function is time 
since start of exposure (in our case, vaccination). In the case of other drugs where the 
exposure is not a point exposure, there is no need to specify a nominal risk period, the 
duration of exposure is used as the risk period.
Recall that the likelihood function of SCCS derived in Chapter 2, for a single exposure, 
is given by:
l frfi ^ ')exp fo’few (61)
f=R i / > ( t ) e x p  {Xim d t ~
where and are the start and end of observation period for individual i, Uj is age of 
individual i when event j  occurs, ip(t) is age-specific relative incidence function and Xi(t) 
is exposure history of individual i (see Chapter 2 for more details). From the likelihood 
function (6.1), the exposure-related relative incidence function is required to be a positive 
function. Therefore, we use a linear combination of cubic M-spline basis functions, which 
are positive functions, to represent it. An M-spline of order q, as described in Chapter 4,
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is a positive function constructed by combining pieces of polynomial functions of degree 
q — 1 connected at knots. To keep positivity of the M-splines when combined linearly, we 
constrain their coefficients to be non-negative. Therefore, the function representing the 
exposure effect in equation 6.1, exp {^(t^  )/?}, will be replaced by a function of time since 
exposure represented as a linear combination of M-splines of order four:
I 5 X i  g{Pi)Mi(t -  c), c < t < d
L)(t  ~  C) =  <
1, otherwise,
where g(Pi) are parameters to be estimated to determine the shape of the function, c is
age at start of exposure, d is age at end of the nominal risk period and m  is the number of
M-spline functions. We shall choose g(/3i) = fif to ensure positivity of the function. The
value m  depends on the number of interior knots and the order of M-splines chosen: m =
number of interior knots +  order. Usually a number of interior knots between 8 and 12
is sufficient (Joly et a l , 1998). We choose equidistant knots between 0 and maximum of
d i ~ C i  (or the length of the nominal risk period for point exposures like vaccine), inclusive,
and add an extra q — 1 equidistant knots below the minimum and above the maximum
knots to construct the M-spline basis functions, di is age at the end of exposure for
individual i. When di = oo we set it equal to the value of bi.
Replacing the exposure effect in Equation (6.1) by a linear combination of cubic M- 
splines gives the log-likelihood function
i ~  c<))I{Ci<tii- di) \  (62)
«  U  \ £  W)(E£i m ( t  - '
where / (q  < tij < d^ ) is an indicator variable that takes the value one if the event time 
is within the nominal risk period and zero otherwise.
The age-specific relative incidence is represented by a step function, as in the standard 
SCCS method. Thus, we subdivide the observation period of each case into intervals
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(lih,Uih]i h indexing the age group, with age-specific relative incidence exp(a^). Without 
loss of generality, we can choose these intervals to be sufficiently narrow (by splitting them) 
that they are properly contained in (c*, c£J or its complement in (ai: The log-likelihood
is then:
N ni1 — Inp. (  exp(a /t(t,j))(££l 3<d*) \
h h  V ^ exP ^ ) C ^  K ' }
where h(i,j)  is the age interval containing Uj.
The integral in the denominator of the log-likelihood function (6.3) can be replaced 
by a linear combination of integrated splines (I-splines), since the integral of an M-spline 
function of order q can be expressed as an I-spline of order q +  1. Hence, denoting the 
length of interval h for the ith individual by =  uih — lih , our log-likelihood function 
will be:
. y ' V ' l  ( _________________ e x p K (i,, .) ) ( £ £ !  _________________
u h  °g VE e x p - Ci) - T Z i f l W i h  - Ci))^^<*)
(6.4)
To estimate the parameters of interest from the log-likelihood in (6.4), we introduce 
a roughness penalty term that controls the smoothness of the exposure-related relative 
incidence function. As in (O’Sullivan, 1988a) the penalty is based on the second derivative 
of the linear combination of cubic M-splines. Thus, the penalised log-likelihood function
is:
2
?2
p i  =  l ~  ( Y ] ! 3i m i ( u ) I d u
= I -  A K /J ffA # ) (6.5)
where I is the log-likelihood function given in Equation 6.4, A is an m  x m  matrix with 
(r, I) element f  M ”(u)Mi(u)du and A > 0 is a smoothing parameter that controls the 
balance between smoothness of the function and fit to the data. One can also use a dif­
ference penalty as in (Eilers and Marx, 1996). The smoothing parameter A is chosen by
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maximising an approximate cross-validation score while keeping the age effect to be con­
stant (i.e. setting the =  0). The approximate cross-validation score to be maximised 
is similar to the score in Equation 5.8 of Chapter 5 and is given as
V(X) = 10) -  tv([H -  2AS]-1# ) , (6.6)
since pf is used to keep positivity of the exposure relative incidence function
S =  4 (Ao(/3/3t )) +  2(diag(A/32)).
Once the smoothing parameter is chosen, we maximise the penalised log-likelihood func­
tion (6.5) for fixed A to estimate the parameters related to age and exposure effects.
6.1.1 Approxim ate Confidence Bands
In the context of cross-validated smoothing spline models, Wahba (1983) proposed 
Bayesian technique to generate confidence bands in which an improper prior for the func­
tion to be estimated was constructed using an integrated Wiener process. Silverman 
(1985) modified the idea of Wahba (1983) and came up with the same results using sim­
pler and more intuitive priors. Silverman (1985) uses the roughness penalty term in 
a penalised log-likelihood function to be a prior log-likelihood. In simulation studies, 
Bayesian confidence intervals based on this approach proved to have good coverage prop­
erties, provided coverage is measured across the function, rather than point wise (Wood, 
2006b). O’Sullivan (1988a) proposed the use of an approximate Bayesian technique for 
generating confidence bands for penalised likelihood estimators in the context of survival 
analysis, used in several applications including O’Sullivan (1988b) and Joly et al (2002). 
Following O’Sullivan (1988a) we use the Bayesian-like technique to generate confidence 
bands for the exposure-related relative incidence estimators.
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The penalised log-likelihood function (6.5) has two parts; the log-likelihood function 
(I) and the penalty component (A((/32)TA/32)). Then considering the penalty term to be 
a prior log-likelihood for /3 leads in principle to the penalised log-likelihood function (6.5) 
to be a posterior log-likelihood for (3. Expanding the posterior log-likelihood in a second 
order Taylor series about the posterior mode of (3 gives an approximate covariance of (/3) 
to be Vpi, where Vpi is the negative of the inverted hessian of the penalised log-likelihood 
function evaluated at the penalised maximum log-likelihood estimates.
Our approximation of the exposure-related relative incidence function used g({3i) = (3f 
to keep positivity of the function, we therefore need to know the covariance of /%. The 
required covariance matrix can be obtained using the delta method as
Vtr = 4diag(/3)[T^](diag(/3))T.
Hence an approximate 95% confidence interval for the exposure-related relative incidence 
at a point r  is
C j { t )  ±  M ( T)T VtrM (T)
where r  is time since first exposure and M (r)T =  (Mi (t), . . . ,  Mm(r)).
Alternatively, to ensure that the confidence bands lie above zero, they can be obtained 
on the log scale as
u (t)  exp{±1.96^/M ( T ) TVtrM (r ) /u j ( r ) } .
The confidence bands obtained in this way, however, are not really confidence bands for 
oo (t) rather they are confidence bands for a)(r) =  E(cu(r)), which can be taken as smoothed 
version of lo(t ) (Wasserman, 2006). Therefore, we have to be cautious in reporting the 
results as the confidence interval will not be centered around the true function u;(r) due 
to the smoothing bias.
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6.1.2 F itting the M odel
In order to fit the SCCS model with smooth exposure effect the data are required to be 
pre-processed based on age groups and the nominal risk period chosen, in a similar way to 
the parametric version of SCCS. The observation period of each event is subdivided into 
intervals and the data are reformatted such that each row contains information about 
a specific interval. The information contained in each interval after reformatting are: 
number of events (0 or 1), age at event (same for all intervals), upper limit, lower limit, 
length of the interval, age at start of exposure (same for all intervals of an event), age 
group and exposure status (a binary variable that indicates whether the specific interval 
lies within the control or the nominal risk period). For example suppose individual 1 
who has been observed from age 0 — 730 days experienced an event of interest at age 
161 days and was vaccinated at 605 days of age. Then choosing the age cut points to be 
426,487,548,609 and 670 days and a nominal risk period of 49 days the data for individual 
1 are expanded as in Table 6.1
Table 6.1: Data from a single event reformatted such that the observation period is divided based 
on age groups and a nominal risk period
Indiv Events Eventday Upper lower Length Age at Age Exposure
limit limit Exposure group status
(t) (u) (1) (e) (c)
1 1 161 0 426 426 605 1 0
1 0 161 426 487 61 605 2 0
1 0 161 487 548 61 605 3 0
1 0 161 548 605 57 605 4 0
1 0 161 605 607 2 605 4 1
1 0 161 607 609 2 605 4 0
1 0 161 609 670 61 605 5 0
1 0 161 670 730 60 605 6 0
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Once the data are reformatted the required ingredients of the log-likelihood function 
can be computed after selecting the number of knots that define the exposure-related 
relative incidence function. The function is defined between zero and the length of the 
nominal risk period or maximum of age at the end of exposure minus age at the start 
of exposure for non-point exposures. However, the time since exposure for events that 
occur before exposure is negative. Therefore, to compute the M-splines we replace the 
negative time since exposure values by zero and for events that occur beyond the nominal 
risk period we change their time since exposure value to the length of the nominal risk 
period. These changes will have no effect because the linear combination of the M- 
spline functions is forced to be one for the events occurring in the control periods by 
the indicator variable introduced in the log-likelihood function (6.4). And the I-splines 
in the denominator of the log-likelihood can be obtained in same way. After computing 
the M and I-splines at the required values, we choose the smoothing parameter using the 
approximate cross validation method by assuming no age effect. We then maximise the 
penalised log-likelihood function (6.5) fixing the smoothing parameter at the optimum 
value.
6.2 Simulation Study
To evaluate the performance of the new approach and compare it with the standard 
SCCS model, we conducted a simulation study. In this section we describe the design of 
the simulation study and results.
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6.2.1 Design of the Simulation Study
We fixed the number of cases in all the data sets to be generated at 1,000. The length 
of the observation period for all cases was chosen to be 730 days, where age at the start 
of observation a* =  0 days and age at the end of observation bi = 730 days for all cases. 
Ages at vaccination or start of exposure (c*) were uniformly distributed, see Section 7.4 
of Chapter 7 for performance of the new method when q  are not uniform ly distributed.
Four different scenarios of true exposure-related relative incidence function were con­
sidered and generated from beta densities (Figure 6.1).
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Figure 6.1: True exposure-related relative incidence curves used in simulating the samples
These functions show how the true exposure relative incidence values change with time 
since vaccination or start of exposure. The risk periods considered in all scenarios were 
of length 49 days. Hence 49 relative incidence values were generated based on the shapes 
chosen and obviously the true exposure relative incidence values outside the risk period
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(in the control periods) were taken to be one. The effect of age was represented using a 
step function in which we used six age groups; (0 — 426], (426 — 487], (487 — 548], (548 — 
609], (609 — 670] and (670 — 730] with true relative incidence rates 1,2,5,8,10 and 15 
respectively. Performance of the method developed in this chapter when the true age- 
specific relative incidence function is different from a step function (a sine function) can 
be seen from Section 7.4 of Chapter 7.
6.2.2 D ata Generation
To generate number of events per individual and ages at event, first the observation 
period of each case is divided into intervals based on age and exposure groups. The 
intervals within the exposure risk period have length of one day because the true exposure 
relative incidence values change with age. Then incidence rates at each interval are 
computed as the age-specific incidence rate times the exposure-related relative incidence. 
Within the control periods, this is simply the relative incidence of the age group. From 
these, an average incidence rate for each individual is calculated to generate the marginal 
number of events per individual from a truncated Poisson distribution. Given the number 
of events for an individual generated from the truncated Poisson and incidence rates 
in each interval within the observation period, a multinomial distribution was used to 
identify in which interval the events occurred. Then a uniform distribution was used to 
generate event ages within the interval found to have an event. For each scenario 100 
samples of 1,000 cases were generated in this way.
6.2.3 Analysis
Each of the simulated data sets were analysed using both the standard SCCS and 
the new approach with risk periods totalling 49 days following exposure (as simulated)
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or with an extended nominal risk period of 98 days. In the standard SCCS, the risk 
period of 49 days following an exposure was divided in to seven groups of length seven 
days (with seven parameters). We also used an extended nominal risk period of 98 days, 
and fitted a standard SCCS model with 14 seven-day groups (and 14 parameters). In 
addition, we fitted the standard SCCS model with 49-day risk intervals (and hence one 
or two parameters, according to the nominal risk period). In all the spline-based analyses 
we used nine interior knots and the approximate cross-validation score was employed to 
choose the smoothing parameter. The standard SCCS method was fitted to evaluate the 
performance of the new method relative to it.
To compare the performance of the spline-based and standard SCCS methods we calcu­
lated the distances between the estimated and true exposure relative incidence functions. 
We used the Integrated Squared Error (ISE) to measure the distance, that is
f  (uj(t — c) — £j(t — c))2dt,
J c
where u(t — c) is the true exposure-related relative incidence function, Cj{t — c) the es­
timated relative incidence function, c age at the start of exposure and d age at the end 
of exposure or nominal risk period. We computed the mean (MISE) and the standard 
deviation (SD) of the integrated squared error values obtained from the 100 samples. In 
addition to the MISE we used plots to make comparisons.
6.2.4 Results
In this section we present results of the simulation study. Figures 6.2 and 6.3 show 
the estimated exposure-related relative incidence curves obtained by fitting the spline- 
based and standard SCCS methods to the 100 randomly selected samples. The mean and 
standard deviation of the integrated squared errors are presented in Table 6.2.
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Figure 6.2: Estimated relative incidence curves obtained by fitting the spline-based arid standard 
SCCS to 100 randomly selected samples with the true relative incidence functions in thick white. 
Top row: estimates from the spline-based method; bottom row: results from the standard SCCS. 
Nominal risk period of f.9 days was used.
The results presented in Figure 6.2 are obtained when the risk period is kept at 49 
days post exposure (which is equal to the risk period used to simulate the d a ta ). The top 
row presents results from the spline-based method and in the bottom  row are results from 
the standard method. Results obtained by analysing the 100 randomly selected samples 
using both methods with a nominal risk period of 98 days are presented in Figure 6.3. 
The curves estimated from the standard method are step functions. The results from 
the spline-based analysis show th a t the shapes of the true relative incidence curves (thick 
white lines) were captured well by most of the estimated curves and all are included within 
the range of estimated curves in all scenarios. The variability of the estim ated curves by 
the spline method is less as compared to the curves estimated by the standard  SCCS 
method. Especially in scenario 2, where the true function is a constant, the variability 
from the standard method is very high. This is because we are estim ating a constant
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using seven or 14 parameters, which indicates loss of efficiency from the standard SCCS 
when we use a large number of exposure groups.
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Figure 6.3: Estimated relative incidence curves obtained from fitting spline-based and standard 
SCCS to 100 randomly selected samples with nominal risk period of 49 days. The thick white 
curve represents the true relative incidence function. Top row: estimates from spline method; 
bottom row: results from standard SCCS.
Similar to the results from the spline method, the true relative incidence curves lie 
within the estimated curves obtained from fitting the standard SCCS method.
Table 6.2 presents MISE and and standard deviation of the integrated squared er­
rors for all the four exposure-related relative incidence function scenarios presented in 
Figure 6.1.
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Table 6.2: Mean integrated squared error (MISE) and standard deviation (SD) obtained from 
spline-based and standard SCCS models. Each simulated data set was fitted twice by the two 
methods with nominal risk periods of 49 and 98 days____________________________
Spline-based SCCS Standard SCCS with Standard SCCS with
groups of length 7 days groups of length 49 days
Scenario MISE SD MISE SD MISE SD
Potential risk length of 49 days
1 7.982 5.685 14.993 8.202 37.934 3.494
2 9.575 10.190 31.368 16.434 5.498 7.559
3 5.453 5.625 12.338 6.207 22.388 2.924
4 6.478 8.376 14.650 7.300 43.490 4.593
Potential risk length of 98 days
1 14.875 7.096 20.072 7.926 38.121 3.414
2 34.112 13.747 38.750 18.549 8.012 10.127
3 6.439 5.283 20.000 18.791 22.654 2.659
4 8.151 6.823 19.037 8.201 44.232 3.059
Table 6.2 shows that the mean integrated squared errors (MISE) are all lower for 
the spline method than the standard method, except for scenario 2, in which the true 
exposure-related relative incidence was constant. For this scenario, the correctly specified 
step function model (with one or two parameters) outperforms the spline model, though 
interestingly, the over-specified step function model (with seven or 14 parameters) does 
not. Comparable but slightly degraded results were obtained for scenarios 1, 3 and 4 with 
the 98-day nominal risk period as with the correct 49-day risk period. For scenario 2, the 
spline method produced worse results with the 98 day risk period compared to 49 day 
nominal risk period.
Figures 6.4 and 6.5 present the systematic error or bias at a point r  (time since 
exposure) and standard deviation of estimated exposure relative incidence values at a
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point r . The bias was calculated as
average(cu(r)) — cu(r),
where cj(t ) is the true relative incidence at point r , cj(t ) estimated relative incidence at 
point t  and the average is the mean of the estimated relative incidences at point r  over 
the 100 runs of simulations. The standard deviation is taken over the 100 a)(r) values.
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Figure 6.4: Bias (top row) and standard deviation (bottom row) of estimates obtained by fitting 
the spline-based SCCS (solid lines) and the standard SCCS (dotted lines) with nominal risk 
period of 49 days to the simulated data sets. 7 exposure groups were used when fitting the 
standard SCCS.
Figure 6.4 shows the bias (top row) and variability (standard deviation, bottom row) 
of estimates from the standard (with 7 parameters) and the spline-based SCCS methods 
with a 49 day post exposure nominal risk period. The bias of the standard method 
has a saw-tooth appearance in scenarios 1, 3 and 4 related to discontinuities at the cut-
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points, whereas the spline method occasionally shows some bias at endpoints, notably for 
scenarios 2 and 3. The spline method produces lower standard deviations, except at the 
endpoints.
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Figure 6.5: Bias (top row) and standard deviation (bottom row) of estimates obtained by fitting 
spline-based SCCS (solid lines) and standard SCCS (dotted lines) to the simulated data sets. 
A nominal risk period of 98 days was used, divided into 14 exposure groups when fitting the 
standard SCCS.
Similar results were obtained when the nominal risk period was extended to 98 days 
post exposure, as presented in Figure 6.5. However, for scenario 2 there is higher absolute 
bias for splines than the standard method around 49 days since exposure where the true 
relative incidence value of 4 drops to 1. The variability is still higher for the standard 
method than the spline method.
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6.3 Application
In this section, we illustrate the use of the new method that represents vaccine effect 
using a smooth function (a linear combination of M-splines) and the standard SCCS 
method, for comparison purposes, to two data sets. The first application is on a data set 
of MMR vaccine effects introduced in Section 5.4 of Chapter 5. Although the method 
developed here focuses on representation of vaccine effects, it can be applied to non 
vaccine exposures and therefore we apply it to data on the effect of thiazolidinediones use 
in causing fracture.
6.3.1 Analysis of Febrile Convulsion D ata
The aim of this analysis is to investigate a potential association between febrile con­
vulsions and measles/mumps/rubella (MMR) vaccine using the new spline-based and 
standard SCCS methods. The data set, as described in Chapter 5, comprises of 2,389 
children aged between 29 and 730 days in the period 1991-1994. They experienced 3,826 
febrile convulsion events in total, indicating that there were children with more than one 
event of febrile convulsion. In this example, we used 50 days post MMR vaccine as a 
nominal risk period for all cases to represent the exposure effect with splines. Since all 
individuals have the same nominal risk period of 50 days, we defined 12 equidistant inner 
knots between 0 and 50 days. Age was included in the model as a step function. There 
were 21 age groups of length 30 days while the first and last groups were of length 32 and 
40 days respectively.
A linear combination of cubic M-splines was used to represent the MMR-related rel­
ative incidence function. The value of the smoothing parameter selected by the ap­
proximate cross-validation score was 0.031. We present the relative incidence function
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estimated by maximising the penalised log-likelihood function (6.5) along with its ap­
proximated confidence bands in Figure 6.6. The figure shows no risk of febrile convulsion 
in the first three days post MMR vaccination and a borderline non-significant relative 
incidence of 1.248 at the fourth day. However, there is a significantly increased risk be­
tween five and 11 days after exposure to the vaccine. The relative incidence at the 5th 
day is 1.922 and increases smoothly to 3.647 at the eighth day and then the risk decreases 
to 1.244 at 12 days since exposure. There is also an increased risk of febrile convulsion 
due to MMR vaccine between 19 and 21 days post vaccination. At all other times after 
vaccination there is no significantly increased risk of febrile convulsion.
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Figure 6.6: Smooth estimate of the relative incidence function related to exposure to MMR 
vaccine (bold line) and 95% confidence bands (doted lines).
We also fitted the standard SCCS method, where age and exposure effects are rep-
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resented by piecewise constant functions, to the data set on febrile convulsion. We used 
the same 21 age groups described above to model the age effect and for the exposure 
effect we divided the 50 days post MMR vaccine nominal risk period in to 10 groups. The 
ten exposure groups had cut points at 6,11,18,22,26,30,36,40 and 45 days since vac­
cine. The results from this analysis are presented in Table 6.3 and Figure 6.7. Figure 6.7 
presents the exposure to MMR vaccine specific relative incidence functions estimated from 
the standard SCCS model (step function) and the spline-based SCCS method (smooth 
function).
Table 6.3: Relative incidence (RI) estimates of exposure to MMR vaccine and lower and upper 
95% confidence intervals obtained from fitting parametric SCCS method with 10 exposure groups 
and 21 age groups________________________________________________
Exposure Group Relative Incidence 95% Confidence Interval
(Days) (RI) Upper Lower
0-6 1.226 0.922 1.629
6-11 3.489 2.881 4.225
11-18 0.827 0.600 1.139
18-22 1.493 1.087 2.050
22-26 1.089 0.752 1.577
26-30 1.167 0.816 1.671
30-36 1.159 0.862 1.559
36-40 1.368 0.980 1.909
40-45 0.977 0.687 1.390
45-50 1.103 0.790 1.539
Figure 6.7 shows that the results obtained from the two methods are similar since the 
exposure groups used in the standard method are correctly specified. However, different 
categorizations may give different results for the standard SCCS method, which is a 
disadvantage of the method if the correct exposure groups are not known.
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Figure 6.7: Relative incidence functions related to MMR vaccine estimated from fitting the stan­
dard model with 10 exposure groups (step function) and spline-based SCCS (smooth function).
6.3.2 Analysis of Fracture Data
The methods developed in the present chapter can be applied more widely. We illus­
trate this with data on fractures and thiazolidinediones, which were analysed by Douglas 
et al. (2009) using the standard case series method. Thiazolidinediones are a class of 
medicines used to treat type 2 diabetes.
Diabetes is a lifelong condition that causes a person’s blood sugar level to become too 
high. In the UK, approximately 2.9 million people are affected by diabetes. There are 
also thought to be around 850,000 people with undiagnosed diabetes (NHS, 2013). There
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are two main types of diabetes, referred to as type 1 and type 2. Type 2 diabetes occurs 
when the body does not produce enough insulin to function properly, or the body’s cells 
do not react to insulin. This is known as insulin resistance. Type 2 diabetes is far more 
common than type 1 diabetes. In the UK, about 90% of all adults with diabetes have 
type 2 diabetes (NHS, 2013). Type 2 diabetes usually affects people over the age of 40, 
although increasingly younger people are also being affected.
Diabetes cannot be cured, but treatment aims to keep blood glucose levels as normal 
as possible to control symptoms and minimise health problems developing later. In some 
cases of type 2 diabetes, it may be possible to control symptoms by altering your lifestyle, 
such as eating a healthy diet and exercise. However, as type 2 diabetes is a progressive 
condition, it may eventually be needed to take medication to keep blood glucose at normal 
levels. To start with the medication usually takes the form of tablets, but later on it may 
include injected therapies, such as insulin.
There are different types of medicines recommended to treat diabetes 2, including met­
formin, sulphonylureas, thiazolidinediones. Thiazolidinediones also known as glitazones, 
make body cells more sensitive to insulin so that more glucose is taken from blood. The 
first type of thiazolidinediones, pioglitazone, is usually used in combination with met­
formin or sulphonylureas, or both. They may cause weight gain and ankle swelling (NHS, 
2013). Another thiazolidinedione, rosiglitazone, was withdrawn from use in 2010 due to 
an increased risk of cardiovascular disorders, including heart attack and heart failure.
The aim of the study in Douglas et al. (2009) was to investigate whether there is 
an increased risk of fracture associated with the use of thiazolidinediones. The fractures 
considered were classified according to fracture site (ankle, arm, chest/rib, face, hand, 
hip, leg, pelvis, shoulder, skull, wrist, spine, multiple sites and unknown site).
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The data used in the analysis were primary care computerized clinical records from 
the United Kingdom-based General Practice Research Database (GPRD). 1,819 patients 
aged about 40 years or older prescribed at least one thiazolidinedione and with at least 
one fracture event were included in the analysis. The data included patients with multiple 
fractures: 283 (16%), 64 (4%), and 25 (1%) had two, three, and four or more fractures, 
respectively. Multiple fractures were included in the analysis if the fractures happened at 
different sites or at the same site but at least 6 months apart. Out of the 1,819 patients 
990 (54%) were women with mean age at first thiazolidinediones prescription of 65.4 years 
and mean age for men was 57.9 years.
In Douglas et al (2009), the authors defined the control period to be from start 
of observation period until first prescription of a thiazolidinedione and the risk period 
was from age at start of thiazolidinedione use until age at end of observation period. The 
length of exposure following each individual prescription was calculated using information 
recorded in the GPRD on pack size and dosing frequency. Thiazolidinedione treatment 
was assumed to be continuous where any apparent treatment break was less than 60 
days, to allow for partial noncompliance and situations where patients may have built up 
treatment stocks (Douglas et al, 2009). Age at end of observation was then taken to be 
age at the earliest of any treatment break longer than 60 days or the end of recorded follow 
up in the database. The mean duration of control periods prior to thiazolidinedione use 
was 9.5 years, and the mean duration of exposure to a thiazolidinedione was 2.3 years.
Different analyses, using the standard SCCS method, were done by Douglas et al. 
(2009) including analysis for all fracture sites together with any type of thiazolidinediones 
(pioglitazone or rosiglitazone) exposure, for females only, males only, analysis by fracture 
site, analysis by taking patients who were exposed only to one type of thiazolidinediones
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etc. Here we present only one of their analyses with all fractures together and exposure to 
any thiazolidinedione use and reanalyse the same using the new method of representing 
the exposure effect.
Unlike vaccines, thiazoledinediones are not point exposures, however we can use a sim­
ilar approach as with vaccines by taking z(u) = z  for u > c, the age at first thiazeledine- 
dione, so W CE(t) = z f*  w(t — u)du and in the SCCS context it will be W CE(t) = 
zw(t — u). In the SCCS likelihood function the value z is cancelled out similar to the 
baseline incidence. This leads to the same likelihood function. We reanalyzed the data 
using the new version of SCCS where time since exposure is represented by a linear com­
bination of M-splines. In our analysis, we used the same exposure risk periods as in 
Douglas et al (2009). The maximum duration of exposure to thiazolidinedione was 2,364 
days. Hence our exposure-related relative incidence function was represented by a linear 
combination of cubic M-splines defined between 0 and 2,364 days since first exposure. We 
chose 14 equidistant knots between 0 and 2,364 days inclusive, i.e we have 16 M-spline 
basis functions. The time-varying confounding covariate age was taken into account using 
a piecewise constant function with 42 age groups: the first age group is less than 14,610 
days (40 years) of age, followed by five age groups of length two years, 28 groups of one 
year length, seven groups of length two years and the last age group with age greater than 
33,603 days (92 years).
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Figure 6.8: Negative of the approximate cross validation score versus the smoothing parameter 
to choose the value of the smoothing parameter that maximises the approximate cross validation 
score.
To estimate the parameters of interest, we first selected the optimum smoothing pa­
rameter, A, that maximises the approximate cross-validation score in Equation (6.6). This 
optimum A was 288 (Figure 6.8). Figure 6.8 plots the grid of smoothing parameter val­
ues, A, versus the negative of the approximate cross validation score and shows that the 
optimum value for the smoothing parameter is 288. We then maximised the penalised 
log-likelihood function in Equation (6.5) for fixed A =  288 to get the required parameters. 
The estimated exposure-related relative incidence function and its approximate confidence 
bands are presented in Figure 6.9.
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Figure 6.9: Relative incidence function estimate related to thiazolidinedione use (bold line) and 
95% confidence intervals (dotted lines).
From Figure 6.9, it can be seen th a t the relative incidence of fracture due to  thiazo­
lidinedione use increases as time since exposure increases. There is no significant increased 
risk of fracture in the first two months of exposure and the relative incidence is border­
line significant from two months to about one year and half, but there is a significantly 
increased risk of fracture due to exposure to thiazolidinedione thereafter, and the maxi­
mum relative incidence of 2.103 is reached after about 5 years of exposure. The relative 
incidence may start to decrease and the confidence bands widen after 5 years.
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Figure 6.10: Relative incidence functions related to thiazolidinedione use estimated by fitting 
the standard SSCS model with 13 exposure groups (step function) and the spline-based SCCS 
(smooth function).
In their standard SCCS analysis, Douglas et al (2009), defined five exposure groups 
of (0 — 1), (1 — 2), (2 — 3), (3 — 4) and (4 — 7) years since first exposure and obtained 
relative incidence estimates of 1.26,1.49,1.70,2.31, and 2.00 respectively. We repeated 
the analysis but with a different number and length of exposure groups. We divided the 
time since first exposure in to 12 groups of lengths six to nine months. Results from 
this analysis are presented in Figure 6.10 and Table 6.4. The results obtained from the 
standard SCCS method with 12 exposure groups are similar to those obtained by the 
spline method.
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Table 6.4: Relative incidence (RI) estimates of exposure to thiazolidinedione and lower and 
upper 95% confidence intervals obtained from fitting parametric SCCS method with 12 exposure 
groups and 4 2  age groups__________________________________________
Exposure Group Relative Incidence 95% Confidence Interval
(Years) (RI) Upper Lower
0.0 - 0.5 1.242 1.024 1.506
0.5 - 1.0 1.233 0.996 1.527
1.0- 1.5 1.262 0.997 1.596
1.5 - 2.0 1.691 1.335 2.143
2.0 - 2.5 1.748 1.346 2.269
2.5 - 3.0 1.587 1.174 2.146
3.0 - 3.5 2.099 1.546 2.850
3.5 - 4.25 2.223 1.646 3.003
4.25 - 5.0 2.284 1.591 3.280
5.0 - 5.5 2.059 1.183 3.583
5.5 - 6.0 1.690 0.770 3.709
6.0 - 7.0 0.894 0.122 6.535
6.4 Discussion
In this chapter, we proposed using penalised regression splines to model the effect of 
point exposures due to vaccination, and drug-related exposures more widely, in the self­
controlled case series method. We model the exposure-related relative incidence function 
as a linear combination of cubic M-splines. This approach avoids the limitations of the 
standard and semi-parametric SCCS methods that use step functions with pre-specified 
cut-points to assess the exposure effect.
Our spline-based SCCS method can be considered as a special case of weighted cumu­
lative exposure models used in environmental epidemiology, which have also made good 
use of spline models (Hauptmann et a l , 2000; Sylvestre and Abrahamowicz, 2009). These
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approaches have used information criteria to choose the number of knots in defining the 
B-spline basis functions. In our case, we intentionally selected a large number of knots and 
introduced a penalty term to the log-likelihood function to avoid over-fitting, the smooth­
ing parameter being chosen by an approximate cross validation score (O’Sullivan, 1988a; 
Joly et al., 1998, 2002). An approximate Bayesian like method was used to produce con­
fidence bands for the exposure-related relative incidence function. However, this method 
does not take the variability due to choosing the smoothing parameter into account. 
Bootstrapping is another option to generate the confidence bands but is computationally 
expensive.
Simulation studies showed that the new approach generally has a better performance 
than the use of step functions in the context of the SCCS method. The new method was 
applied to two data sets to investigate the association between febrile convulsions and 
MMR, and between fracture and thiazolidinedione use. The estimates obtained from the 
new method are consistent with the results from the standard SCCS method when the 
exposure groups are correctly specified. Increasing the number of a priori defined exposure 
groups in a standard SCCS model may help in capturing the true exposure-related relative 
incidence curve better, but at the cost of reduced efficiency. The new method is likely 
to be particularly useful in the absence of a clear, a priori hypothesis regarding the risk 
period. It can also be used to obtain an overall risk profile, or, if required, to specify risk 
periods upon which to base standard SCCS analyses in other data sets.
While our focus has been on developing methods for studying the safety of vaccines, 
they have wider applicability, as we have shown in our example on fractures and thiazo­
lidinediones. In the example on fractures and thiazolidinediones, we showed an application 
of the new method when the exposure period was from age at first prescription of the drug
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until the end of the observation period when there is no control period after the end of 
exposure. In addition, the method can be applied when there are interrupted exposures, 
that is individuals will have different length of exposure periods and the observation period 
goes beyond the end of exposure. This is done by assuming that the periods before the 
start of exposure and immediately after the end of exposure up to the end of observation 
period are control periods. However, in many pharmacoepidemiological studies it may be 
necessary to study the effect of exposure in the wash-out period, a period immediately 
after the end of exposure to drug. In this respect the new SCCS approach needs further 
extension.
Chapter 7 
Non-Param etric Self-Controlled Case 
Series M ethod
In Chapter 5, to avoid the limitations of the standard and semi-parametric versions of the 
SCCS method in modelling the age effects we represented the age-specific relative inci­
dence by a linear combination of M-spline functions. While the age effect was represented 
by a smooth function (based on splines), the effect of exposure was modelled using a step 
function. In Chapter 6, instead of using a step function we proposed using a linear combi­
nation of M-splines to model the effect of exposure, as a function of time since exposure. 
However, the age effect was represented by a step function. Both these extensions to 
the standard SCCS method involve step functions. Therefore, in this chapter we propose 
modelling both age and exposure effects using splines to create a fully non-parametric 
extension to the SCCS method. After some initial remarks in Section 7.1, the likelihood 
function of the non-parametric SCCS method is derived in Section 7.2. In this section, we 
also describe and define derivatives and integrals of M and I splines, and the integral of a 
product of two spline functions. Section 7.3 presents the penalised log-likelihood function
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of the non-parametric SCCS method and discusses the selection of smoothing parameters. 
In Section 7.4, we evaluate the performance of the new method using simulations. We 
apply the non-parametric SCCS method to data on febrile convulsion and MMR vaccine 
in Section 7.5 and finally follow this with a discussion in Section 7.6.
7.1 M odelling Age and Exposure Effects Using Splines
The use of regression splines in the context of the self-controlled case series method 
has shown an improved performance compared to the use of step functions as presented in 
Chapters 5 and 6. Among the motivations for using regression splines based on M-splines 
in these chapters were that the spline functions give flexible and plausible shapes of age 
and exposure-related relative incidence functions and avoid numerical integration of the 
integral in the denominator of the SCCS likelihood function. This numerical integration 
is avoided because the integral of an M-spline is an I-spline, therefore the integral of a 
linear combination of M-splines can be expressed as a linear combination of I-splines. 
Based on similar arguments, both age and exposure effects can be represented as linear 
combinations of M-spline basis functions. In this chapter, since age and exposure are to 
be represented by linear combinations of M-splines at the same time, the denominator of 
the SCCS likelihood function involves the integral of a product of two spline functions. 
This cannot be represented by a linear combination of I-splines only, so the integration 
cannot be avoided in the same way. Therefore, based on the definition of the integral of 
an M-spline developed by Ramsay (1988), we define first, second and third integrals of an 
I-spline. In the following section we derive the likelihood function of the SCCS method 
when both age and exposure effects are approximated by linear combinations of M-spline 
basis functions.
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7.2 Likelihood Function
To derive the likelihood function of the non-parametric SCCS method, we begin with 
the general SCCS likelihood function derived in Chapter 2, Equation 2.9 and, for one 
exposure, given as
l  f m
7=77=1 Ja‘ V’W exp {Xi(t)D} dt 
which in Chapter 6, we generalized to
t = TT f t  ~  Cj) i \
where a* and are the start and end of the observation period for individual i, ^ (t)  is the 
age-related relative incidence function, oj(t — c) is the exposure-related relative incidence 
function which takes the value one if the event day is not between age at start of exposure 
(ci) and age at end of exposure (d*). In the standard SCCS method, ip(t) and ui(t — c) 
are represented by step functions; in the semi-parametric version of SCCS, ^(t)  is left 
unspecified and uj(t — c) is fitted as a step function; in Chapter 5, ip(t) was approximated 
by splines and u)(t — c) by a step function, and in Chapter 6, ^(t)  was represented as a 
step function and uj(t — c) as a linear combination of M-spline functions. In this chapter, 
we approximate both ip(t) and uj(t — c) as linear combinations of cubic M-spline basis 
functions.
As in Chapter 5,4>(t) is defined between a =  min{aj; i = 1, . . . ,  N }  and b =  max{6j; i = 
1, . . . ,  N }, where N  is the total number of cases in the study. Since ^(t)  is a relative effect 
it has to be a positive function and to get such a function based on M-splines we constrain 
the coefficients to be non-negative and get the expression for ijj{t) as in Equation 5.2
m i m i
=  = ^2a$M u(t). (7.2)
i—i  i = i
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The g(ai) are parameters used to determine the shape of t) and are constrained to be 
non-negative by taking g{a{) = af . Mu(t) is the Ith M-spline basis function related to 
age, mi is the number of parameters or the number of M-spline basis functions which is 
equal to the sum of the number of interior knots and the order of the basis functions.
Similarly, as in Chapter 6, an exposure-related relative incidence function with non­
negative coefficients is defined between 0 and max{(di — a)\i  = 1 , . . . ,  N}, where c* and 
di are the start and end of age at exposure respectively for individual i. When the 
exposure is a point exposure, e.g a vaccine, a nominal risk period is defined which can 
be unbounded to the right. The nominal risk period is a period within the observation 
period where the exposure-related relative incidence can be different from 1 and outside it 
the exposure-related relative incidence function takes the value 1. Therefore, it is defined 
as: /
Y7=\ P?M2i{t -  c), c < t < d
LO (7.3)
1, otherwise,
where ra2 is the number of M-spline basis functions used to define the exposure-related 
relative incidence function, u(t — c) and M2z(t — c) is the Ith basis function related to 
exposure. In this Chapter the knots which are used to define the M-splines related to 
the age effect and the exposure effect are chosen to be equidistant including the arbitrary 
knots added below and above the minimum and maximum values of the variable.
Now replacing ip(t) and uj(t — c) in Equation (7.1) by the spline functions in Equa­
tions (7.2) and (7.3) respectively gives the likelihood function for the non-parametric 
SCCS as
fiM  £  ( E l \  « f M u ( t ) )  (E Z i  -  a ) ) 1^ ^  d t
and the log-likelihood function is
C h a p t e r  7. N o n -P a r a m e t r ic  S e l f -C o n t r o l l e d  C a s e  S e r ie s  M e t h o d 148
, f '  y V V  C T  ( £ S  f t m t g  -  c))Jfa<twai) A (74) 
« u 6; ( E z . ( E « a t ) '
To further simplify the denominator of the log-likelihood function (7.4) (so that it 
avoids numerical integration), we will use integration by parts. This will involve deriva­
tives and integrals of linear combinations of M-spline functions and integrals of the in­
tegrals. Therefore, before we proceed with simplifying the log-likelihood function, we 
describe derivatives of M-splines and define integrals of I-splines in the following subsec­
tions.
7.2.1 Derivatives of M-splines
Prom Chapter 4, we have that M-splines of order q are defined as divided differences 
of truncated power functions, that is, for a given knot sequence k\ = k2 = • • • =  kq <
k q + 1 <  ’ ’ ' <  k q + 8 <C k q + s + i  =  k q . | - s + 2  =  • • • =  k 2q-\-s
M'(i|<?) = ■ 9 , Bt{t\q) = (-1)*#/, ■ • •, h +q]T?(k)
M + q  ~  H
where T q{k) is a truncated power function of order q given by T q{k) = (t — k)q+ l . There­
fore, the first derivative of an M-spline function is
m m  , , a w n )
and the derivative of a truncated power function of order q is given by
=  { q -  l ) ( t _  * )£ *  =  ( ,  _  (*)
then using the definition of divided differences in Section 4.3.2, we have
d M , m  =  {_ l M q  _ 1J  [kw , k l+q} T ^ \ k )  -  [klt..., kl+q.,)T ^ -l\k )
dt \ ki-^ .q ki
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_ JL _ (_ i) .- i(g _ i) ([*,,...,f t^ ,]^ * -1)^) -  [fcm ,. . . ,k^T^Hk))
((-!)»->(, -  !)[*,... -  (-1 r H q  -  l)[kl+1, . .  , , k l+q\ T t l\ k ) )
q 1)) -A f(+i( t |(g -  1))).
kl+q h
In general, the j th derivative of an M-spline function of order q, Mi(t\q), is
dj Mi(t\q) =  q / dj~1M i(t\(q-  1)) _  dP~lMi+1{t\{q -  1))\  
dP ki+q — ki \  dP~l dP~l )  ’
so the j th derivative of a function which is a linear combination of M-spline basis functions, 
f i t )  = I X i  oqMi(t\q) , can be given as
dj f(t )  _  y ^ Q, dj Mi(t\q)
dP dP
1=1
7.2.2 Integrals of I-splines
Ramsay (1988) defined the integral of an M-spline of order q as an I-spline which is a 
piecewise polynomial of order q +  1. The definition is given in Chapter 4 for a sequence 
of knots ki = k2 = • • • =  kq < kq+1 < • • • < kq+s < kq+s+1 =  kq+s+2 =  • • • =  k2q+s used to 
define an M-spline of order q and kh < t  < kh+i as
i(t\q) = f  Mi(u\q)du,
J  a
SO
0, l>  h
h - q  + l < l < h
1 / < h — q +  1,
where the lower limit of the integrals is the minimum knot, let it be denoted by a. Based
on this definition for the integral of an M-spline we define the integral of an I-spline. Let
the integral of Ii{t\q) be denoted by Ij{t\q). Using the same sequence of interior knots
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employed to define the M-splines, for kh < t <  kh+1 the integral of an I-spline, I}{t\q), has 
three different expressions depending on the value of I. For I > h the value of an I-spline 
is zero so its indefinite integral will be a constant, and hence
!X(%) = f  Ii(u\q)du =  0.
J  a
For h — q + l < l < h & n  I-spline, Ii(t\q), is given by
m= l
therefore its integral will be
*t h
n m  = [  E ( w . - M M,n(ai\ + 1 )du
J a ,  Q +  1m=l
=  f ( W ’ km) f  Mm(u\q + l)du.
J S  9 +  1 J‘
f* Mm(u\q +  l)du in the above expression is the integral of an M-spline of order q + 1 that 
gives another I-spline, Im(t\(q +  1)) =  J2n=m(kn+q+2 “  kn)—^ 2) for h -  q < m < h, so
1 } m  =  £  ( W i - u  J 2 (  w  -  f c , ) - - ^ 2+ 2 ) .
m= l  n = m  ^
For I < h — q +  1, that is for any value of t > ki+q the value of Ii(t\q) = 1. This is 
because Mi(t\q) — 0 for all values of t > ki+q. Now the integral of h{t\q) has two parts 
for t > ki+q, the integral of the function up to ki+q and from ki+q to t. That is,
[ h+q I,(u\q)du+ f  I.Md)du =  .(^+9+1 ~ k"») f h+q Mm(„|g + 1)du\  +(t _  kl+q).
Jkl+<1 \m=l Q-r 1 j  a J
Therefore, in summary the integral of an I-spline is given by
0, I > h
\  'h  (fcm+qr+l k™) , i    i \ M n (t\q+2) h — n  -L i  C  1 <  h
Z-^m—l q+ 1 2-^n=m\Kn+q+2 q+ 2 » tl q  ~r 1 S  ‘  S
+ p.. I (fcm+g+l-fcm) / .  t n Afn (fc|+fl|g+2) I L , 1
1 Kl+q +  Z ^ m = i  g + 1  Z ^ n = m i ^ r i + 9 + 2  “  ^2---------j t  <  / I  -  £  +  I .
C h a p t e r  7. N o n -P a r a m e t r ic  S e l f -C o n t r o l l e d  C a s e  S e r ie s  M e t h o d 151
The second integral of an I-spline, the integral of I}(t\q) can be obtained in a similar way 
and is defined as, I?(t\q) = f* I}(u\q)du.
0,
L L l  (W ;+1 k m ) E lU n r* " ) l a  Mn(“ l? + 2)d“ >
l> h
h — q + 1 < I < h
V -  t h + q  + “2^
. + e !L i  E t™  (*"+& r M /« ,+’ m» w ? + 2)rf«- /  < h - 1 + i -
but f* Mn(u\q +  2)du and j + q Mn{u\q +  2)du are I-splines of order q +  2 therefore,
0,
i f m  =
E h (km+q+l—km) (fcn+q+2~fcn)
m= l  q+1 Z ^n=m  q+2
X^h (U , , b \ Mr(t|g+3)Z^ r=nV/cr+g+3 0+3 j
Z>/ i
h — q + 1 <1< h
t L  —  + b ,  I **+<? I V '^'1 ( k m + q + l - k m )2 -t- 2 -r Z-im=l g+1
E h (kn+q+2-kn) TC^ h / »  \  Mr (ki+q\q+3) ; ^  L  _  , 1n= m  J+2 Z^ r=nVfcr+g+3 ~  ^3  , I < tl ~ q + 1.
Finally the third integral of an I-spline, If(t\q) = f* I?(u\q)du, is given as 
0, I > h
E h {km+q+\—km) sp h  ( kn+q+2—kn) ST^ h (kr+q+3—kr)
m = l q+1 2—m = m  q+2 2 -/r= n  q+3
S 'h  ( 1 I \  Mv (t\q+A)
2—/V=r V. u+9+4 k v )  q+4 j
i f m  =
h — q + 1 < I < h
*3 t2ki+q + tk? klI-\~Q l~\~Q
I Y ^h (km+q+l—km)  ST'h (kn+q+2—kn)
' 2—/m=l q+1 2—m =m  q+2
Eh (kr+q+3-kr) \~^h ( ,  U \ Mv (kt+q\q+4) l ^ U  „  I 1r= n  q+3 2 -iv = r \ V+Q+4 Kv )  q+/± •> I <. (I q+1.
Now going back to the log-likelihood function, since the exposure-related relative in­
cidence function, cj(t — c), takes the value 1 in the control periods, (<2j,C;] and 
within the observation period, the denominator of the log-likelihood function (7.4) can be
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rewritten as
pa rai pdi /  7771 \  /  \  y11
/  Y~2PiM2i(t-Ci) \dt  + y ^a fM u ty d t
Jai 1 = 1  J« \ i=i /  \z=i /  •'* z=i
Furthermore, the first and the last terms are integrals of only one function, the age- 
specific relative incidence ip(t), whereas the second term is the integral of a product of 
two spline functions. From Chapter 4, we have that the integral of an M-spline of order 
q is an I-spline of order q + 1, hence the integral of the linear combination of M-splines 
can be expressed as a linear combination of I-splines. Therefore, we replace the integrals 
in the first and third terms by linear combinations of I-spline basis functions which leads 
to a denominator with the expression
mi mi pdi ( ml \  ( m2 \  mi mi
^2a?I1i(ci)-'^2a?I1i(ai)+ / I ^c% M u{t)  I I -  <*) I d t + ^ a f l u f c ) - ^  ajlu(di).
l=i i=i Ci \l=l / \i=l J i=i i=i
The In (t) are I-splines related to the age effect and I21 (t) will be used to denote I-splines 
related to the exposure effect. The remaining part in the denominator of the log-likelihood 
function of the non-parametric SCCS is the nominal risk period (ci? di\ where the exposure- 
related relative incidence can take a value different from 1. This part contains an integral 
of the product of the two spline functions, and cj(t — c). In the following subsection 
we write an expression for this integral.
7.2.3 Integrating the Product of Two Spline Functions
To evaluate the integral of the product of the age-related relative incidence function 
and exposure-related relative incidence function, Jij)(t)uo{t — c)dt, we use integration by 
parts.
Integration by parts makes integrating a product of functions easier by relating them 
to the integral of their derivative and antiderivative and is defined as follows. Given two 
continuously differentiable functions f (t )  and g(t), the indefinite integral of f(t)g(t)  can
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be given as
J  f(t)g(t)dt = f(t) J  g ( t )d t-  J  ^ f ( t ) J  g(t)d tjd t
where f '(t)  is the first derivative of f(t).
Applying integration by parts to the integral of the product of age and exposure effects 
in the non-parametric SCCS likelihood, we have
J  — c)dt = 4>(t) J  uj(t — c)dt — /  m  J  uj(t — c)dt^ dt (7.5)
where ^'(t) is the first derivative of t). Since ip(t) and uj(t — c) are linear combinations of 
M-spline basis functions, f  u(t — c)dt can be expressed as a linear combination of I-splines 
denoted by IE(t — c)
pt pt jn 2 m 2
IE{ t - c ) =  / uj(u -  c)du = 1 ^ 2 (3?M2i(u -  c)du =  ^  (3?I2t(t -  c).
Jc Jc 1=1 1=1
Letting the integral of the linear combination of I-splines, IE(t—c) be denoted by I ^ ( t—c), 
the integral of I^(t — c) by IE(t — c) and the integral of I%{t — c) by J |( t  — c),
Ig(t — c) = f  IE(t — c)dt, Ig(t — c) = f  Ig(t — c)dt and / | ( t  — c) = f  I^(t  — c)dt, 
so the expression in Equation (7.5) becomes
J  — c)dt = il){t)IE(t — c) — J  {^'{t)IE{t — c)) dt.
The last term of this equation is again an integral of a product of two non-constant 
functions. We therefore apply integration by parts repeatedly until none of the terms is 
an integral of two non-constant functions:
J  4>(t)u(t -  c)dt = ij)(t)IE(t -  c) -  J  t)IE{t -  c)) dt
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t)IE(t -  c 
1p(t)IE(t ~  C 
i>(t)iE(t -  c 
~  C
i > ( t ) i E ( t  -  c
-  C
m  J  I E (t — c)dt  — /  ip"(t) J  I E ( t ~  c )d t ^  dtJ 
J  ^ " ( t ) I E ( t - c ) d t
rp'(t)IE(t -  c) +  ^"(t) J  IE(t -  c)dt -  J  J  IE(t -  c)dt^j dt 
i/j'(t)IE(t -  c) +  ij"(t)IE(t - c )  -  J  {ip"'(t)IE(t -  c)dt) dt 
ij;'(t) IE{t -  c) +  ill”(t)I2E(t -  c) -  ipm{t) J  IE( t -  c)dt 
i)'(t)IlE{t -  c) +  i)"{t)I2E{t -  c) -  il)'"(t)I%(t -  c)
where il)'(t), 'ip,f(t) and are the first, second and third derivatives of ip(t) respectively. 
^"'(t) is a constant function that does not depend on t because ij){t) is a piecewise cubic 
function. Therefore, the integral of the product of ijj{t) and uj(t — c) in the nominal risk 
period (ci5 dj\ is
f  xl){t)u{t -  Ci)dt = {^{di)IE{di-Ci)-'il),(di)IE{di-Ci)+i),'{di)IE{d i-c i)-'ijjm(di)I%{di
J a
-  {^(ci)IE(0) -  ^'(ciUKo) + 0) -  ^'"(c^/J^O)).
Then the log-likelihood function of the non-parametric SCCS method, obtained by re­
placing the appropriate expressions for the / a°l ip{t)dt, J^1 ip(t)uj(t — c)dt and f** il){t)dt in 
the denominator, is
(E Si «,2m„(%)) (E£N  m
l = Y . Y . l°z
*=i j=i B
(7.6)
where
B  =
m i mi mi mi
^2a}l,{ci)  - £ a f o f a )  +  y^af/((6 j) - ^ T t f M d i )
1=1 1=1 1=1 1=1
+  (ip(di)IE(.di -  a )  -  il>'(dt)IE(d,t -  a )  + ip"(ci)I2E{di -  d)  -  ip'"(di)I%(di -  c,)) 
-  {i>{ci)IE{0) -  ^ '(c i)4 (0) +  r ( c i ) I 2E(0) -  f ' ( d i ) l U 0))
and I E{ t - c )  =  Y7= i 7l(f- c) =  E S  A2/fi(<-c)> 7f(*-c) =  EIH\ A24(*-c)
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Ih(t — c), I%t(t — c) and I%t(t — c) are the first, second and third integrals of the Ith 
I-spline (l2i(t — c)) related to exposure, respectively.
7.3 Penalised Log-Likelihood
The numbers of knots, which determine the numbers of M-spline basis functions that 
make up the age-specific and exposure-related relative incidence functions are chosen a 
priori. Maximising the log-likelihood function (7.6) after choosing too large a number of 
knots over-fits the true curves, while selecting too small a number of knots leads to under­
fitting overly smoothed curves. Therefore, to control the smoothness of the estimated 
functions we fix the numbers of knots at higher values than are believed to be enough 
to fit the functions and introduce roughness penalty terms to the log-likelihood function 
(7.6). Following Joly and Commenges (1999), we choose a roughness measure to be the 
sum of the square norms of the second derivatives of the age and exposure effect functions. 
This leads to the penalised log-likelihood function
/ (  mi \  2 r (  7712 \  2( ^ 2 a f M 'u(u ) J d u - x 2 J  ( '^ 2 P iM 2i(u) j  du
=  / ( a , j3 ) - A 1((a 2)r A 1a 2) - A 2((/32)TA2/32) (7.7)
where a  is a vector of parameters aq, . . . ,  ami, that define the age-specific relative inci­
dence function and a 2 =  a ? ,. . . ,  /32 =  ft2, . . .  ,/?^2 are parameters related to the
exposure effect, Ai is an m i x mi matrix with (r ,/) element /  Mir (w)M^(w)du, A 2 is 
an m 2 x m2 matrix with (r ,/) element J  M'2r(u)Mh(u)du, /(a , /3) is the log-likelihood 
function (7.6). Ai and A2 are non-negative smoothing parameters that control the trade 
off between the model fit and smoothness of the functions. So the penalised log-likelihood 
function (7.7) is maximised, for fixed Xi and A2 values, to estimate the parameters related
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to age and exposure effects.
We choose the smoothing parameters using the approximated cross validation method 
discussed in Chapters 5 and 6. Ai is first chosen by maximising the cross validation score 
presented in Chapter 5 by taking no exposure effect then A2 is chosen by maximising the 
cross validation score in Chapter 6 taking the age effect to be zero. The scores to be 
maximised to select Ai and A2 respectively are:
V,(A,) 1(a) 1 ■■([//,-2A ,S ,, 'Ii,). ~ ~ (7.8)
and
V2( \ 2) = 10)  -  t r ([H2 -  2X2S2]~1H2), (7.9)
where /(&) is the log-likelihood function in Equation (7.6) where exposure effect is taken 
to be zero and evaluated at the maximum penalised likelihood estimates (a). H \  =  
dadocT (**) the log-likelihood part of the Hessian of the penalised log-likelihood, taking 
zero exposure effect, evaluated at the penalised maximum likelihood estimates dt. Si =  
4 (A io (aa T)) +2(diag(A ia2)). Similarly, 10)  is the log-likelihood (7.6) taking age effect 
to be zero, H2 = qJq^t 0 )  is the Hessian when the age effect is considered to be zero and 
S2 =  4 (A2o(/3/3t )) +  2(diag(A2/32)).
In Chapter 5, we showed that the parameter of interest, the exposure-related relative 
incidence value, is not unduly sensitive to changes in the smoothing parameter that con­
trols the roughness of age-specific relative incidence function. Therefore, in this chapter 
an alternative approach is to consider the smoothing parameter related to age effect, Ai, 
to be fixed at some reasonable value. Then after choosing the smoothing parameters the 
log-likelihood function (7.7) is maximised for fixed Ai and A2.
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7.4 S im u la tio n  S tu d y
To evaluate the performance of the new non-parametric SCCS method and to compare 
it with the extensions made to the standard SCCS method in Chapters 5 and 6, we 
conducted a simulation study.
7.4.1 Design of th e  S im ulation  S tudy
The number of cases used in this simulation was 1000, each with ages at the s ta rt and 
end of the observation period of 0 and 730 days respectively. For each case, the risk period 
between the s tart of exposure c* and end of exposure d% was taken as 49 days. The baseline 
incidence was generated from a sine function, defined as A0(t) oc 8(sm(0.01 x t)) +  9 a t age 
I. The true age-related relative incidence function is presented in Panel a of Figure 7.1. 
Ages at s tart of exposure c*, for i : 1 , . . . ,  1000, were sampled within (0,730] from an 
exponential density with rate 0.003. The histogram of c* is shown in Panel b of Figure 7.1.
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Figure 7.1: True age-related relative incidence function in Panel (a) and distribution of ages at
start of exposure in Panel (b), which were used to simulate data sets
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For the given age-related relative incidence function and distribution of age at expo­
sure, we investigated four scenarios of exposure-related relative incidence function, co(t—c). 
These functions take a value one outside the risk period (q, dj, that is when time since 
start of exposure t — c < 0 or t — c > 49. These scenarios were also used in Chapter 6 
and are presented in Figure 6.1.
Without loss of generality we consider each case to have experienced only one event. 
Then the daily incidence rates within the observation period are evaluated as the product 
of the age-related relative incidence and the exposure-related relative incidence. An event 
day for each individual was generated from a multinomial distribution. The probability 
of an event at a given day within the observation period was computed as the incidence 
rate for that day divided by the sum of the rates for all the days within the observation 
period. For each scenario 100 data sets were simulated.
7.4.2 Analysis
The data sets generated were analyzed by the three new versions of SCCS presented 
in this thesis: (1) smooth age effect with parametric exposure effect (step function) (2) 
parametric age effect (step function) with spline-based exposure effect and (3) the non- 
parametric SCCS proposed in this chapter.
For the first method, seven exposure groups of length seven days between 0 and 49 were 
chosen to represent the exposure effect by a step function. For methods (1) and (3), to 
represent the age effect with a spline function 9 interior knots between the minimum of ages 
at the start of observation (zero) and the maximum of the ages at the end of observation 
periods (730) were chosen. For the age effect, since exposure-related parameters are not 
duly sensitive to changes in the smoothing parameter related to age effect, we chose
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a smoothing parameter for the first sample in a given scenario by the cross validation 
method and used the same value for the remaining samples.
For the second method, where age is represented with a piecewise constant function, 
six age groups with cut points at 0, 120, 240, 360, 480, 600 and 730 days were pre-specified. 
To represent the exposure effect with a spline function in methods (2) and (3), a nominal 
risk period of 49 days was chosen. 12 interior knots between zero and 49 were selected. 
The smoothing parameter of the exposure was chosen by the cross validation method for 
all the samples in the two methods. In addition, we fitted method (2), but with only 
three age groups with cut points at 0, 240, 480 and 730 days, to see how a change in age 
groups affects the results.
To compare the performance of the three methods we used the mean of integrated 
squared errors (MISE) (see Sections 5.3 and 6.2 for the definition of MISE) and their 
standard deviations (SD) in estimating the age and exposure-related relative incidence 
functions. To compute the MISE and SD related to the age effect, we used the cumulative 
age-specific relative incidence function, for the true and estimated functions, constrained 
to have a maximum value of one to make the three methods comparable.
7.4.3 Results
Results of the simulation study are presented in this section. Table 7.1 presents the 
MISE and SD results in estimating the age and exposure effects using the three methods 
developed in this thesis. The method proposed in Chapter 6 was fitted twice for each 
generated data set using 6 and 3 age groups.
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Table 7.1: Mean integrated squared error (MISE) and standard deviation (SD) obtained from 
the three spline-based SCCS methods: SCCS with smooth age effect, SCCS with smooth exposure 
effect (twice with 6 and 3 age groups) and SCCS with both age and exposure effects represented 
by splines. Each simulated data set was fitted by the three methods using a nominal risk period 
of 49 days. The true age-specific relative incidence function was generated from sine function
Smooth age Smooth exposure Smooth exposure 
6 age groups 3 age groups
Smooth age & exposure
Scenario 1
Effects MISE (SD) MISE (SD) MISE (SD) MISE (SD)
Exposure 13.182 (6.581) 7.318 (4.792) 7.393 (4.835) 7.220 (4.433)
Age 0.110 (0.103) 0.181 (0.086) 1.466 (0.102) 0.110 (0.106)
Scenario 2
Exposure 22.959 (10.249) 10.849 (12.996) 10.507 (12.678) 9.298 (7.188)
Age 0.117 (0.105) 0.202 (0.107) 1.483 (0.102) 0.123 (0.106)
Scenario 3
Exposure 9.856 (5.597) 5.438 (6.466) 5.552 (6.597) 4.393 (4.372)
Age 0.107 (0.089) 0.187 (0.093) 1.476 (0.111) 0.109 (0.090)
Scenario 4
Exposure 10.007 (4.882) 6.388 (8.451) 6.424 (8.207) 4.890 (6.328)
Age 0.126 (0.108) 0.204 (0.103) 1.490 (0.121) 0.129 ( 0.107)
The results in Table 7.1 suggest that the new method performs well. In estimating the 
age-specific relative incidence function the non-parametric method has equivalent perfor­
mance as method (1) with smooth age effect and has better performance as compared to 
method (2).
In estimating the exposure-related relative incidence function, the non-parametric 
method showed the highest performance as compared to both methods (1) and (2). For 
method (2), when the age groups used in modelling the age effect are reduced to three, the 
performance of the method reduces, which indicates that mis-specification of age groups
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may lead to a reduced performance of this method. However, for scenario2 surprisingly 
the performance increased when the number of age groups is reduced. The non-parametric 
method developed in this chapter does not have a limitation related to mis-speeification 
of age and exposure groups.
The estimated age-related and exposure-related relative incidence functions along with 
their true curves are presented in Figures 7.2, 7.3, 7.4 and 7.5 for scenarios 1, 2, 3 and 4 
respectively (the model with three age groups is not presented). The curves related to the 
age effect are plotted by constraining the cumulative relative incidence at the maximum 
of the ages at the end of observation period to be one.
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Figure 7.2: Estimated relative incidence curves for scenario 1; the top panels show age-related 
relative incidence curves and the bottom panels exposure-related relative incidence curves. In 
panels a are results from SCCS with smooth age effect, panels b SCCS with smooth exposure 
effect and panels c SCCS with both age and exposure represented with splines. The white solid 
lines in all panels represent the true functions.
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The figures suggest tha t the non-parametric method seems to perform well in estim at­
ing both the age and exposure-related relative incidence curves. In all the cases the true 
functions are within the range of the estimated curves and the estim ated curves seem to 
follow the trend of the true functions. However there are some estim ated exposure-related 
curves th a t over-fitted the true curve for scenario 2, (Figure 7.3), where the true func­
tion is a constant. These could be due to numerical problems in choosing the smoothing 
parameter.
The performance of the three methods is reduced for scenario 2 where the true 
exposure-related relative incidence function is a constant function.
a. Smooth age b. Smooth exposure c. Smooth age and exposure
O
O
OO
O o 0 200 400 600
oqcTO
C
o
E ooooO 0 200 400 600
i (Days)
Time since start of exposure (Days) Time since start of exposure (Days) Time since start of exposure (Days)
Figure 7.3: Estimated relative incidence curves for scenario 2; the top panels show age-related 
relative incidence curves and the bottom panels exposure-related relative incidence curves. In 
panels a are results from SCCS with smooth age effect, panels b SCCS with smooth exposure 
effect and panels c SCCS with both age and exposure represented with splines. The white solid 
lines in all panels represent the true functions.
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Figure 7.4: Estimated relative incidence curves for scenario 3; the top panels show age-related 
relative incidence curves and the bottom panels exposure-related relative incidence curves. In 
panels a are results from SCCS with smooth age effect, panels b SCCS with smooth exposure 
effect and panels c SCCS with both age and exposure represented with splines. The white solid 
lines in all panels represent the true functions.
C h a p t e r  7. N o n - P a r a m e t r i c  S e l f - C o n t r o l l e d  C a s e  S e r i e s  M e t h o d 164
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Figure 7.5: Estimated relative incidence curves for scenario 4; the top panels show age-related 
relative incidence curves and the bottom panels exposure-related relative incidence curves. In 
panels a are results from SCCS with smooth age effect, panels b SCCS with smooth exposure 
effect and panels c SCCS with both age and exposure represented with splines. The white solid 
lines in all panels represent the true functions.
7.5 A p p lica tio n
We illustrate the non-parametric self-controlled case series method by applying it to 
data on MMR vaccines and febrile convulsions. The data were introduced and described 
in Chapter 5. The number of cases in the data set is 2, 389 children aged between 29 
and 730 days with 3, 826 events. As in Chapter 6, we chose the nominal risk period post 
MMR vaccine to be 50 days.
Linear combinations of cubic M-splines are used to represent the age and exposure 
effects. For the MMR vaccine related relative incidence function we used 12 equally
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spaced knots between 0 and 50. The smoothing parameter A2 for the exposure effect was 
chosen by the cross validation method and was found to be 0.031. For the age-related 
relative incidence, we used 12 interior knots and chose the smoothing param eter using 
the cross validation method by keeping the exposure effect zero. The value selected was 
1.07 x 109. Then for the given values of the smoothing parameters, we maximised the 
non-parametric SCCS penalised log-likelihood function (7.7). The estim ated age and 
exposure-related relative incidence curves are presented in Figure 7.6.
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Figure 7.6: Relative incidence curves estimated by fitting non-parametric SCCS. Panel (a) shows 
the estimated constrained age-related relative incidence function Panel (b) represents estimated 
exposure-related relative incidence curve (solid line) along with 95% confidence bands denoted 
by the dashed lines
Panel (a) of Figure 7.6 shows the estimated age-related relative incidence function, 
where the cumulative age effect is constrained to have a value one at the maximum end of 
observation period. This figure is similar to the curve in Figure 5.7 in which the age effect 
was estim ated based on splines but the exposure effect was estimated by a step function. 
Panel (b) of the figure shows the relative incidence curve post MMR vaccine. From the
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figure, it can be seen that there is a significant increase in the risk of febrile convulsion 
from six to 12 days after exposure to MMR vaccine. Five and 13 days after vaccination 
have a borderline insignificant risk of febrile convulsion. There is no increased risk in other 
periods. These results are similar to the results obtained from the MMR exposure-related 
relative incidence function estimated in Section 6.3 of Chapter 6. However there is a 
slight difference in the results, in Figure 6.6 there is an increased risk of febrile convulsion 
between 19 and 21 days following an MMR vaccine but not in panel (b) of Figure 7.6. 
This difference could be because of modelling age effect using a step function in Chapter 6.
The confidence bands for the exposure-related relative incidence function were eval­
uated using the approximate method presented in Section 6.1.1 of Chapter 6. However, 
the 95% coverage probabilities of these confidence bands in the current setting need to 
be studied. An alternative method to use is bootstrap method as suggested by Joly and 
Commenges (1999).
7.6 Discussion
The extension developed here combines the extensions developed in Chapters 5 and 6. 
In Chapter 5, only the age effect was approximated by a linear combination of M-spline 
basis functions and the exposure effect was represented by a piecewise constant function. 
In Chapter 6, splines were used only to estimate the exposure-related relative incidence 
function and age was taken into account based on step functions. In this chapter, the 
effects of both age and exposure in the SCCS model are represented by linear combinations 
of M-spline basis functions simultaneously. The new method avoids the mis-specification 
bias that may occur due to poor choice of age or exposure groups in the previous two 
chapters due to the use of step functions.
C h a p t e r  7. N o n -P a r a m e t r ic  S e l f - C o n t r o l l e d  C a s e  S e r ie s  M e t h o d 167
The denominator of the log-likelihood function of the new method includes the integral 
of a product of two spline functions, namely the age-related and the exposure-related 
relative incidence functions. Rather than using numerical integration techniques, we 
evaluated this integral analytically using integration by parts. This required evaluation 
of the first, second and third integrals of an I-spline function, based on the definition of 
the integral of an M-spline given by Ramsay (1988).
A simulation study was conducted to evaluate the performance of the new method, 
non-parametric SCCS. It was found that the new method has good performance as com­
pared to the extensions presented in Chapters 5 and 6. According to the results the new 
method has comparable or better performance to the previous two extensions. The new 
method also has an advantage over the others in the fact that the other methods can 
give biased estimates if the a priori specified age or exposure groups are poorly or mis- 
specified. In addition, the non-parametric method avoids the limitation of the extension 
in Chapter 6 that if the age groups used to represent the age-specific relative incidence 
are too many, the method may go into computational problems.
Chapter 8
General Conclusions and Further 
Research
The self-controlled case series method is one of the study designs that are used to in­
vestigate safety of vaccines and other drugs after they are licensed for use. The main 
advantages of the SCCS method over cohort and case-control methods are that it is only 
based on information on individuals with a disease event (cases), so no separate con­
trols are required, it implicitly controls all fixed confounding variables and under many 
circumstances it has good efficiency (Whitaker et al., 2006).
8.1 Summary and Conclusions
The SCCS method does not automatically control for time-varying confounders, so 
they have to be identified and included in the model. There are two ways of including 
the time-varying covariate age: the standard (parametric) SCCS that uses step functions 
by specifying age groups a priori and the semi-parametric SCCS which leaves the shape 
of the age effect unspecified. A review of SCCS studies on safety of vaccines since 1995
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when the method was first published up to the beginning of 2014, showed that in general 
the method was applied appropriately. Of the reviewed studies, 81 used the standard 
SCCS method, only one used the semi-parametric method, one reported that age was 
included as a continuous variable and one study used linear and quadratic functions to 
model the age effect. One study used fractional polynomials to estimate the steps of a 
piecewise constant age effect. Four of the reviewed studies used an extended version of 
the standard SCCS method that allows event dependent future exposures.
In Chapter 2, a simulation study was conducted to investigate the limitations of the 
parametric and the semi-parametric SCCS methods. The results showed that in the 
parametric SCCS the age groups which should be chosen a priori may lead to biased 
exposure-related relative incidence estimates if they are incorrectly specified. On the other 
hand, fitting the semi-parametric method may become impossible to compute (at least 
in R) when the number of cases is moderately large. For example, the semi-parametric 
method does not run for more than 500 cases using the R software package.
To circumvent these limitations, we proposed modelling the effect of age in the SCCS 
method using smooth functions, namely a linear combination of cubic M-splines (Ghebremichael- 
Weldeselassie et a l , 2014a). Spline methods are curve fitting methods which have a flavour 
of both parametric and non-parametric methods. They are piecewise polynomials (and 
hence parametric functions) connected at points known as knots. Regression splines and 
smoothing splines are types of splines which differ depending on the number of knots used 
to connect the pieces of polynomials. Smoothing splines take data points to be the knots, 
hence a large number of parameters may need to be estimated; regression splines use fewer 
knots. Penalised regression splines are a compromise between regression and smoothing 
splines. This is the approach we used in the thesis. Splines are more flexible than global
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parametric functions and give biologically plausible shapes. We used penalised regres­
sion splines based on M-splines. In the SCCS model age effects should be non-negative 
since they are relative effects. M-splines are particularly useful in the SCCS model be­
cause they are positive functions and their linear combination can be non-negative by 
constraining the coefficients to be non-negative. In addition, the integral in the SCCS 
likelihood function can be obtained analytically by the use of M-splines because their 
integrals are I-splines.
A simulation study showed that the new method developed in Chapter 5 has a higher 
or equivalent performance to the semi-parametric and standard SCCS methods with cor­
rectly specified age groups when the sample size is moderate. The new method showed an 
improved performance as compared to the standard SCCS with mis-specified age groups. 
Moreover, unlike the semi-parametric method, the new spline-based method works well 
for large data sets.
Estimation of parameters in this method is based on a penalised log-likelihood function 
where the smoothing parameter attached to the penalty term is chosen by using a cross 
validation method. It was found that the parameters related to the exposure effect are 
not overly sensitive to changes in the smoothing parameter value.
In Chapter 6 we proposed using a linear combination of cubic M-splines to represent 
the exposure effect (time since start of exposure) to avoid the limitations of using a step 
function (Ghebremichael-Weldeselassie et al., 2014b). Similar to the first extension devel­
oped, this method also showed an increased performance over the standard SCCS method 
based on the simulation studies conducted. This new method is particulary useful when 
the risk period is long. For example to investigate the association between oral antibiotic 
prescription and pregnancy (Petersen et al, 2010), where the event outcome is prescrip­
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tion of oral antibiotic and exposure the nine months of pregnancy. Another example is to 
investigate the adverse effect of a point exposure to idiopathic thrombocytopenic purpura 
(ITP) vaccine which has a risk period of 42 days (Miller et al, 2001). The method is also 
useful when the the risk period is unbounded. The risk period is said to be unbounded 
when the risk period of the cases ends at the end of observation. For example, to in­
vestigate the association between exposure to thiazolidinedione use which could last for 
several years and an outcome event of fracture (Douglas et al., 2009). The method can 
be applied when the cases have identical or varying risk lengths.
And finally an extension that combines the first two extensions was developed in 
Chapter 7 where age and exposure effects were modelled by spline functions. We used a 
linear combination of M-splines. In order to fit both effects with flexible functions at the 
same time, we developed first, second and third integrals of an I-spline. This method was 
evaluated by a simulation study that showed a good performance. The non-parametric 
SCCS method does not suffer from mis-specification bias unlike the first two extensions 
of the standard and the semi-parametric SCCS methods.
The method proposed in Chapter 5 is important when the adverse outcome varies 
widely with respect to age over the observation period, which may be particularly true in 
child and elderly populations. It may also be useful to allow for strong seasonal effects 
when the underlying time line is calendar time. This method could also prove useful when 
no prior knowledge of appropriate age effects is available. The methods in Chapters 6 
and 7 will be most useful when there is no prior hypothesis about the risk period, or 
the way in which risk changes over the risk period is of interest. They can be used to 
determine appropriate exposure groups to be used with the standard SCCS method then 
the exposure-related relative incidences obtained from both the standard and spline-based
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methods can be plotted and compared.
8.2 Future Research
The method developed in Chapter 5, where age was included as a spline function, was 
applied to investigate the association between paediatric vaccines and febrile convulsions. 
It was observed that the use of splines in place of a step function to represent the age 
effect resulted in a notable difference in the relative incidence of exposure to DTP vaccine. 
This result shows that mis-specification of the age effect might result in significant bias 
in the exposure-related relative incidence function. From the review in Chapter 2, several 
studies including Ali et al (2005); Burwen et al (2006); Juurlink et al (2006); Zinman 
et al (2009) excluded age effects from their analyses since their observation periods were 
short. In this respect a simulation study to investigate the effect of ignoring the age effect 
on exposure parameters when observation periods are short may be useful.
Further extension of the spline-based SCCS method developed in Chapter 6 to non­
vaccine pharmacoepidemiology, notably to incorporate the effect of dose within a more 
general weighted cumulative exposure model framework, would be desirable. Moreover, 
further extension, in terms of incorporating more than one exposure at the same time 
to assess their association to a single outcome event, would be useful. However, if the 
exposures do not overlap it may be possible to use the developed approach; overlapping 
exposures would lead to a product of two spline functions (related to the two exposures) 
within the overlapping intervals. With no overlaps, the relative incidence at a given 
point in an interval is the product of the age-related relative incidence and a relative 
incidence related to one of the two exposures. So a second exposure can be included 
in the log-likelihood function (6.4) by multiplying the numerator of the function by a
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linear combination of cubic M-splines for the second exposure with an indicator variable 
similar to the first one. And in the denominator the exponent of in the function is 
multiplied by an indicator for the second exposure (1 — /(s* < lih < /*)), where s< and 
fi are the ages at start and end of the exposure respectively, and an expression similar 
to the first exposure multiplies the denominator. If the two exposures overlap, there will 
be a product of two spline functions (related to the two exposures) in the log-likelihood 
function, therefore a similar approach to the method developed in Chapter 7 can be used, 
while the age effect is represented by a step function.
Another extension to the method developed in Chapter 6 is to include a washout 
period effect, which would be straightforward to include as a step function. A washout 
period could also easily be included as a spline function if exposure periods are all of 
the same length. If exposure periods are of differing lengths this would be more difficult 
because each individual’s exposure period will end at a different level.
The performance (coverage probabilities) of the approximate confidence bands used 
in Section 7.5 of Chapter 7 could be evaluated further by simulations.
The spline-based methodologies developed in this thesis require the assumptions stated 
in Section 2.1.1 of Chapter 2 to be met. However, the SCCS method has been extended in 
order to weaken the assumptions required. Farrington et al (2009) extended a method to 
allow non-exogenous exposures and Kuhnert et al (2011) developed a method to handle 
event-dependent exposures and deaths. These other extensions allow event dependent 
observation periods (Farrington et al, 2011) and dependent recurrences (Farrington and 
Hocine, 2010). Simpson (2013) extended the standard SCCS to allow the occurrence of an 
event to increase the future event risk. To this end, spline-based methods that incorporate 
these extensions may be useful.
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The estimation methods in all the extensions developed in this thesis involve a two 
step procedure, selecting the smoothing parameter of one variable taking the other from 
the log-likelihood out then estimate all the required parameters for a fixed value of the 
smoothing parameter. It might therefore, be worthwhile to explore methods that estimate 
parameters in a single step.
Post-licensure studies of vaccines and other drugs are often conducted to investigate 
their safety against rare events and since the SCCS method uses only cases (individuals 
who experienced the event), such studies may only have small numbers of cases available. 
Fitting piecewise cubic polynomials (spline functions) to small data sets could be difficult, 
but kernel smoothers can be fitted even for a small number of observations. Therefore, 
the use of kernel smoothers in the SCCS context for small sample sizes, and of course for 
large sample sizes should they offer any improvements over splines, may be worthwhile to 
investigate.
The review of vaccine studies in Chapter 3 showed that only small number of studies 
applied the extensions of the standard SCCS method. This may be because the extensions 
are much more technically challenging than the basic SCCS model. Therefore providing 
accessible software tools to implement these extensions in a unified framework within the 
standard software packages and preparation of tutorials is important.
8.3 Final Remarks
The methodologies developed in this thesis greatly improve the performance of the self­
controlled case series method in estimating both the age effect and time-varying exposure 
effects. They avoid the limitations of the parametric and semi-parametric SCCS methods. 
The sensitivity of the parametric SCCS to mis-specification of age groups is avoided by the
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extensions developed in Chapters 5 and 7. In estimating time-varying exposures, there is 
no need to pre-specify exposure groups in the methodologies developed in Chapters 6 and 
7 unlike the parametric and semi-parametric SCCS methods. All the methods developed 
can be applied to data sets with large number of cases.
Bibliography
Abrahamowicz, M., Bartlett, G., Tamblyn, R., and du Berger, R. (2006). Modeling cumu­
lative dose and exposure duration provided insights regarding the associations between 
benzodiazepines and injuries. Journal of Clinical Epidemiology 59(4), 393-403.
Ali, M., Do, C. G., Clemens, J. D., et al. (2005). The use of a computerized database 
to monitor vaccine safety in Viet Nam. Bulletin of the World Health Organization 83, 
604-610.
Altman, D. G. (1991). Categorizing continuous variables. British Journal of Cancer 64(5), 
975-975.
Andrews, N. J. (2002). Statistical assessment of the association between vaccination and 
rare adverse events post-licensure. Vaccine 20, S49-S53.
Andrews, N., Miller, E., Waight, R, Farrington, P., Crowcroft, N., Stowe, J., and Taylor, 
B. (2001). Does oral polio vaccine cause intussusception in infants? Evidence from a 
sequence of three self-controlled cases series studies in the united kingdom. European 
Journal of Epidemiology 17, 701-706.
Andrews, N., Miller, E., Taylor, B., Lingam, R., Simmons, A., Stowe, J., and Waight, P. 
(2002). Recall bias, MMR, and autism. Archives of Disease in Childhood 87, 493-494.
176
BIBLIOGRAPHY 177
Andrews, N., Stowe, J., Miller, E., and Taylor, B. (2007). Post-licensure safety of the 
meningococcal group C conjugate vaccine. Human Vaccines 3, 59-63.
Andrews, N., Stowe, J., Wise, L., and Miller, E. (2010). Postlicensure comparison of the 
safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b 
vaccine and a 5-in-l diphtheria/tetanus/acellular pertussis/haemophilus influenza type 
b/polio vaccine in the United Kingdom. Vaccine 28, 7215-7220.
Barlow, W.E., Davis, R.L., Glasser, J.W., Rhodes, P.H., Thompson, R.S., Mullooly, 
J.P., Black, S.B., Shinefield, H.R., Ward. J.I., and Marcy, S.M. (2001). The risk of 
seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. 
New England Journal of Medicine 345, 656-661.
Becker, N. G., Li, Z., Kelman, C.W. (2004). The effect of transient exposures on the risk 
of an acute illness with low hazard rate. Biostatistics 5, 239-248.
Berhane, K., Hauptmann, M., and Langholz, B. (2008). Using tensor product splines in 
modeling exposure-time-response relationships: application to the Colorado Plateau 
uranium miners cohort. Statistics in Medicine 27, 5484-5496.
Breslow, N.E., Lubin, J.H., Marek, P., and Langholz, B. (1983). Multiplicative models 
and cohort analysis. Journal of the American Statistical Society 78(381), 1-12.
Burwen, D. R., La Voie, L., Braun, M. M., Houck, P., Hudson, R., and Ball, R. (2006). 
Evaluating adverse events after vaccination in the medicare population. Pharmacoepi­
demiology and Drug Safety 15, 168.
Cameron, J. C., Walsh, D., Finlayson, A. R., and Boyd, J. H. (2006). Oral polio vaccine
BIBLIOGRAPHY 178
and intussusception: A data linkage study using records for vaccination and hospital­
ization. American Journal of Epidemiology 163, 528-533.
Carlin, J. B., Macartney, K. K., Lee, K. J., et al. (2013). Intussusception risk and dis­
ease prevention associated with rotavirus vaccines in Australia’s national immunization 
program. Clinical Infectious Diseases 57, 1427-1434.
Curry, H.B., and Schoenberg, I.J. (1947). On Polya frequency IV: The spline functions 
and their limits. Bull Amer. Math. Soc. 53, 1114.
Curry, H.B., and Schoenberg, I.J. (1966). On Polya frequency IV: The fundamental spline 
functions and their limits.. J. dAnaluse Math. 17, 71-107.
de Boor, C. (1978). A Practical Guide to Splines. New York: Springer-Verlag.
Delaney, J. A., and Suissa, S. (2009). The case-crossover study design in pharmacoepi­
demiology. Statistical Methods in Medical Research 18, 53-65.
Dimatteo, I., Genovese, C.R. and Kass, R.E. (2001). Bayesian curvefitting with free-knot 
splines. Biometrika 88, 1055-1071.
Dodd, C. N., Romio, S. A., Black, S., et al. (2013). International collaboration to assess 
the risk of Guillain-Barre’ Syndrome following Influenza A (H1N1) 2009 monovalent 
vaccines. Vaccine 31, 4448-4458.
Douglas, I.J., Evans, S. J., Pocock, S., and Smeet, L. (2009). The risk of fractures associ­
ated with thiazolidinediones: A self-controlled sase-series Study. PLoS Medicine 6(9), 
el000154.
BIBLIOGRAPHY 179
Dourado, I., Cunha, S., Teixeira, M. D., et al. (2000). Outbreak of aseptic meningitis 
associated with mass vaccination with a Urabe-containing measles-mumps-rubella vac­
cine - Implications for immunization programs. American Journal of Epidemiology 151, 
524-530.
Eilers, P. H. C., and Marx, B. D. (1996). Flexible smoothing with B-splines and penalties. 
Statistical Science 11, 89-102.
Escolano, S., Hill, C., and Tubert-Bitter, P. (2013). A new self-controlled case series 
method for analyzing spontaneous reports of adverse events after vaccination. American 
Journal of Epidemiology 178, 1496-1504.
Farez, M. F., Ysrraelit, M. C., Fiol, M., and Correale, J. (2012). H1N1 vaccination does 
not increase risk of relapse in multiple sclerosis: A self-controlled case-series study. 
Multiple Sclerosis 18, 254-256.
Farrington, C. P. (1995). Relative incidence estimation from case series for vaccine safety 
evaluation. Biometrics 51, 228-235.
Farrington, C. P. (2004). Control without separate controls: evaluation of vaccine safety 
using case-only methods. Vaccine 22, 2064-2070.
Farrington, C.P., Anaya-Izquierdo, K., Whitaker, H. J., Hocine, M. N., Douglas, I., and 
Smeeth, L. (2011). Self-controlled case series analysis with event-dependent observation 
periods. Journal of the American Statistical Association 106, 417-426.
Farrington, C. P., Hocine, M.N. (2010). Within-individual dependence in self-controlled 
case series models for recurrent events. Journal of the Royal Statistical Society Series 
C 59, 457-475.
BIBLIOGRAPHY 180
Farrington, C. P., Miller, E., and Taylor, B. (2001). MMR and autism: further evidence 
against a causal association. Vaccine 19, 3632-3635.
Farrington, C. P., Nash, J., and Miller, E. (1996). Case series analysis of adverse reactions 
to vaccines: A comparative evaluation. American Journal of Epidemiology 143, 1165— 
1173.
Farrington, P., Pugh, S., Colville, A., Flower, A., Nash, J., Morgan-Capner, P., Rush, 
M., and Miller, E. (1995). A new method for active surveillance of adverse events from 
diphteria-tetanus-pertussis and measles mumps rubella vaccines. Lancet 345: 567-569.
Farrington, C. P., and Whitaker, H. J. (2006). Semiparametric analysis of case series data 
(with Discussion). Journal of the Royal Statistical Society Series C-Applied Statistics 
55, 553-580.
Farrington, C.P., Whitaker, H. J., and Hocine, M. N. (2009). Case series analysis for 
censored, perturbed or curtailed post-event exposures. Biostatistics 10, 3-16.
France, E. K., Glanz, J.M., Xu, S, Davis, R.L., et al.(2004). Safety of the trivalent inacti­
vated influenza vaccine among children. Archives of Pediatric and Adolescent Medicine 
158, 1031-1036.
France, E. K., Glanz, J., Xu, S., et al. (2008). Risk of immune thrombocytopenic purpura 
after measles-mumps-rubella immunization in children. Pediatrics 121, E687-E692.
Friedman, J. H. (1991). Multivariate adaptive regression splines. Annals of Statistics 19, 
1-67.
Galeotti, F., Massari, M., D’Alessandro, R., et al. (2013). Risk of Guillain-Barre’ syn-
BIBLIOGRAPHY 181
drome after 2010-2011 influenza vaccination. European Journal of Epidemiology 28, 
433-444.
Ghebremichael-Weldeselassie, Y., Whitaker, H. J., and Farrington, C. P. (2014a). Self 
controlled case series method with smooth age effect. Statistics in Medicine 33(4), 639 
-  649.
Ghebremichael-Weldeselassie, Y., Whitaker, H. J., and Farrington, C. P. (2014b). Flexible 
modelling of vaccine effect in self-controlled case series models. Submitted
Glanz, J. M., McClure, D.L., Xu, S, Hambidge, S.J., et al. (2006). Four different study 
designs to evaluate vaccine safety were equally validated with contrasting limitations. 
Journal of Clinical Epidemiology 59, 808-818.
Gold, M., Dugdale, S., Woodman, R. J., and McCaul, K. A. (2010). Use of the Australian 
Childhood Immunisation Register for vaccine safety data linkage. Vaccine 28, 4308- 
4311.
Green, P.G. and Silverman, B.W. (1994). Nonparametric Regression and Generalized Lin­
ear Models. London: Chapman & Hall.
Greenland, S. (1995a). Avoiding power loss associated with categorization and ordinal 
scores in dose-response and trend analysis. Epidemiology 6(4), 450-454.
Greenland, S. (1995b). Dose-response and trend analysis in epidemiology - Alternatives 
to categorical analysis. Epidemiology 6(4), 356-365.
Grosso, A., Douglas, I., MacAllister R., Petersen, I., Smeeth, L., and Hingorani, A. D. 
(2011). Use of the self-controlled case series method in drug safety assessment. Expert 
Opinion Drug Safety 10(3), 337-340.
BIBLIOGRAPHY 182
Gwini, S. M., Coupland, C. A. C., and Siriwardena, A. N. (2011). The effect of influenza 
vaccination on risk of acute myocardial infarction: Self-controlled case-series study. 
Vaccine 29, 1145-1149.
Hambidge, S. J., Glanz, J. M., Prance, E. K., et al. (2006). Safety of trivalent inactivated 
influenza vaccine in children 6 to 23 months old. Jama-Journal of the American Medical 
Association 296, 1990-1997.
Hastie, T., Tibshirani, R., and Friedman, J. (2001). The Elements of Statistical Learning. 
New York: Springer-Verlag.
Hauptmann, M., Wellmann, J., Lubin J.H., Rosenberg, P.S., and Kreienbrock, L. (2000). 
Analysis of exposure-time-response relationships using a spline weight function. Bio­
metrics 56(4), 1105-1108.
Hauptmann, M., Berhane, K., Langholz, B., and Lubin J.H. (2001). Using splines to anal­
yse latency in the Colorado Plateau uranium miners cohort. Journal of Epidemiology 
and Biostatistics 6, 417-424.
Hauptmann, M., Pohlabeln, H., Lubin, J.H., Jckel, K.H., Ahrens, W., Brske-Hohlfeld, I., 
and Wichmann, H.E. (2002). The exposure-time-response-relationship between occupa­
tional asbestos exposure and lung cancer in two German case-control studies. American 
Journal of Industrial Medicine 41, 89-97.
Hens,N., Shkedy, Z., Aerts, M., Faes, C., Van Damme, P., and Beutels, P. (2012). Modeling 
Infectious Disease Parameters Based on Serological and Social Contact Data. New York: 
Springer.
BIBLIOGRAPHY 183
Hocine, M. N., Farrington, C. P., Touze, E., et al. (2007). Hepatitis B vaccination and 
first central nervous system demyelinating events: Reanalysis of a case-control study 
using the self-controlled case series method. Vaccine 25, 5938-5943
Hocine, M. N., Musonda, P., Andrews, N. J., and Paddy Farrington, C. (2009). Sequential 
case series analysis for pharmacovigilance. Journal of the Royal Statistical Society Series 
A-Statistics in Society 172, 213-236.
Hocine, M. Guillemot, D, Tubert-Bitter, P, Moreau, T. (2005). Testing independence 
between two Poisson-generated multinomial variables in case-series and cohort studies. 
Statistics in Medicine 24, 4035-4044.
Huang, W.T., Gargiullo, P.M., Broder, K.R., Weintraub, E.S., Iskander, J.K., Klein, N.P., 
and Baggs, J.M. (2010). Lack of Association Between Acellular Pertussis Vaccine and 
Seizures in Early Childhood. Lancet 126, E263-E269.
Hughes, R. A., Charlton, J., Latinovic, R., and Gulliford, M. C. (2006). No association 
between immunization and Guillain-Barre’ syndrome in the United Kingdom, 1992 to 
2000. Archives of Internal Medicine 166, 1301-1304.
Joly, P., Commenges, D., and Letenneur, L. (1998). A penalized likelihood approach 
for arbitrarily censored and truncated data: Application to age-specific incidence of 
dementia. Biometrics 54, 185-194.
Joly, P., and Commenges, D.(1999). A Penalized Likelihood Approach for a Progressive 
Three-State Model with Censored and Truncated Data: Application to AIDS. Biomet­
rics 55(3), 887-890.
BIBLIOGRAPHY 184
Joly, P., Commenges, D., Helmer C., and Letenneur L. (2002). A penalized likelihood 
approach for an illness-death model with interval-censored data: application to age- 
specific incidence of dementia. Biostatistics 3(3), 433-443.
Juurlink, D. N., Stukel, T. A., Kwong, J., et al. (2006). Guillain-Barre’ syndrome after in­
fluenza vaccination in adults - A population-based study. Archives of Internal Medicine 
166, 2217-2221.
Klein, N. P., Fireman, B., Yih, W.K., et al. (2010). Measles-mumps-rubella-varicella 
combination vaccine and the risk of febrile seizures. Pediatrics 126, el-e8.
Kramarz, P., DeStefano, F., Gargiullo, P. M., et al. (2000). Does influenza vaccination 
exacerbate asthma? Analysis of a large cohort of children with asthma. Archives of 
Family Medicine 9, 617-623.
Kramarz, P., DeStefano, F., Gargiullo, P. M., et al. (2001). Does influenza vaccination 
prevent asthma exacerbations in children? Journal of Pediatrics 138, 306-310.
Kuhnert, R., Hecker, H., Poethko-Mller, C., et al. (2011). A modified self-controlled 
case series method to examine association between multidose vaccinations and death. 
Statistics in Medicine 30, 666-677.
Kuhnert, R., Schlaud, M., Poethko-Mller, C., et al. (2012). Reanalyses of case-control 
studies examining the temporal association between sudden infant death syndrome and 
vaccination. Vaccine 30, 2349-2356.
Langholz, B., Thomas, D., Xiang, A., and Stram, D. (1999). Latency Analysis in Epi­
demiologic Studies of Occupational Exposures: Application to the Colorado Plateau 
Uranium Miners Cohort. American Journal of Industrial Medicine 35, 246-256.
BIBLIOGRAPHY 185
Lee, K.J., and Carlin, J.B. (2014). Fractional polynomial adjustment for time-varying 
covariates in a self-controlled case series analysis. Statistics in Medicine 33(1), 105- 
116.
Lumley, T., Levy, D. (2000). Bias in the case-crossover design: implications for studies of 
air pollution. Environmetrics 11, 689-704.
Miller, D.L., Ross, E.M., Alderslade, R., Bellman, M.H., and Rawson, N.S.B. (1981). 
Pertussis immunization and serious acute neurological illness in children. British Medical 
Journal 282: 1595-1599.
Miller, E., Andrews, N., Waight, P., and Taylor, B. (2003). Bacterial infections, immune 
overload, and MMR vaccine. Archives of Disease in Childhood 88, 222-223.
Miller, E., Andrews, N., Grant, A., Stowe, J., and Taylor, B. (2005). No evidence of 
an association between MMR vaccine and gait disturbance. Archives of Disease in 
Childhood 90, 292-296.
Miller, E., Andrews, N., Stowe, J., Grant, A., Waight, P., and Taylor, B. (2007). Risks of 
convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the 
United Kingdom. American Journal of Epidemiology 165, 704-709.
Miller, E., Waight, P., Farrington, P., Andrews, N., Stowe, J., and Taylor, B. (2001). Idio­
pathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood 
84, 227-229.
Mohammed, S. M., Sentrk, D., Dalrymple, L. S., and Nguyen, D. V. (2012) Measurement 
error case series models with application to infection-cardiovascular risk in older patients 
on dialysis. Journal of the American Statistical Association 107, 1310-1323.
BIBLIOGRAPHY 186
Mohammed, S. M., Dalrymple, L. S., Sentrk, D., and Nguyen, D. V. (2013) Design 
considerations for case series models with exposure onset measurement error. Statistics 
in Medicine 32, 772-786.
Mullooly, J. P., Pearson, J., Drew, L., et al. (2002). Wheezing lower respiratory disease 
and vaccination of full-term infants. Pharmacoepidemiology and Drug Safety 11, 21-30.
Mullooly, J. P., Schuler, R., Mesa, J., Drew, L., and DeStefano, F. (2011). Wheezing lower 
respiratory disease and vaccination of premature infants. Vaccine 29, 7611-7617.
Murphy, T. V., Gargiullo, P. M., Massoudi, M. S., et al. (2001). Intussusception among 
infants given an oral rotavirus vaccine. New England Journal of Medicine 344, 564-572.
Musonda, P., Farrington, C. P., and Whitaker, H. J. (2006). Sample sizes for self-controlled 
case series studies. Statistics in Medicine 25, 2618-2631.
Musonda, P., Hocine, M.N., Whitaker, H.J., Farrington, C.P. (2008a). Self-controlled case 
series analyses: small-sample performance. Computational Statistics and Data Analysis 
52, 1942-1957.
Musonda, P., Hocine, M.N., Andrews, N.J., Tubert-Bitter, P., Farrington, C.P. (2008b). 
Monitoring vaccine safety using case series cumulative sum charts. Vaccine 26, 5358- 
5367.
Mutsch, M., Zhou, W. G., Rhodes, P., et al. (2004). Use of the inactivated intranasal 
influenza vaccine and the risk of Bell’s palsy in Switzerland. New England Journal of 
Medicine 350, 896-903.
Naleway, A. L., Belongia, E. A., Donahue, J. G., Kieke, B. A., Glanz, J. M., and Vaccine
BIBLIOGRAPHY 187
Safety, D. (2009). Risk of immune hemolytic anemia in children following immunization. 
Vaccine 27, 7394-7397.
Navidi, W. (1998). Bidirectional case-crossover designs for exposures with time trends. 
Biometrics 54 , 596-605.
NHS (2013). http://www.nhs.uk/conditions/diabetes-type2/pages/introduction.aspx Ac­
cessed 23/06/2013.
O’Sullivan, F. (1986). A statistical perspective on ill-posed inverse problems (with discus­
sion). Statist. Sci. 1 , 505-527.
O’Sullivan, F. (1988a). Fast computation of fully automated log-density and log-hazard 
estimators. Siam Journal on Scientific and Statistical Computing 9(2), 363-379.
O’Sullivan, F. (1988b). Non parametric estimation of relative risk using splines and cross- 
validation. Siam Journal on Scientific and Statistical Computing 9(3), 531-542.
Payne, D. C., Aranas, A., McNeil, M. M., Duderstadt, S., and Rose, C. E. (2007). Concur­
rent vaccinations and US military hospitalizations. Annals of Epidemiology 17, 697-703.
Petersen, I., Gilbert, R., Evans, S., Ridolfi, A., and Nazareth, I. (2010). Oral antibiotic 
prescribing during pregnancy in primary care: UK population-based study. Journal of 
Antimicrobial Chemotherapy 65, 2238-2246.
R Development Core Team (2012). R: A Language and Environment for Statistical Com­
puting. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, 
URL http://www.R-project.org
BIBLIOGRAPHY 188
Ramsay, J. O. (1988). Monotone Regression Splines in Action. Statistical Science 3, 425- 
461.
Ramsay, J. O. and Silverman, B.W. (1997). Functional Data Analysis. New York: 
Springer-Verlag.
Romio, S., Weibel, D., Dieleman, J. P., et al. (2014). Guillain-Barre’ Syndrome and Adju- 
vanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled 
Case Series in Europe. PLoS ONE 9.
Rondeau, V., and Gonzalez, J.R. (2005). Frailtypack: A computer program for the anal­
ysis of correlated failure time data using penalized likelihood estimation. Computer 
Methods and Programs in Biomedicine. 80, 154-164.
Royston, P., and Altman, D.G. (1994). Regression using fractional polynomials of contin­
uous covariates: parsimonious parametric modelling (with discussion). Appl. Statist.. 
43, 429-467.
Royston, P., and Altman, D.G. (1997). Approximating statistical functions by using frac­
tional polynomial regression. Computer Methods and Programs in Biomedicine. 46(3), 
411-422.
Ruppert, D. Wand, M.P., and Carroll, R.J. (2003). Semiparametric Regression. Cambridge 
Series in Statistical and Probabilistic Mathematics. Cambridge: Cambridge University 
Press.
Sardinas, M. A. G., Cardenas, A. Z., Marie, G. C., et al. (2001). Lack of association 
between intussusception and oral polio vaccine in Cuban children. European Journal of 
Epidemiology 17, 783-787.
BIBLIOGRAPHY 189
Silverman, B.W. (1985). Some aspects of the spline smoothing approach to nonparametric 
regression curve fitting. J. R. Statist Soc. B  47, 1-52.
Simpson, S.E. (2013). A Positive Event Dependence Model for Self-Controlled Case Series 
with Applications in Postmarketing Surveillance. Biometrics 69, 128-136.
Simpson, S. E., Madigan, D., Zorych, I., Schuemie, M. J., Ryan, P. B., and Suchard, M. 
A. (2013). Multiple self-controlled case series for large-scale longitudinal observational 
databases. Biometrics 69, 893-902.
Smeeth, L., Thomas, S. L., Hall, A. J., Hubbard, R., Farrington, P., and Vallance, P. 
(2004). Risk of myocardial infarction and stroke after acute infection or vaccination. 
New England Journal of Medicine 351, 2611-2618.
Smith, M. and Kohn, R. (1996). Nonparametric regression using Bayesian variable selec­
tion. Journal of Econometrics 75, 317-344.
Smith, P.L. (1979). Splines as a useful and convenient statistical tool. American Statisti­
cian 33(2), 57-62.
Stowe, J., Kafatos, G., Andrews, N., and Miller, E. (2001). Idiopathic thrombocytopenic 
purpura and the second dose of MMR. Archives of Disease in Childhood 93, 182-183.
Stowe, J., Andrews, N., Wise, L., and Miller, E. (2006). Bell’s palsy and parenteral 
inactivated influenza vaccine. Human Vaccines 2, 110-112.
Stowe, J., Andrews, N., Wise, L., and Miller, E. (2008). Investigation of the Temporal As­
sociation of Guillain-Barre’ Syndrome With Influenza Vaccine and Influenzalike Illness 
Using the United Kingdom General Practice Research Database. American Journal of 
Epidemiology 169, 382-388.
BIBLIOGRAPHY 190
Stowe, J., Andrews, N., Taylor, B., and Miller, E. (2009). No evidence of an increase of 
bacterial and viral infections following Measles, Mumps and Rubella vaccine. Vaccine 
27, 1422-1425.
Suissa, S. (2007). Immortal time bias in pharmacoepidemiology. American Journal of 
Epidemiology 167, 492-499.
Sylvestre, J., and Abrahamowicz, M. (2009). Flexible modeling of the cumulative effects 
of time-dependent exposures on the hazard. Statistics in Medicine 28(27), 3437-3453.
Tata, L. J., West, J., Harrison, T., Farrington, P., Smith, C., and Hubbard, R. (2003). 
Does influenza vaccination increase consultations, corticosteroid prescriptions, or exac­
erbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax 
58, 835-839.
Taylor, B., Miller, E., Farrington, C. P., et al. (1999). Autism and measles, mumps, 
and rubella vaccine: no epidemiological evidence for a causal association. Lancet 353, 
2026-2029.
Taylor, B., Andrews, N., Stowe, J., Hamidi-Manesh, L., and Miller, E. (2007). No in­
creased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. 
Archives of Disease in Childhood 92, 887-889.
Thomas, D.C. (1988). Models for exposure-time-response relationships with applications 
to cancer epidemiology. Annual Reviews of Public Health 9, 451-482.
Traversa, G., Spila-Alegiani, S., Bianchi, C., et al. (2011). Sudden unexpected deaths and 
vaccinations during the first two years of life in Italy: A case series study. PLoS ONE 
6, el6363.
BIBLIOGRAPHY 191
Vacek, P.M. (1997). Assessing the effect of intensity when exposure varies over time. 
Statistics in Medicine 16, 505-513.
van der Maas N.A.T, Bondt, P.E.V.-d., de Melker, H., Kemmeren, J.M. (2009). Acute 
cerebellar ataxia in the Netherlands: A study on the association with vaccinations and 
varicella zoster infection. Vaccine 27: 1970-1973.
Vines, S. K., Farrington, C. P. (2001). Within-subject exposure dependency in case- 
crossover studies. Statistics in Medicine 20, 3039-3049.
Wahba, G. (1983). Bayesian confidence intervals for the cross validated smoothing spline. 
J. R. Statist. Soc. B 45, 133-150.
Wand, M.P., Jones M.C. (1995). Kernel Smoothing. London: Chapman & Hall/CRC.
Ward, K. N., Bryant, N. J., Andrews, N. J., et al. (2007). Risk of serious neurologic 
disease after immunization of young children in Britain and Ireland. Pediatrics 120, 
314-321.
Wasserman, L. (2006). All of Nonparametric Statistics. New York: Springer.
Weinberg, C.R. (1995). How bad is categorization. Epidemiology 6(4), 345-347.
Weldeselassie, Y. G., Whitaker, H. J., and Farrington, C. P. (2011) Use of the self­
controlled case-series method in vaccine safety studies: review and recommendations 
for best practice. Epidemiology and Infection 139, 1805-1817.
Whitaker, H. J., Farrington, C. P., Spiessens, B., and Musonda, P. (2006). Tutorial in 
biostatistics: The self-controlled case series method. Statistics in Medicine 25, 1768- 
1797.
BIBLIOGRAPHY 192
Whitaker, H. J., Hocine, M. N., Farrington, C. P. (2007) On casecrossover methods for 
environmental time series data. Environmentrics 18, 157-171.
Whitaker, H. J., Hocine, M. N., and Farrington, C. P. (2009). The methodology of self­
controlled case series studies. Statistical Methods in Medical Research 18, 7-26.
Wood, S. (2006a). Generalized Additive Models. Boca Raton: Chapman & Hall/CRC.
Wood, S.N. (2006b). On Confidence intervals for generalized additive models based on 
penalized regression splines. Aust. N. Z. J . Stat 48(4), 445-464.
Xu, S., Hambidge, S. J., McClure, D. L., Daley, M. F., and Glanz, J. M. (2013). A 
scan statistic for identifying optimal risk windows in vaccine safety studies using self­
controlled case series design. Statistics in Medicine 32, 3290-3299.
Zhao, L. P., and Kolonel, L. N. (1992). Efficiency loss from categorizing quantitative 
exposures into qualitative exposures in case-control studies. American Journal of Epi­
demiology 136(4), 464-474.
Zinman, L., Thoma, J., Kwong, J. C., Kopp, A., Stukel, T. A., and Juurlink, D. N. (2009). 
Safety of influenza vaccination in patients with myasthenia gravis: A population-based 
study. Muscle & Nerve 40, 947-951.
A ppendix A
R eview  of Vaccine Studies
This appendix presents the form which was used to review SCCS vaccine studies in Chap­
ter 2.
Type of paper:
Focused on estimating relative incidences for one or more vaccine/adverse □ 
event combinations using the case series method (alone or alongside other 
methods)?
Methodological paper with an example data set? If so give reference for □ 
original data but continue filling in form:
Methodological paper with no relevant data on vaccines? (If so, stop now). □ 
General paper (eg review, or epidemiology paper) with only passing refer- □ 
ence to case series methods? (If so, stop now).
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Vaccines and adverse events studied (If there are several, list just
the main result or results, and indicate there are others):_______
Vaccine Adverse event Post vaccination risk period RI (Cl)
Data on events and vaccination:
Clear description provided of how data were obtained? 
Sufficient detail to verify that ascertainment of vacci­
nations and events were independent?
Precise dates available, or imputed (if the latter, give
details)?
Repeat events excluded or included (if included, give
detail of how separate episodes are defined)?
Vaccines given in single or multiple doses (give de­
tails)?
Was a case note review undertaken (give details: all 
or sample)?___________________________________
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Study type:
Hypothesis generating (no prior hypothesis)?
Confirmatory (first study, but based on a prior hy­
pothesis)?
Repeat (previous studies already undertaken)?
Not clear which of the above?
Did study involve a comparison of case series with
another method (give details)?___________________________________
Population and observation period:
Age range of cases:
Calendar period of study:
Observation period rigorously defined (in such a way
that analysis could be repeated)?_________________________________
Age groups (and other temporal adjustments) used in analysis:
Specified rigorously (in such a way that analysis could
be repeated)?
Specified vaguely?
Used but not specified?
Give details of age groups: how many, how wide?
Sensitivity to age groupings investigated?
No age stratification used?
Any other temporal adjustment( season, year etc)?
Oive details________________________________________________________
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Rationale for risk periods used in analysis:
Was the choice of risk period(s) based on prior stud­
ies?
Based on general knowledge, but not previous studies? 
Not justified in any way?
Exogeneity assumption:
Did the authors discuss whether the assumption is 
likely to hold, namely (a) observation periods do not
depend on event (b) events do not affect exposures 
Was a pre-exposure risk period used (if so, give de­
tails)?
Other relevant discussion or methods used?
Sample size details:
Number of cases and events included in the analysis 
(for analyses of several events or vaccines, give full 
details).______________________________________
Other relevant details:
Any relevant exclusions or inclusions?
Other statistical features:
Tests for interaction with fixed covariates? 
Dose-specific effects investigated? 
p-values quoted for vaccine effects? 
Software used?
Anything else of interest?
Other comments:
Unusual features:
Good practice:
Bad practice:
Details of results with other methods (if used): 
Any other comments:
